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Type 2 diabetes and its associated co-morbidities have a significant impact on Māori 
and other indigenous populations. The prevalence of type 2 diabetes in Tairāwhiti was 
far greater for Māori than non-Māori (11% vs 4%). Māori experience poor diabetes 
related outcomes: premature mortality, co-morbidities, greater severity of disease and 
complications, poorer access to health services and diabetes related care and poorer 
management and treatment of diabetes. This thesis reviews the literature on diabetes 
amongst Māori and other indigenous peoples; medicines use and access for Māori, other 
indigenous people and those living in rural areas. The literature review found that, in 
common with other indigenous peoples, Māori shared a greater prevalence of diabetes, 
modifiable and non-modifiable risk factors for diabetes, and diabetes-related 
complications, particularly in the younger population. 
This thesis includes three inter-related studies to investigate access to medicines and 
use of medicines by Māori with type 2 diabetes in Tairāwhiti, within a Te ao Māori 
world view. 
The first, quantitative, study uses data from pharmacy dispensing computers to explore 
whether patterns of medicines use match the pattern of need for medicines. This study 
found that there was inequity and disparity in medicines used in the treatment and 
management of type 2 diabetes between Māori and non-Māori in Tairāwhiti. The rest of 
the thesis explores potential reasons for these inequities. 
The second, qualitative, study explored the lived experience of Māori people with 
diabetes in Tairāwhiti. People have different health beliefs and attitudes, but this should 
not be a barrier for them to receive the best care. Communication is a key element at all 
levels of care. Whānau and health professionals are encouraged to engage in healthy 
conversations to improve whānau outcomes. The traditional biomedical model of 
disease and recommended best practice for management of diabetes focuses on self- 
management, which is not consistent with a te ao Māori view, which is a collective 
whānau approach. The relationship between whānau and health professionals 




professionals connect with whānau in a meaningful way, they enable whānau to make 
and work towards positive change. 
The Tairāwhiti context shapes people’s access to medicines in many ways. These are 
outlined and explored in the third study which looks at how medicines are distributed 
in the Tairāwhiti region and reports on interviews with people who picked up their 
medicines from pharmacy depots in the region. This highlights the challenges for those 
living in remote rural areas of Tairāwhiti to accessing quality medicines and health 
services. 
The thesis ends with recommendations, including the need to improve communication 
and relationships between whānau and health professionals. These are key to 
improving knowledge and achieving positive outcomes. Health professionals must have 
an awareness and understanding of different health beliefs and attitudes and the value 
this brings to their practice. Additional research and action are needed regarding the 
cost of medicines, accessibility and the quality of medicines in rural areas. Key 
stakeholders need to work together to improve the management and treatment of 
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Hinengaro expression of thoughts and feelings of our mind, heart, 
conscience 
 






Kaiāwhina support person 
Kanohi ki te kanohi face to face 
Kata kata humour, laughing 
 




Kori kori tinana line dancing 
 
Kupu hōu word 
 
Maemae a sore or hurt 
 




















Ringatū religious group/following 
 




Te rohe o Te Tairāwhiti  the Tairāwhiti region 
 




Tino Rangātiratanga self-determination 







Whakaaro message, story 
 




Whakataukī proverb, saying 
 
Whānau family, kin 
 


















Kō Horouta te Wāka 
 
Kō Manawarū, kō Puketapu, kō Papatu ngā Maunga 
Kō Te Arai te uru Kō awa 
Kō Ngāi te Awe Awe, Ngāti Kaipoho, Ngāti Maru, Ngāi Tāwhiri, ngā hapu. 
 
Kō Rongowhakaata te iwi 
Kō Ruapani te tangata 










To look and move forward, you must know who you are and where you are from. To 
do this one must look back at the past, where you have come from and acknowledge 
what you see, as illustrated in the following whakataukī: 
 
“Kia whaka tō muri te haere whaka mua” 
 
“My past is my present is my 
future  
I walk backwards into the future 
with my eyes fixed on my past” 
 
 
“Insight and the research that produces or yields the insights is not the product of one 
person, one mind, or one heart. It both takes many people and is a reflection of many 




1.2 Thesis - Overview 
The all-encompassing approach to the thesis is grounded in te ao Māori, with a focus 
on Māori with type 2 diabetes and diabetes medicines use in Tairāwhiti, New Zealand, 
where the thesis is positioned. The author, draws on a mixed method approach in 
three interrelated studies, as this best captures, reflects and interprets the different 
meanings of the study data and the essence of whānau stories.  
 
 
1.3 Thesis - Aims 
The overarching aim of the thesis is to explore the access to medicines and the use of 
diabetes medicines by Māori with type 2 diabetes in Tairāwhiti. To do this, the first 
chapter aims to provide the context and background of Tairāwhiti; a profile of the 
place and its people, a brief description of diabetes; the health system in New Zealand 
and local diabetes services available at the time of the study. The second chapter, 
describes the te ao Māori approach and the Kaupapa Māori1 tikanga2 applied during 
the study. A descriptor of the Kaupapa Māori tikanga (Māori values and practices) is 
provided and how these tikanga are connected and relate to the characteristics of our 
tūpuna3 and displayed in Table 3. These tikanga guide and support the research and 
the researcher during the PhD journey. Thanks’ and gratitude to Te Hauora o 
Tūranganui a Kiwa4  Chief Executive, Reweti Ropiha, for allowing the use of this 
resource, during the PhD journey. 
Relevant and appropriate literature; books, studies, readings were sourced before and 
during the research. A comprehensive formal literature review (chapter three), 
undertaken in 2017, aims to support and provide context to the findings identified in 
this thesis; of similar indigenous populations; to establish any commonalities or 
differences between Māori and other indigenous populations; diabetes medicines and 
access to medicines. The fourth chapter examines the use of diabetes medicines and 
analyses the inequitable and disparate use of diabetes medicines between Māori and 
non-Māori in Tairāwhiti, using data from the Equity in Prescription Medicines use in 
Tairāwhiti (EIPMU 2005-2006) study. The EIPMU study, funded by a Grant (07/139) 
                                                             
1 Kaupapa Māori – Māori approach 
2 Tikanga – values and practices 
3 Tūpuna – ancestors, grandparents 
4 Te Hauora o Tūranganui a Kiwa – Turanga Health 
 
3  
from the Health Research Council of New Zealand, included a PhD scholarship, and 
marked the beginning of the author’s PhD journey in 2008.  
The remaining thesis aims to explore the possible reasons and context of those 
findings. Whānau shared their experiences, recount their story of diabetes and 
diabetes medicines are described and detailed in chapter five. Chapter six, builds on 
data from the Andrew Davies (2011) study, and examines the challenges and barriers 
encountered with the access to medicines and issues related to the quality of 
medicines for people living in rural remote areas of Tairāwhiti. The final chapter 
(seven) is a summary of the thesis, recommendations for consideration and possible 
opportunities for research in the future. 
 
 
1.4 Personal statement 
This thesis is a testament to the good will of many people, for your generosity and 
incredible support. I want to express my immense gratitude to those of you that have 
allowed me the space to “get it done”, thank you once, thank you twice, and thank you 
three times. I will be paying forward forever. Your unconditional awhi and tautoko over 
the many years has made this possible. I acknowledge those that are no longer here and 
my mum, dad (heavenly), siblings, husband, children, mokopuna, grandparents, nannies 
and papa’s, aunties, uncles and cousins. 
I am from a loved and caring place of small and humble beginnings. My parents were 
hard working, and not rich in terms of monetary wealth. They taught us respect, 
kindness and humility, to be grateful for what you have, tenacity and resilience. A great 
work ethic, the difference between right and wrong, determination – to not be afraid 
and “give things a go” and thankfully a quirky sense of humour. 
In many small communities, there are whānau known for their expertise or a particular 
skill, “specialist” role around the Marae – whether it be out the “back” gathering and 
preparing kai (one whānau had their own cookers and pots) or at the “front” preparing 
for manuhiri. This process organically transpired in the Marae, seamlessly, without any 
emails, messenger, or texts. Dad was a plumber-drainlayer by trade. He often was asked 
to fix blocked toilets or drains at the Marae. As a whānau we were not really “pā” or 
“kapa haka” people, but were part of the many Marae activities. 
 
4  
Ironically, I could not wait to leave home at the end of high school. My application to 
train as a dental nurse was declined. This was a major disappointment, and I did not 
have a plan B. I worked in the fields (weeding, pruning grapes, picking apples) for about 
6 months, when an aunt visited, she asked if I would like to “go to Wellington”- stay with 
them and find a job. Mum and dad were not very keen on the idea (I was the oldest and 
the first to leave home), and after much discussion they agreed. My bag was packed and 
I was on that car – the bright city lights beckoned, and the few savings in my bank book 
(no eftpos or credit cards), no thought for my parents or grandparents or siblings, just 
adventure and fun times. I worked in different jobs (washing dishes, cooking, cleaning, 
care giving for the elderly), and I bought my first car (we learnt to drive tractors and 
motorbikes in the country). Nursing sparked my interest, and I enrolled and completed 
the 18-month hospital based enrolled nursing training at Lower Hutt Valley Hospital. 
Being married with a young family, away from whānau supports, was a challenging 
time. I returned to tertiary study as an adult student, completed a Bachelor in Health 
Sciences and was a registered nurse, juggling work, study and whānau time. My first job 
as a registered nurse was in Paediatrics, working with unwell tamariki and their 
whānau, in a hierarchical bureaucratic health system, twelve-hour shifts and travelling 
up to an hour to work, was gruelling. We looked to change our lifestyle and it was time 
to move back to Gisborne. 
On our return home, I worked in the local hospital for a short time, then moved to the 
community for the last twenty years. It has been rewarding and challenging over the 
years. It soon became apparent there was an absence of many older pakeke5 around the 
Marae and in the community; some had died, while others were less mobile due to their 
health conditions. 
With the absence of pakeke there was grief and pain for whānau, but also a sense of loss 
in terms of loss of whakapapa (family history), mātauranga (knowledge), tikanga 
(values and practices), local kawa/lore, and tacit knowledge. There was a loss of those 
who knew where whānau lay in the urupā6 (unmarked graves), or the best place and 
time to plant or store kai, or fish, or harvest, the rules and responsibilities. These 
aspects of our community that contribute to who we are, were being lost. How could 
this be with modern science and medicine? I questioned my own practice as a nurse 
                                                             
5 Pakeke - adult 
6 Urupā - cemetery 
 
5  
and those of my colleagues. I had more questions than answers. What, why and how 
could I do something about this picture? Whānau that I cared for in the community 
were dying before their time and/or were not in good health. What could I do to make a 
difference? Hence my PhD journey, this hīkoi (journey) is my way to contribute: to my 
whānau, whanui and the wider community. 
 
 
1.5  Chapter one - Aim 
To provide a context and introduce Tairāwhiti the study area, in terms of demography 
of the population, history and insight into the drivers of “what” and “why” the author 
took up the wero (challenge) of the study. Underpinning the thesis is te ao Māori. 
 
1.5.1 Objectives 
• A description of the Tairāwhiti region 
• An overview of the New Zealand health system 
• Description of diabetes 
• Diabetes related services in Tairāwhiti 
 
 
1.6  Overview - Te ao Māori 
This thesis is grounded in te ao Māori. I have attempted as the author to weave the 
fundamental values of te ao Māori based on the key characteristics of my tūpuna7 
throughout the thesis these are described in chapter two. The study “participants” 
(referred to as whānau8 in this thesis) were Māori. Being Māori is who I am. The guiding 
principles or fundamental values of te ao Māori; Whānaungatanga9, Manaakitanga10, 
Rangātiratanga11, and Kōtahitanga12 are also discussed in chapter two and assist the 
author by: 
i) providing a framework and world view that contextualises the writing of the thesis 
ii) underpinning whānau stories and experiences  
                                                             
7 Tūpuna - ancestor 
8 Whānau – extended family 
9 Whānaungatanga – Kinship, sense of family connection 
10 Manaakitanga – Kindness, generosity 
11 Rangātiratanga – Chieftain, right to exercise authority 
12 Kōtahitanga – Unity, togetherness 
 
6  
iii) reflecting the author’s worldview 
 
This study and the people in it are situated in the Tairāwhiti region, of New Zealand; an 
area heavily influenced and populated by Māori relative to the rest of New Zealand. As 
the author I whakapapa to Rongowhakaata, an iwi of Tūranganui-a-kiwa13, where I was 
born and raised in a small rural community. I have worked as a registered nurse in the 
community, with the local iwi Māori Hauora, for more than two decades. It was 
important, as a fledgling Māori researcher, to ground the study within a Kaupapa Māori 
framework. It was a natural fit, being Māori, also living and working in a predominately 
Māori whānau community. 
The translation of some Māori words to English can alter their meaning and intent. To 
preserve the meaning of the conversation, and avoid distracting the reader and 
interrupting the flow of the thesis, I have chosen to keep some Māori words in the text. 
A glossary (page xxii) is provided with the translation, at the front of the thesis. 
  
                                                             









Figure 1: Map of New Zealand 








The Māori name for the district is Tairāwhiti meaning “The coast (Tai) where the new 
sun (rā) shines (whiti)”. Te rohe o Te Tairāwhiti begins north at Pōtikirua by the East 
Cape and ends south at the Mōhaka river and runs inland to Matawai and down to the 
western edge of the Te Uruwera National Park. Retrieved July 15, 2010, from 
https://en.wikipedia.org/wiki/Gisborne_District#Name_and_history 
Tairāwhiti lies on the eastern coastline of the North Island, New Zealand. It is an 
isolated area, bordered to the south and west by the Huiarau and Raukumara ranges, 
and the Pacific Ocean to the east and north. The only city in the region is Gisborne. 
The closest cities to Gisborne are Napier (Hawkes Bay) 216 km to the south (State 
highway 2) two and half to three hours’ drive via a very hilly, windy sealed road. 
Whakatane (Bay of Plenty) 202 km to the northwest on State Highway 2, is a three-
hour windy drive on a sealed road, or around State Highway 35, a 334 km very scenic, 
windy road in poor condition, that is very narrow in places, with limited passing 
areas, can take up to four or more hours to reach Opotiki. Retrieved June 10, 2011, 
from https://www.hauoratairāwhiti.org.nz 
The total land area for Tairāwhiti is 8,351 square km (3, 224 square miles). It is the 
most sparsely populated area in the North Island of New Zealand, and has a population 
density of 5.2 per square km (13.5 per square mile). By comparison, the neighbouring 
regions, Bay of Plenty and Hawke’s Bay have population densities of 18.0 and 10.1 
people per square kilometre, respectively. Tairāwhiti accounts for 3 % of New Zealand’s 
land mass and 1.1% of the total population. Apart from Gisborne (34, 274) there are 
only very small communities throughout Tairāwhiti, as seen in Table 6, chapter six, and 






Figure 2: Rural communities in Tairāwhiti 






The historical context of Tairāwhiti is important to understand, as these events continue 
to impact on today and shape the future of Tairāwhiti and New Zealand. 
New Zealand was once an isolated wilderness of forest, sea and mountains. Māori came 
to Aotearoa (New Zealand) in a series of epic canoe voyages from eastern Polynesia (in 
the Pacific) between 1200 and 700 years ago. Populations soon settled in both the North 
and South Island of Aotearoa, New Zealand. Because the area was rich in natural 
resources and food sources, populations were soon actively trading and negotiating 
across the country. 
During the 18th and 19th century, Pacific nations including Aotearoa were colonised and 
heavily influenced by the European imperial powers. For many indigenous people the 
colonisation process meant dispossession and confiscation of their land and resources, 
warfare, and social changes, exposure to epidemic diseases and a decline in populations 
mainly due to disease (Anderson et al., 2006). 
In New Zealand, the first contact between Māori and Europeans was in 1642 by the 
Dutch explorer Abel Tasman in the northern part of the South Island. In 1769, the 
arrival of Englishman Captain Cook and Frenchman de Surville to Aotearoa heralded the 
initial wave of imperialism. Early pioneers, missionaries and interlopers soon followed, 
each with their own purpose and opposing worldviews. Although well-meaning and 
with their own good intentions, interaction between Māori and colonialists resulted in 
altercation and the annexation of land and the local inhabitants.  
Māori had established, thriving settlements in and around the country. Some Māori 
were peaceful, while others were not. Māori were actively trading (goods and services) 
amongst themselves and with the very early European traders and local missionary 
families. This resulted in the introduction of tools, guns, new ideas and resources, new 
foods, pests and disease. Similar to other colonised settlements and countries, land 
was in demand, to house and feed the increasing populace of European settlers. 
Introduction of the musket revolutionised intertribal warfare. The “Musket Wars” 
refers to intertribal warfare that waged from 1810 until the 1830’s, decimating Māori, 
shifting the traditional tribal boundaries and forcing many to flee their traditional 




In 1835 the Declaration of Independence document between the Crown and some 
northern Māori chiefs (Confederation of United Tribes), gave sovereignty of New 
Zealand to Māori. However, due to the increasing number of British and European 
migrants, a Treaty agreement (known as the Treaty of Waitangi) was proposed by 
British Crown representatives, with 500 Māori Chiefs, making New Zealand a British 
colony. There are English and Māori language versions of the Treaty of Waitangi. Most 
of the Māori Chiefs signed the Māori language version of the Treaty. Many of the 
significant words used in the Treaty of Waitangi had slightly different meaning, and 
led to different expectations of the outcomes of the Treaty of Waitangi (Waitangi 
Tribunal, 2004). 
The Treaty of Waitangi (TOW 1840) signalled to some groups that the rights and 
responsibilities of the Crown and tangata whenua14 would be safe guarded. However, 
disputes over land ownership are ongoing. Armed conflict over sovereignty of the land 
between Māori and the Crown continued, for example the New Zealand Land Wars 
between 1845 and 1872, in the central North Island. Many Māori died and hapū were 
decimated defending their land. Those iwi that formed alliances with the Crown at the 
time of the Land Wars retained their lands while the insurgents did not (Waitangi 
Tribunal, 2004). 
The Treaty held no statutory recognition until the enactment of the Treaty of Waitangi 
Act 1975, and the establishment of the Waitangi Tribunal (1975), as a permanent 
Commission of Inquiry. This Act legitimised Māori iwi claims and grievances against the 
Crown, and breaches of the principles of the Treaty of Waitangi. The Treaty of Waitangi 
(1840) is a founding document of New Zealand and the cornerstone in all New Zealand 
policy. Interpretation of the Treaty of Waitangi and rights of Māori continue to be a 
challenge for New Zealand. 
People of Tairāwhiti are said to trace their ancestry from Māui, the ancestor of Toi 
(Salmond, 1992). Toi is thought to be one of the early ancestors living prior to the 
arrival of the Hawaiiki migrants and a descendant of Māui-Tikitiki-a-Turanga, who 
fished up the land (known as the North Island, New Zealand) with his canoe 
Nukutaimemeha (Buck, 1949). 
Prior to Cook’s arrival in 1769, hapu from the main tribal/iwi groups populated 
                                                             
14 Tangata whenua – people of the land 
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Tairāwhiti: Rongowhakaata, Ngāi Tahu po (Ngāi Tāmanuhiri), Te Aitanga a Mahāki and 
Te Aitanga a Hauiti, Ngāti Porou in settlements around and along the coastal areas and 
hinterland. 
In 1769 Captain Cook and company are said to have sighted and made landfall at Te 
Toka-a-Taiau (The rock of Taiau – is said have been located at the mouth of the 
Tūranganui River until the late 1870’s, then dynamited for harbour development) 
(Walker, 2014). An altercation took place between Cook’s crew and local hapū 
members, and hapū members were shot and killed. Captain Cook and company 
subsequently departed and the people (indigenous and early settlers) of Tūranganui 
(Turanga - Gisborne) continued to live and trade relatively peacefully from the early to 
mid-1880’s, with a population in 1865 of approximately 1500 Māori and 60 to 70 
settlers in the district (Waitangi Tribunal, 2004). 
The New Zealand Land Wars raged between the 1845 to early 1872, between colonial 
forces and the Māori King, in and around the central North Island of New Zealand. 
However, Māori in Turanga (Gisborne) maintained a neutral stance supporting neither 
the British Crown nor the Māori King. In March 1865, representatives of a religious 
movement (Pai Mārire) travelled from Opotiki to Turanga, promising protection of 
land and independence to the Turanga Māori against an apparently aggressive Crown. 
This instigated unrest among some Māori and settlers (Waitangi Tribunal, 2004). 
Simultaneously along the East Coast, conflict was occurring between the Crown, Ngāti 
Porou and the Pai Mārire. The Crown principal (Donald McLean) used Ngāti Porou iwi 
and colonial forces to destroy the Pai Mārire influence along the East Coast and the 
independence of the Turanga tribes. As Colonial forces advanced on Turanga, they 
issued an ultimatum to the Turanga Māori, to surrender all arms, pledge their oath of 
allegiance to the Crown and surrender all non Turanga Pai Mārire members. Turanga 
Māori, however, held steadfast and remained at Waerenga-a-Hika pa site, where 800 
Māori including 300 women and older children were thought to be located. This 
constituted nearly the entire population of Turanga at the time (November 1865). In 
November 1865, Colonial troops and Ngāti Porou Crown force laid siege at the 
Waerenga-a-Hika pa. A five-day battle ensued, 71 Māori were killed, some escaped, and 
 
13  
others surrendered to crown forces. After the attack, the Crown deported and detained 
some 123 prisoners on Wharekauri (Chatham Islands), without charge or trial. In 1869 
during an attack at Ngatapa pa, between 86 to 128 unarmed people (thought to have 
fled from the massacre at Waerenga -a - Hika pa), are said to have been executed 
(Waitangi Tribunal, 2004). 
The City of Gisborne (Turanga) was established in 1869, on 741 acres of Tūranganui no. 
2 block, land that was acquired from 17 chiefs of Rongowhakaata and Te Aitanga-a- 
Mahaki tribes for 2000 pounds. The area was divided into 160 sections for residential, 
civil, commercial and educational purposes. The name Gisborne is from William 
Gisborne, the Colonial Secretary for the Crown at the time (McAloon, 2008).  
Māori made a significant contribution to the New Zealand war efforts during World War 
1. After the war (1914 to 1918), veterans returning home were offered farms and 
vocational training under the Discharged Soldiers Act 1915. Māori veterans however, 
were assumed to have tribal land connections available on their return. Most of these 
lands were marginal remote land blocks that failed to provide a viable income. A ballot 
system was used to allocate farmland for mainly pakeha veterans. 
The 28th (Māori) Battalion were a group of some 3,700 Māori volunteer soldiers that 
formed the rifle unit in 1939. The 28th Battalion was divided into 5 companies (A, B, C, D, 
E) based on their racial and tribal affiliations. C Company recruits (945) were from the 
East Cape -Tairāwhiti region. One hundred and seventy-seven men from C Company, 
lost their lives (18.6% death rate), 70% were wounded or became prisoners of war 
(Soutar, 2014). As a memorial to those that served in the C Company or the 28th (Māori) 
Battalion and others from Tairāwhiti (Soutar, 2014). The C Company House was built 
and dedicated to those who lost their lives or served and died in other wars overseas, 
the building is located next to the Tairāwhiti museum. 
After World War II (1939 to 1945) returning veterans received low interest business, 
housing and furniture loans and preferential allocation of state houses. Trade training 
opportunities especially in the building industry were made available and those 
choosing to study were supported with allowances for career training. By 1953 the 
government had bought just over 1 million acres (405,000 hectares). WWII veterans 
with farming experience were offered economically viable properties (14,000 World 
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War II veterans were assisted to acquire farms) and by 1964 a buoyant export market 
ensured continued viability of those properties (McAloon, 2008). 
The Tairāwhiti region has a history of conflict and war between iwi and the crown. In 
1992, Turanga iwi: Rongowhakaata, Te Aitanga a Mahaki, and Ngai Tāmanuhiri, lodged 
claim WAI 283 with the Waitangi Tribunal, recounting the stories and grievances of 
their people and iwi. In 2009, Turanga iwi agreed to work towards separate Deeds of 
Settlement. Some iwi settled with the Crown; Ngai Tāmanuhiri and Rongowhakaata 
settled in 2011. Ngāti Porou lodged claim WAI 814 to the Waitangi Tribunal and settled 
in 2010. 
The region is nearly all-in post-settlement phase, with a small number of Tairāwhiti 
iwi having claims lodged at the Waitangi Tribunal that are not yet settled. The 
monetary settlement and post settlement activity continues (the return of confiscated 
land and taonga) and have contributed in part to the restitution for some of the 
grievances claimed by iwi of Tairāwhiti. 
 




The New Zealand Deprivation Index is a small area measure of the socioeconomic status 
of a population. It is calculated from nine dimensions of deprivation. Information about 
the dimensions is derived from the census data, and applied to small geographical areas. 
Small areas (mesh blocks) are then ranked and divided into 10 deciles (Salmond, 
Crampton, & Atkinson, 2007). Decile 1 (green) areas are least deprived and decile 10 






Figure 3: NZ Deprivation Index of Tairāwhiti 2006 






Figure 4: Tairāwhiti population by quintile 2015/2016 
Retrieved March 10, 2010, from https://www.health.govt.nz/new-zealand-health-
system/my-dhb/tairāwhiti-dhb/population-tairāwhiti-dhb   
 
 
Figure 4 shows the proportion of the Tairāwhiti population living in the most deprived 
(46%) to the least deprived (9%) areas (by quintile). Nearly half the total population 
live in the most deprived areas 7 to 10 (Figure 5). A higher proportion of Māori than 
















Figure 5: Area distribution by NZ Deprivation 2013 


































Figure 6: Proportion of the population by deprivation in Tairāwhiti 2013 
(Statistics New Zealand, 2006) 
 
 
1.10 Ethnicity and Age profile 
The proportion of Māori and non-Māori (48.7% vs 48.8%) in Tairāwhiti (Figure 7 and 
8) is similar. The proportion of Māori is high compared to the national population 
(Māori 15.5%), and there are low numbers of Pacific Island people and Asian. Most of 
the Tairāwhiti population (34,274), live within the city boundary of Gisborne. Of those 
living on the East Cape, over 80% are Māori, and a greater proportion are under 14 
years. Populations living in the rural areas of Tairāwhiti (Figure 8 and 10), are expected 
to decline by 2031 (Bull, 2011). 
  
 






Figure 7: Tairāwhiti population by ethnicity compared to the National population 2015/16 











Figure 9: Tairāwhiti population by age compared to National population 2015/16 
(Ministry of Health, 2016) 
 
Compared to the National population (Figure 9), Tairāwhiti has a young population. A 
greater proportion of this group are Māori <35 years (Figure 11). Comparative to non- 
Māori, there are fewer older Māori (>40 years) in Tairāwhiti. There are even fewer 
Māori in the older age group (>70 years) (Figure 11) (Ministry of Health, 2012a). 
 
Figure 10: Age distribution by city, rural and East Cape 2006 










1.11  Māori Language 
In 2006, the prevalence of Māori speaking te reo Māori in Gisborne was greater than the 
rest of New Zealand. A high proportion of te reo Māori speakers are over 60 years. 
Although the numbers are small, the proportions were larger in the older age groups 
(Figure 12). Tairāwhiti has the fifth highest region of te reo Māori speakers in the 










1.12  Economy and income 
The Gross Domestic Product (GDP) is one indicator used to measure standard of living. 
GDP is the total value of output or income earned from goods and services produced. 
Tairāwhiti had the lowest GDP per capita at $34,472 by region, nationally (Ministry of 
Health, 2013). Forty two percent of people over 15 years in the Gisborne region had a 
total income of $20,000 or less, compared to 38% for all of New Zealand. Half of those 
earning $20,000 or less were Māori. The average income is $24,000 compared to 
$28,500 the national average. Nearly a quarter of the population in Tairāwhiti are 
unemployed, and almost half of those unemployed are Māori. Primary industries are the 
major employers in the region, predominantly employing labourers in fishing, farming, 
forestry and horticulture. These are industries at high risk of accidents and incidents, 
and potentially resulting in fatalities (Paling, 2014). 
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1.13  New Zealand health system 
The Ministry of Health is the governing agency for the health sector in New Zealand, The 
Ministry of Health applies a population-based funding model to resource the 21 District 
Health Boards, which are responsible for providing and funding health services in their 
regions (NZHD Act 2000). National performance targets are set by the Ministry of 
Health and each DHB’s role and responsibility are to measure and meet their 
performance against the targets. In New Zealand, health care is largely funded by tax 
monies. Some services are free to all New Zealand residents (including public hospital 
services such as inpatient care and treatment, and specialist appointments). Other 
services are partially funded by the government and may require a patient contribution 
e.g., general practice and prescription medicines, allied services, radiology or private 
Accident and Emergency services. 
District Health Board membership consists of 11 members (7 publicly elected). The 
Minister of Health may appoint up to four members to ensure a range of perspectives, 
skills and knowledge are represented on the board. The chair and the deputy chair are 
appointed by the Minister of Health from the elected and appointed members. The 
elected members serve a three-year tenure and may stand for re-election every three 
years during local council elections. 
Primary Health Organizations (31), established in 2000, are funded by District Health 
Boards to provide essential primary health services, mostly through general practices 
or contracted providers, to people enrolled with the PHO (Ministry of Health, 2002). 
The Pharmaceutical Management Agency (PHARMAC), is responsible for managing 
pharmaceutical expenditure in New Zealand. They negotiate with the pharmaceutical 
industry about prices for medicines and maintain the Pharmaceutical Schedule. The 
Schedule is a list of medicines subsidised in New Zealand, the price and subsidy of those 
drugs and any restrictions on access to the subsidy. To be eligible for subsidised 
medicines, drugs must be prescribed by a medical practitioner (or, in some instances, 
pharmacist prescribers, clinical nurse specialists, nurse prescribers, dentists and 
midwives). Some medicines listed on the Pharmaceutical Schedule are also available 
over the counter; these are subsidised if prescribed, but not if bought over the counter 




At the time of the EIPMU study (2005-2006) the maximum prescription fee for fully 
subsidised medicines were NZ$15 for those without a Community Services Card. The 
Prescription Subsidy card allowed eligible family and or households free medicines once 
they had paid for 20 new prescription medicine items in a year. Medicines partially 
subsidised or unsubsidised had to pay in full or incur an extra “part charge”. Medicines 
bought without prescription or over the counter medicines (OTC), had to be paid for in full. 
 
1.13.1 Health care in Tairāwhiti 
Tairāwhiti is one of three regions (including Northland – North Island, West coast – 
South Island) in New Zealand that includes areas with “special area status” established 
under section 117 of the Social Security Act (1964). This means, no cost for primary 
medical care provided by salaried doctors to patients domiciled in these communities. 
In the Tairāwhiti DHB, this applies to those who live on the East Coast (south of Paritu 
to Potaka, Wharekaka, East Cape (Ministry of Health, 2013) and Western rural, 
Northwest Rere, Ormond to Wairata, Tarndale-Rakauroa (Ministry of Health, 2013). 
Tairāwhiti has a 30-bed general hospital and associated ancillary specialist and support 
services in Gisborne. Clinical specialist clinics are serviced by visiting specialty 
clinicians (i.e., renal, cardiac, diabetes, cancer and geriatrician) who travel from other 
DHBs. There are small private hospitals (surgical/dementia) and private specialist 
clinics in the community. On the East Coast, Te Puia hospital (six beds) is owned and 
administered by Ngāti Porou Hauora. Visiting specialist clinics are held at Te Puia 
hospital (diabetes, cardiac, renal), as is the Ministry of Health’s Mobile Health team – a 
surgical bus (once or twice a year). Five clinics are located in rural communities along 
the East Coast providing primary care services in the community by Ngāti Porou 
Hauora. The Western rural area has a clinic at Te Karaka also providing primary care 
services in the community, is owned and administered by Te Hauora o Tūranganui a 
Kiwa. 
Tairāwhiti was one of the earlier regions to implement the Primary Health Care 
Strategy (2001), and the establishment of Primary Health Organizations (PHO). The 
primary health care reforms aimed to improve health and reduce health inequalities. 
There are two PHOs in Tairāwhiti, providing funded very low-cost access to care, 
targeted at vulnerable populations – that is those in the greatest need: low income, 
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Māori and Pacific people, living in high deprivation areas – groups with traditionally 
poorer health outcomes than the rest of the population. 
 
1.13.2 Pharmacies 
At the time of the EIPMU (2005 -2006) study, there were eight community pharmacies 
in Tairāwhiti, all within the Gisborne city. People registered with providers funded 
under “designated special area status” localities in Western rural and East Coast areas 
have the option to collect their medicines from a designated depot. In this case, 
prescriptions are faxed to the pharmacy and the medicines are couriered from the city 
pharmacy to depots situated on the East Coast and the Western rural areas. This 
“Depot” system is discussed further in chapter (6). 
 
 
1.14 Diabetes overview 
Diabetes is a global problem and one of four priority non-communicable diseases 
(NCDs) targeted for action by world leaders. Diabetes is a progressive chronic disease 
that occurs when the pancreas does not produce enough insulin (a hormone that 
regulates blood sugar, or glucose), or the body cannot effectively use the insulin it 
produces. The number of new cases (incidence) and prevalence of diabetes have 
increased over the past few decades and are expected to continue increasing 
(International Diabetes Federation, 2017). 
 
1.14.1 What is Diabetes? 
Diabetes is a condition where there is too much glucose in your blood and the 
body cannot use it properly because the pancreas does not produce any insulin or 
not enough insulin to help the glucose enter the body’s cells, or the insulin that is 
produced does not work properly (also known as insulin resistance). Insulin is a 
hormone produced by the pancreas that supports the glucose to enter the body’s 
cells – where it is used as fuel for energy. Glucose comes from the food we eat and 
is also produced by the liver. There are different types of Diabetes. Type 1 is 
where glucose cannot enter the body’s cells to be used as fuel because there is no 
insulin to unlock the cells. In type 2 diabetes, there is not enough insulin or the 
insulin that is produced is not working properly. Gestational diabetes affects 
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woman during pregnancy and usually resolves post pregnancy (Sam & Meernan, 
2009). 
Diabetes of all types can lead to complications in many parts of the body and increase a 
person’s overall risk of premature death. Possible complications include heart attack, 
stroke, kidney failure, amputation, vision loss and nerve damage. In pregnancy, poorly 
controlled diabetes increases the risk of foetal and maternal complications. 
 
1.14.2 Aetiology 
Diabetes happens when there is a dysfunction in insulin production and/or insulin 
action leading to the body being unable to metabolise blood glucose. Insulin is the 
hormone formed by the group of beta cells in the Islets of Langerhans within the 
pancreas. It regulates the body’s blood glucose levels, with a dual role; firstly, to 
transport glucose from the blood stream into fat and muscle cells, to be used for energy; 
and secondly to prompt the liver to maintain glucose levels in the blood. Glucose in the 
blood stream comes from consumed carbohydrates and is an essential source of energy. 
The liver also produces glucose by converting fats and proteins and provides a constant 
supply of glucose when not eating. When there is insufficient insulin secretion or action, 
or both, this leads to hyperglycaemia or high blood glucose levels, a common 
consequence of uncontrolled diabetes. Over time, if not managed, it can cause serious 
damage to the microvascular and macrovascular vessels of the body. 
Type I Diabetes: (previously known as insulin-dependent, immune-mediated juvenile 
or childhood-onset diabetes) develops at any age. Type 1 diabetes occurs when there is 
beta cell destruction, leading to total insulin deficiency. Management requires insulin be 
given to a person (injection/insulin pump). Type 1 diabetes can result from the body 
destroying the insulin-producing beta cells of the pancreas (an autoimmune mediated 
response). The rate of destruction is variable. Alternatively, type 1 diabetes can be - 
idiopathic. That is have permanent inadequate secretion of insulin insulinopenia, are 




The symptoms include excessive excretion of urine (polyuria), thirst (polydipsia), 
constant hunger, weight loss, vision-changes and fatigue (maybe sudden onset). 
Type 2 Diabetes: (previously known as non-insulin-dependent or adult-onset), (>90% 
of whanau with diabetes in New Zealand) is characterised by insulin resistance with 
relative insulin deficiency, or an insulin secretory defect (with or without insulin 
resistance). 
Cells do not utilise available insulin, and the demand for insulin production increases 
and the pancreas does not produce enough insulin, reasons for which remain unknown 
(New Zealand Guidelines Group, 2012). 
The symptoms include those described above for type 1, but with less sudden onset. 
Symptoms may not occur until several years after diabetes develops. 
Gestational Diabetes: (GDM) universal screening using glycated haemoglobin (HbA1c) 
identifies women with probable undiagnosed diabetes or prediabetes (ideally before 20 
weeks). This applies regardless of whether the condition persists after pregnancy; 
women with an HbA1c ≥ 50 mmol/mol, should be under the care of a service that 
specialises in diabetes in pregnancy. Undetected impaired glucose tolerance pre-
pregnancy cannot be excluded. Symptoms are similar to type 2 diabetes and GDM is 
usually diagnosed in prenatal screening. Elevated maternal glucose levels are 
associated with an increased rate of complications for the baby including: large size and 
birth weight, trauma, hypoglycaemia and jaundice. The aim of treatment is to reduce 
the risk of complications for the baby by maintaining control of maternal glucose levels. 
Children of women who have had GDM are at increased risk of obesity and abnormal 
glucose metabolism during childhood and adult life, and developing type 2 diabetes 
later in life. Pregnant women without diabetes will be screened for possible gestational 
diabetes between weeks 8 and 12 of the pregnancy and an oral glucose tolerance test 
(OGTT) will be carried out between weeks 24 and 28 (Ministry of Health, 2014). 
Impaired Glucose Tolerance (IGT) and impaired fasting glucose (IFG): is a stage in 
transition to diabetes that is sometimes called Pre-Diabetes. People with IGT or IFG are 
at risk of progressing to type 2 diabetes. This is not necessarily inevitable with the 
appropriate interventions and management. Those with IGT (30%) are likely to return 
to normal glucose tolerance over a period of years (McAuley et al., 2003; UK Prospective 
Diabetes Study (UKPDS) Group, 1998b). 
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1.14.3 Risk factors for diabetes 
The risk factors for developing type 2 diabetes include: genetics, family history, a 
sedentary lifestyle, smoking and obesity. A sedentary lifestyle and obesity are what 
primarily drive the resistance to the action of insulin. If people reduce their insulin 
resistance through weight loss, increasing activity, nutrition changes and medication, 
they can increase their pancreatic insulin production. The risk factors for diabetes have 
increased significantly in New Zealand over the last decade especially for the younger 
population of Māori, Pacific Island peoples and Asian/Indian people (New Zealand 
Guidelines Group, 2012). 
 
1.14.4 Diabetes management and treatment 
Diabetes is a progressive disease and the earlier interventions (pharmacological or non- 
pharmacological) are implemented the better the chances of delaying or reducing the 
severity of the disease (Davies, Tringham, Troughton, & Khunti, 2004; Makrilakis, Liatis, 
Grammatikou, Perrea, & Katsilambros, 2010; Tipene-Leach et al., 2004). The 
consequences of ineffective management and treatment of diabetes are poor clinical 
outcomes. These can include: cardiovascular disease, heart attack, renal disease, kidney 
failure and dialysis, peripheral vascular disease (PVD), limb amputation, blindness and 
premature mortality. 
The New Zealand Guideline Group published evidence-based recommendations and 
guidelines between 1999 and 2012 (New Zealand Guidelines Group, 2012) for the 
management and treatment of diabetes. These recommend the practitioner develop an 
individual stepwise approach with treatment advice and support for the management 
of patients with type 2 diabetes. The guidelines were reviewed and updated by the 
Ministry of Health (New Zealand Guidelines Group, 2012) and replaced with the 
Ministry of Health, New Zealand Primary Care Handbook Update (2012). Health 
professionals and funding agencies (Pharmac) provide guideline updates and 
recommendations for disease states; cardiovascular risk assessment and diabetes 
screening, smoking cessation, stroke and transient ischaemic attack, heart failure, 
prevention of infective endocarditis, rheumatic fever and sore throat management, 
weight management, renal disease.  
The primary aim of the treatment and management of type 2 diabetes is to achieve and 
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maintain the individuals’ blood sugar below targeted levels. The biomarker measured as 
HbA1c - Haemoglobin A1c (HbA1c) assay, indicates a person's average blood glucose 
(sugar) levels over the previous 2 to 3 months. The fundamental treatment for people 
with type 2 diabetes is education and the maintenance of a healthy lifestyle. 
Recommended interventions include diabetes education, healthy diet, physical activity 
blood glucose self-monitoring and medicines. Medications for diabetes are usually oral 
antidiabetes medication and/or insulin. The treatment regimens are dependent upon 
patient engagement and clinical indicators such as blood results, blood pressure, height 
and weight, waist circumference or girth, foot assessment and retinal screening. 
Discussion between the practitioner and the patient is critical for successful patient 
outcomes. 
The New Zealand Primary Care Handbook Update (2012) recommends patient 
education and lifestyle modification as the initial intervention, with success measured 
by HbA1c over a 3-month period. If the patient is symptomatic and/or the HbA1c 
remains high (HbA1c >55 mmol/ml <65mmol/mmols), they should continue with their 
modified lifestyle, in addition to starting metformin, an anti-hyperglycaemic (biguanide) 
the recommended first line drug therapy. If the patient’s Body Mass Index (BMI) is 
under 25 they should be started on a sulphonlyurea instead. The dose should be 
adjusted (titrated) over time, starting on the lowest dose with gradual dose increments 
until the desired effect is achieved. Alternatively, if metformin is not tolerated or is 
contraindicated, a “second line drug therapy”, glipizide, glicazide, (a sulphonylurea) 
should be initiated and adjusted for the appropriate dose. If this is not tolerated, a 
pioglitazone (thiazolidinedione) should be introduced if appropriate. The “third line 
drug therapy” insulin should be initiated, in a similar manner to oral hypoglycaemic 
drugs, starting on the lowest dose with gradual increments of dose over time. Blood 
glucose is monitored and reviewed regularly during this process. The UKPDS study has 
shown that early initiation of insulin by patients led to a median delay of 7.7 years in 
beta cell damage and disease progression (UK Prospective Diabetes Study (UKPDS) 
Group, 1998a). 
The biguanides decrease blood glucose levels by decreasing liver glucose production, 
decreasing intestinal absorption of glucose, and increasing insulin sensitivity by 
increasing peripheral glucose uptake and utilisation. The sulphonylureas stimulate 
insulin production in the pancreas and increase the effectiveness of insulin in the body. 
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Insulin causes cells in the liver, skeletal muscles, and fat tissue to absorb glucose from 
the blood (Archer, Oderda, Richards, & Turpin, 2013). 
The guidelines recommend practitioners actively manage diabetes and introduce 
insulin as a treatment option early if required. Beta cell function declines over time, 
particularly where patients are struggling to maintain good glycaemic management. The 
early use of medication (metformin) and lifestyle changes are known to reduce 
cardiovascular events and mortality when compared to insulin, sulphonylurea or diet 
alone, and improve outcomes (Eurich et al., 2007; Kooy et al., 2009; UK Prospective 
Diabetes Study (UKPDS) Group, 1998a). Regular, routine monitoring is part of good 
clinical practice, to ensure early detection, prevention and management of 
complications including; retinal and kidney function screening, foot care and checking 
blood glucose. The use of non-glucose pharmacological interventions maybe necessary 
for treating complications and advanced disease states like; hypertension, heart disease, 
retinopathy, renal protection, neuropathy.  
 
 
1.15  Prevalence of diabetes 
1.15.1 International 
Diabetes is one of the most common chronic diseases globally; 1 in 11 adults in the 
world (415 million people) are estimated to have diabetes (International Diabetes 
Federation, 2017). Half the adult population with diabetes in the world do not know 
they have diabetes, that is, 1 in 2 adults with diabetes are undiagnosed. There are five 
million people dying from diabetes in the world (one person every six seconds) and 
12% of total global health expenditure (673 billion USD) is spent on diabetes 
(International Diabetes Federation, 2017). Retrieved November 1, 2016, from 
https://www.idf.org/about-diabetes/facts- figures. Type 2 diabetes makes up 80 – 
90% of diabetes in developed countries and a higher percentage in developing 
countries. Historically, type 2 diabetes was known to affect adults; however, children 
and adolescents are now presenting with type 2 diabetes (International Diabetes 
Federation, 2017). 
The prevalence of diabetes is expected to increase with a predicted 642 million people 
who will have diabetes by 2040. A range of factors contribute to the world-wide 
 
30  
increase in diabetes. Populations’ lifestyles are changing to become more time and 
nutrient poor, the levels of physical activity and participation are decreasing, and 
obesity is increasing, partly because of global urbanization and economic development. 
A diverse range of strategies are needed to address the global burden of diabetes. These 
include community owned and resourced interventions that meet the demand of 
changing lifestyles and populations (Roglic, 2016). 
 
1.15.2 Diabetes prevalence in New Zealand 
In New Zealand, an estimated 3.3 % of the total population are thought to have 
diagnosed diabetes, with the same number of undiagnosed people in the community. 
Type 2 diabetes accounts for more than 90% of diabetes in New Zealand, and is 
managed and treated primarily in primary care. Prevalence rates for type 2 diabetes 
increase with age and there are clear differences between ethnicities in New Zealand. 
Pacific Island and Indian populations have the highest prevalence rates followed by 
Māori and European (Ministry of Health, 2018). 
 
1.15.3 Diabetes prevalence in Tairāwhiti 
The following Tables (1 and 2) present the estimated number of people with diabetes in 
Tairāwhiti for 2005/2006 (prior to data collection for this study). This data is provided 
and modelled by the Tairāwhiti District Health Board, using 2006 NZ Census population 
data, and includes type 1 and type 2 whanau with diabetes aged 25 years and over. The 
count for Asian is included in “other”. The data utilised in the study is prior to the 
establishment of the Virtual Diabetes Register (see below). 
In Tairāwhiti, an estimated 4.23% of the population had diabetes. Data findings in 
chapter four, Figure 13 illustrate the prevalence of type 2 diabetes is far greater for 















Number of  
new people with 
type 2 diabetes 
 
Number of  
people with type 1 
diabetes 
 
Number of  
people with type 1 
and 2 diabetes 
Total 1,683 129 133 1,816 
Māori 1,041 90 55 1,096 
Pacific 20 2 1 21 









In 2007, the Ministry of Health, in collaboration with experts from the New Zealand 
Society for the Study of Diabetes (NZSSD), established the Virtual Diabetes Register 
(VDR). This register combines and filters various sources of health information to more 
accurately determine how many people are diagnosed with diabetes, as well as predict 
who is likely to develop it in the future? The VDR uses data from national databases. 
These include; hospital admissions coded for diabetes; outpatient attendances for 
diabetes; diabetes retinal screening; prescriptions of specific antidiabetic therapies; 
laboratory orders for HbA1c and primary health (general practitioner) enrolments. The 
VDR is the official tool used to determine the prevalence of diagnosed diabetes in New 







people with type 
2 diabetes 
 
Number of  
new people with 
type 2 diabetes 
 
Number of  
people with type 1 
diabetes 
 
Number of  
people with type 1 and 
2 diabetes 
Total 1,748 136 137 1,885 
Māori 1,090 96 57 1,147 
Pacific 23 3 2 25 
Other 635 398 79 714 
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1.15.4 National diabetes related policies and services 
The Ministry of Health, as the governing agency, developed numerous diabetes and 
diabetes related policies, toolkits, standards and guidelines, and set national health 
targets and goals, to be administered and monitored by each of the District Health 
Boards. 
The “Get Checked programme” was operational (June 2002 to 2011) during the study 
period (MOH 2007). This national programme offered a free annual diabetes review for 
all whanau with diabetes in New Zealand, to assist those with diabetes better manage 
their condition, reduce their risk of complications, and improve outcomes by: 
• systematically screening for the risk factors and complications of diabetes to 
promote early detection and intervention (in accordance with evidence-based 
guidelines). 
• agreeing on an updated treatment plan for each person with diabetes. 
• updating the information in the diabetes registers used as a basis for clinical audit 
and planning improvements to diabetes services in the area. 
• prescribing treatment and referring for specialist or other care if appropriate. 
The Ministry of Health reviewed the “Diabetes Get Checked” programme in 2011. The 
review identified the programme was not making any noticeable improvement for 
people with diabetes and the programme was discontinued. 
 
1.15.5 Diabetes services in Tairāwhiti 
Diabetes services located in Tairāwhiti during the study were limited. Monthly clinics 
were held at the local hospital by visiting diabetes related specialists (renal, 
diabetologist, cardiologist) from either the Waikato or Hawkes Bay DHBs. Acute 
admissions to secondary care related to diabetes were managed in general medicine 
services, and a diabetes nurse specialist (0.6 FTE) was located in secondary care. There 
was limited ophthalmology and retinopathy services; laser treatment clinics only 
processed urgent work. The renal service had one physician available for 16 hours 
every three months with a focus on patients receiving continuous ambulatory 
peritoneal dialysis (CAD). Haemodialysis patients were transferred to Waikato DHB. 
Funded podiatry services for diabetes were also limited. 
Local Diabetes Teams (LDT) were established in regions around New Zealand to 
 
33  
provide coordination and support related to diabetes. Tairāwhiti Local Diabetes Team 
(LDT) were somewhat fragmented and lacked cohesion. The LDT was physically located 
in Hamilton with the Midlands LDT at Waikato DHB (a five-hour drive by car) (Brady, 
2007). Outreach clinics were held by specialist services (dietetics, diabetes, renal, 
cardiac, podiatry) on the East Coast and Western rural areas for whanau with diabetes 
located in these areas. 
 
1.15.6 Diabetes in Primary care in Tairāwhiti 
Diabetes related projects were funded and supported by the Tairāwhiti District Health 
Board and Primary Health Organizations in 2000. The impact of these projects on the 
whanau with diabetes is difficult to determine. The projects raised the profile of 
diabetes for health professionals and in the community. These projects ran concurrently 
with the “Get Checked” programme (the national initiative described above). The 
Tairāwhiti District Health Board “Get Checked” programme covered less than 60% of 
whanau with diabetes, 46% were Māori for the year ended 2006. The number of 
diabetes annual checks completed in the “Get Checked” programme in Tairāwhiti 
declined from 639 in 2004/2005 to 558 in 2005/2006, and increased to 624 in 
2006/2007 (Ministry of Health, 2007). 
 
1.15.6.1 Tūranganui Primary Health Organization projects:   
In 2001, two Independent Practice Associations (IPA), First Health and Pinnacle joined 
with Turanga Health (local Māori Health provider) to establish the Tūranganui Primary 
Health Organization (TPHO). The IPA groups represented the general practices in 
Gisborne, except for Te Karaka medical centre – a designated “Special Area” practice, 
which at the time was owned and managed by the Tairāwhiti District Health. Diabetes 
related projects included: 
• Cardiac Disease Risk Assessment – this project targeted Māori and Pacific Island 
males aged 35 – 60 years at increased risk of cardiovascular disease with 
interventions to reduce overall risk. 
• Diabetes programme – a managed approach that included promotion, detection 
and diabetes management. 
• Ischaemic heart disease - identifying those at high risk and ensuring those 
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individuals received best practice according to the National Heart Foundation. 
• The Health Right programme - to support people to manage their chronic 
conditions. 
• Waiting Times project – facilitating and transporting whānau to out 
patient’s department appointments for specialist services including 
diabetes clinics, cardiologist, ophthalmology clinics, and retinal screening 
(Brooking, 2005). 
 
1.15.6.2 Ngāti Porou Hauora Primary Health Organization projects 
In 2002, Ngāti Porou Hauora was established as a Primary Health Organization (Abel, 
Gibson, Ehau & Tipene Leach, 2005). Ngati Porou Hauora, owned and managed an 
urban general practice, the five clinics along the East Coast, and a six-bed hospital 
located in Te Puia Springs. It also provided: 
• Community transport for patients from the rural areas to attend specialist 
appointments in the city, for example renal specialists. 
• Monthly podiatry clinics on the East Coast. 
• Ngāti and Healthy Prevent Diabetes Project targeted at the population to make 
positive changes in lifestyles. The was a two-year community diabetes 
intervention, that aimed to reduce the prevalence of insulin resistance. 
• Mobile Māori nursing services in the community targeted patients with chronic 
conditions including whanau with diabetes (Green & Collins, 2005a; Ministry of 
Health, 2005). 
 
1.15.6.3 Tairāwhiti District Health Board projects:  
The Tairāwhiti DHB carried out the following projects around the time of the study: 
 
• A diabetes mapping project was completed, tracking the overall journey of 
people with diabetes through the diabetes services. The project also identified 
draft objectives, and an action plan developed with key stakeholders. 
• Diabetes referral pathways were negotiated with general practice to reduce 




• Continuous ambulatory peritoneal dialysis (CAPD) and haemodialysis patients 
were supported by a part-time hospital-based renal nurse and renal services at 
Waikato Hospital for the whole region. 
 
The number of diabetes related amputations for the region is unclear. People 
requiring this service mostly transferred to Waikato Hospital and were followed up in 




1.16  Discussion 
The intent has been to highlight for the reader, the complexities and context of the 
region, and the rationale for undertaking the study. The study has personal meaning, as 
a Māori, to describe the ordinary “lens” the thesis is grounded in. Although descriptively 
“ordinary”, as a health professional – it behoves me to suggest, Māori should not accept 
“ordinary”. Moreover, look to generate change, and be the change agent. 
Rich in history, Tairāwhiti is a unique place to live. The prevalence of type 2 diabetes is 
greater for Māori than non-Māori. Māori experience poorer diabetes outcomes and bear 
the greater burden of premature mortality and diabetes related co-morbidities, 
compared with non-Māori. A high proportion of Māori live in Tairāwhiti relative to New 
Zealand, and there is a large cohort of youth, particularly Māori (under 35 years) living 
on the East coast and rural areas of Tairāwhiti, where access to diabetes related 
specialist services and care is poor. People have to travel a considerable distance to 
receive specialist health services and care. In the near future services will need to be 





2 Chapter 2: Kaupapa Māori 
 
 
“To ngākau ki ngā taonga a o tūpuna” 
 
“let your heart cherish the treasures left to us by our grandparents” 
 
 
“Turanga tangata rite” 
 
“Turanga people are all equal – no one stands above the other” 
 
The double meaning inherent in the term “rite” – also refers to collective action – acting 
together as one Turanga. Rangatira of Turanga, gaining mana is by actively maintaining 
a balance in obligations and connections, so that in times of crisis or need people are 
drawn together not apart (Whakataukī – Waitangi Tribunal, 2004). 
 
 
2.1 Māori Philosophy (epistemology) 
Māori had an extensive knowledge base, with systems and processes for sharing and 
protecting knowledge before European arrival in Aotearoa (New Zealand). The advent 
of colonisation introduced different perspectives and philosophies to the indigenous 
population (Māori). These had a profound influence and impact on the traditional ways 
of living and knowing. Over time, colonisation became entrenched in New Zealand, and 
Māori became marginalised. The impact of urbanisation took effect, as early as the 
1920’s, slowly eroding the traditional Māori way of life and knowing. 
Māori wellbeing embodies a holistic philosophy. It encompasses many dimensions, and 
each dimension is interrelated and viewed collectively to form a whole. These 
dimensions are the foundation of wellbeing and Hauora. 
The use of Māori kupu (words) are interspersed throughout the thesis, so as not to lose 
meaning and context in the text. The glossary (page xxii) and footnotes are to support 
the reader in understanding the meaning of the dialogue and the text in te reo Māori. 
Kaupapa Māori emerged as part of the wider ethnic revitalisation movement in New 
Zealand, following the rapid urbanisation of Māori post WWII period. Stalwarts Donna 
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Awatere (1981), Dr Ranginui Walker (1989) and the Black Panther movement to name 
a few, gained momentum and fruition in the 70s and 80s, as political consciousness 
increased among Māori communities. 
Kaupapa Māori – literally means a “Māori way” of doing things and the concept of 
Kaupapa denotes a way of framing and structuring how we think about and do research 
with and for whānau, hapū and iwi. In the context of this study, Kaupapa Māori means 
ensuring the appropriateness of both methodology (a process of enquiry that 
determines the methods applied) and method (tools to produce and critically analyse 
data). Kaupapa Māori approaches incorporate those methods in relation to tikanga 
Māori (Māori values and practices) and provide ethical guidance for research with 
Māori and their communities and the researcher. These include: Manaakitanga15, 
Kotahitanga16, Whānaungatanga17, Rangātiratanga18, are discussed in Table 3: 
• Respect for people (aroha ki te tangata) 
• Being a face that is known in the community (kanohi ki tea) 
• Looking and listening before speaking (titiro, whakarongo, kōrero) 
• Being humble (ngākau māhaki) 
• Being careful in our conduct (kia tūpato) 
• Ensuring we uphold the mana of all people (kaua e takahia te mana o te tangata) 
 
Kaupapa Māori underpins this thesis, which is guided by the tikanga19 mo Te Hauora o 
Tūranganui a kiwa20. This enables the author to articulate and give “purpose and 
meaning” to a “Māori way” in terms of research. A “Māori way”, is who I am and the 
premise in which the study is undertaken. As researcher and participant, I am neither 
one nor the other, but one and the same. It is through this lens of Māori as ordinary in 
the context of this study, that I will endeavour to describe for the reader. 
The aim of this chapter is to contextualise a te ao Māori perspective, by applying the 
tikanga mo Te Hauora o Tūranganui a Kiwa (Turanga Health), as the research 
                                                             
15 Manaakitanga – hospitality, kindness, support 
16 Kotahitanga – unity, togetherness 
17 Whānaungatanga – kinship, relationships 
18 Rangātiratanga – self-determination, autonomy 
19 Tikanga – Māori values and protocols 
20 Te Hauora o Tūranganui a kiwa – Turanga Health 
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methodology and analysis. A culturally responsive method that includes: mātauranga21 
Māori, kaumātua and kuia for their advice, support and guidance to the research and 
the researcher. This will also aid with transparency, humility, valuing of relationships, 
collaborative sense-making and transformative praxis (shifting from the status quo of 
inequity to equitable outcomes). 
Te Hauora o Tūranganui a Kiwa (Turanga Health) is an iwi health provider (my 
employer) based in Tūranga (Gisborne), with a vision “Kia whai oranga-a-whānau mo 
nga whakatipuranga” – “building family wellness for future generations”. The three 
stakeholders of Te Hauora o Tūranganui a Kiwa, are tangata whenua iwi 
(Rongowhakaata, Te Aitanga-a-Māhaki and Ngāi Tamanuhiri), who as the author I 
whakapapa to. Permission for the study was approved by Turanga Health, Chief 
Executive (R. Ropiha) (2006) and Board chairperson (Pehimana Haapu Brown). 
Tikanga comes from an accumulated knowledge of generations of Māori, and 
mātauranga Māori (Mead, 2003). The following core tikanga principles provide the 
framework that underpins and informs the thesis. These tikanga innately link to the 
unique characteristics and features of Te Hauora o Tūranganui a kiwa tūpuna22. Table 3 
describes these tūpuna and what they mean in contemporary settings and practice. The 
detail and content of chapter two, and Table 3, are taken from two unpublished papers; 
Albert Stewart (1995) and Professor Derek Lardelli (1989). These authors articulate 
and translate the meaning of whakapapa and tikanga for Te Hauora o Turanganui a 
kiwa into practice. It is from these sources and those words and advice from kaumatua 
and kuia in my community that I have drawn on, that gives me confidence in 
articulating and presenting the framework in Table 3 as a foundation in which the 
thesis is centred.  
I acknowledge there are expert scholars and researchers in the field of Kaupapa Māori 
and Māori ways of knowing that are nationally and internationally recognized for their 
work. This in its self would be a thesis. The intention of chapter two is to describe and 
provide the authors perspective of a Kaupapa Māori framework, and what this means 
to and for me as the author, in terms of the research, and how Kaupapa Māori best 
serves and guides the research and the researcher.  
                                                             
21 Mātauranga - knowledge 
22 Tūpuna - ancestor  
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2.2 Tikanga mo Te Hauora o Tūranganui a Kiwa 
 
Table 3: Characteristics of Tūpuna, Tikanga and Practice 
 
Tūpuna Tikanga - values Practice 
 
Ruapani – “Mana Atua” 
 
(Is the paramount chef of 
the Tūranganui tribes) 
conveys the characteristics 
of being peaceful and 
humble. He descended 
directly from ancestors 
such as Paoa, Kiwa and 
others from the Horouta23 
migration. He governed in a 
peaceful manner. The 
remnants of his pa, Popoia 
can be seen by a disused 
meat works by the Waipaoa 
river. Ruapani died at 
Arakanihi near Mohaka, his 
remains were taken to 
Wharekōrero, Wainui and 









Being peaceful in nature 
during times of turmoil. 
Actions speak louder than 
words in a harmonious 
amicable manner. Humility 




He ngākau whakaiti 
 
The importance of 
acknowledging the worth of 
others and recognising 
their contributions, not 
criticising or shaming 
others or yourself. Allowing 
one’s integrity to be intact 
no matter what situation 
may arise. 
   
                                                             
23 Horouta – name of a waka 
24 Ngākau – heart, mind, soul 
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Hinenui and Tamanuhiri 
 
Tamanuhiri had three 
wive’s, and persuaded 
Hinenui to be his wife. 
Hinenui initially thought 
she would not be 
considered, as a previous 
union did not bear children. 
To Hinenui’s delight, she 
became pregnant. She then 
utters the words: “Taku hē 
ki te huatea, nō muri ko te 
huauri” (first, there was 
childlessness, then fertility). 
Huauri (fruitfulness) 
became a name for 





To persevere and keep 
going and have courage 
even in the face of adversity 
and to keep trying. Bringing 
to life teachings of the past 
within contemporary times. 
Determination will 
eventually bear fruits to 
those that persevere. 
Kia pono ai ke to Kaupapa 
 





Descended from the 
Horouta waka. She had 
relentless courage and 
exceptional knowledge of 
planting, carrying the first 
kumara seed from Te 
Wherowhero25 to 




Obligations of stewardship. 
The quest for exceptional 
knowledge and being 
relentless and unselfish, 
demonstrating courage for 
the benefit of others. 
 
Manaaki te tangata 
 
Providing support and 
encouragement to others is 
important. Welcoming 
people and seeing to their 
needs is just as important 
as making yourself, them 
and their environment safe 
so that all can participate. 
                                                             
25 Te Wherowhero – Turanga waterway/lagoon 
26 Manawaru – name of mountain 
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This unselfish act ensured 
an abundance of food to 
enable the tribe to survive. 
 
Te Kooti Rikirangi 
 
Unjustly incarcerated on 
Wharekauri27. He escaped 
from there and returned to 
avenge his wrongful 
imprisonment. Renowned 
for his strategic warfare 
using the natural elements 
to evade the militia for over 
fifteen years. Eventually 
pardoned by the 
government. His ability to 
foresee future events set in 
place the foundations of the 
Ringatū church. He acted 
with conviction and often 
set himself impossible tasks 










Illusive and strategic 
thinker. 
The practice of sharing with 
others for mutual benefit. 
 
Pūmau ki te Kaupapa 
 
It is equally important to 
ensure that high standards 
are maintained and to act in 
a manner that is fair and 







Whakamana i te tangata 
 
                                                             
27 Wharekauri – Chatham Island 
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Renowned for his wit and 
valour. Remembered 
mainly for his actions and 
not necessarily for the 
person he was. 
 
Strategic-Kōrero28 face-to- 
face, quick and humorous 
manner. Being prudent and 
witty, to stay ahead of 
things. Skilled in the use of 
words and ideas. 
Where people come from, 
sets the basis for 
acknowledging that you are 
speaking to someone who 
has a whānau, hapü and iwi 
with them. The focus is then 
on the actions of people, not 




The tūpuna described is by no means a comprehensive list. There are many tūpuna 
worthy of mention; the intent is a descriptor of relevant tūpuna and the tikanga mo Te 
Hauora o Tūranganui a kiwa. Each of these tūpuna (Table 3) guided and provided the 
principles on which the thesis is undertaken. 
As the author, I have applied these tikanga (values and practices) as described in 
Table 3, to the thesis, this is to ensure the research; values and respects te ao Māori 
and mātauranga Māori (my Māori worldview, the whānau that participated in the 
research and their whānau support, as a Māori way of knowing). The methodology 
applied is appropriate for this thesis, as I whakapapa to the local iwi of the region, and 
Kaupapa Māori informs my cultural beliefs and perspectives. In addition, the focus of 
the study are Māori with type 2 diabetes, living in a region where half the population 
are Māori (Tairāwhiti). As part of the reflection and process of Kaupapa Māori 
research, the following is a personal testament of my journey that describes my place 
in the community, which informed my approach to this research. 
                                                             
28 Korero - talk 
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2.3 My story 
 
We grew up in a small rural community that was predominantly Māori, in Tairāwhiti, 
where everyone knew most of the whānau in the community. Our parents were raised 
in the same rural community, as had their parents and grandparents (my great, great 
grandparents). Whakapapa linked us to many of the whānau and connected you to 
who you are, a sense of belonging and security to this place, our tūrangawaewae. 
Like many other Māori whānau from small rural communities in New Zealand, our 
parents worked mostly in labouring jobs: horticulture (fieldwork, orchards) and 
domestic duties. Dad was also a tradesman for many years. We also cropped 
(vegetables) on whānau land, to sell at the market. As children and teenagers this was 
after school and holiday jobs – along with the paper run. 
Dad worked for a few companies over the years, then as a sole trader in his later 
years, until he was diagnosed with Alzheimer’s. He was often asked by whānau to the 
Marae, to unblock toilets or drains, or build water tanks. Payment was sometimes in 
kind, a favourite Aunt made delicious brawn29 or Māori bread, someone dropped off 
home kill, lamb tails or kaimoana (seafood), or whānau would plough a paddock for 
cultivating. These are examples resonate and reflect the practice of reciprocity, 
manaaki, awhi and tautoko (to support, advocate). 
We went to the same school our parents attended; during their time if they were 
caught speaking Māori at school they were punished (in the 1940’s). We were not 
encouraged to learn Māori, although Dad often used Māori words in conversation. Our 
Nanny (Mum’s Mum) cared for us, after school, so Mum could work. Our grandparents 
lived nearby in an old whare30. Their kāuta31, was a dimly lit room, with a dirt floor, 
no electricity, an open fire for cooking, one room, where everyone slept (top and tail). 
There was always kai32 at nanny’s house, preserving or bottled kai or kai in the pot or 





                                                             
29 Brawn – prepared meat product 
30 Whare - house 
31 Kāuta – cooking shed, shack, lean to 
32 Kai - food 
33 Manaaki - hospitality 
34 Aroha – love, empathy 
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their whare. These same principles of manaaki, aroha, tautoko, and reciprocity are 
applied during the research process. 
Nanny was a kind woman and would give you her last dollar. As a member of the 
local Māori Women’s Welfare League, she and a friend would travel by bus to 
different hui, meeting new and old friends and whānau. Grandad was a pakeha, who 
worked hard and drank hard, usually flagons of beer and smoked “rollies” (roll your 
own) cigarettes with his mates. They would gather around at the different homes 
sharing stories and a flagon or two. 
My parents were from large families: Mum is one of 12 and Dad is one of 8. When they 
were growing up Dad and his siblings were raised by different whānau members. 
Mum was raised with most of her siblings and they often had extra whānau staying 
with them. A couple of the siblings went to live with other whānau in different 
communities. They had very little in the way of material “things”. Sharing food; beds; 
clothes were second or third hand, sometimes fourth hand me downs. Shoes were 
unheard of - so too were lollies and takeaways. Milking cows (by hand) was a shared 
daily morning chore. We often heard the story of standing in cow poo to keep their 
feet warm during the cold mornings. Washing was in a tub outside, but first you had 
to light the fire to heat the water in the copper outside, and that required some effort. 
Options for washing were the tub or the river or not washing. My parents, aunties and 
uncles recount many wonderful stories and memories. 
Dad and a cousin were whāngai35 to an older aunt (pakeke36). They were adored by 
“Nanny Missus”, she cooked, washed, cleaned, and polished their shoes. At home, 
they conversed in Māori and very little English. Although Dad understood and 
spoke Māori, he very seldom spoke Māori to us growing up. As a young man, he 
worked on the land and with horses. He kept the company of older men folk who 
drank, smoked and played “2 up” (a gambling game). 
Mum worked in mostly domestic duties when she left school, and looked after 
younger siblings or cousins. She moved to the South Island (“urbanisation”) with 
other women from the same community, in the 50’s for work. Some of the women 
married and stayed in the South Island. 
 
 
                                                             
35 Whāngai - foster, adopt 
36 Pakeke - adult 
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We lived a short time in Te Teko (aka “Texas”) in the early 60s, Dad worked on the 
Matahina hydro dam. We had a cousin who stayed with us and in the weekends, we 
would drive (an old car and gravel road) with other families to the beach to gather 
and feast on fish, pipi37 and cockles. We returned to Gisborne and lived down 
“Gumboot lane”, with “Nanny Missus”, a long drop toilet and a bathroom (dad built), 
with a real bath, (we lit the fire to heat water in the copper for the bath). Our cousins 
lived in the only other house down “Gumboot lane”. Our whare was always warm and 
clean. There was a bucket for the toilet at night, (no torches) and in the night that 
bucket would never be there in the morning (in town, some houses put these buckets 
out for the “night cart” to collect). There were many fond memories and experiences 




A significant milestone for my parents was buying their first home, with the 
assistance of the Māori Affairs Department in the late 1950’s. The whare (house), our 
papakāinga (home) continues to be a whānau home, a central point, a gathering place 
for our whānau. Our parents continued to crop whānau land. Dad kept his trade job 
and Mum worked in the local orchards and vineyards. We thought we were really rich 
when we had a black and white television and were kept busy as rangatahi (youth), 
helping out, doing jobs (harvesting, weeding, and planting). We all played sport, Dad 
played badminton, cricket, golf and rugby and was a rugby referee. Mum played 
softball, hockey, golf, and was a hockey representative and coach. 
We lived across the road from one of five local Marae in the community. This was 
where Mum’s gran-uncle lived for a time, a room off the dining room, at the Marae. He 
cooked on the open fire, in the old kāuta. I only ever saw him in shorts and he smoked 
roll your own cigarettes aka “rollies”. Sometimes you would hear him playing the old 
piano in the Marae dining room. I am not really sure how he came to be there, or 
where he went to, perhaps he was eccentric. He would be considered a recluse in 




                                                             




The Marae - a place, for many different events and occasions: birthdays, tangi, hui, 
weddings, Sunday school, kapa haka practice, fundraising activities and card games 
(euchre/manilla – the old, mainly nannies would play all night and into the next 
morning). Sometimes people stayed for a few days and nights, and there would be lots 
of food; eating; laughing; dancing; drinking; smoking; singing. It was a real social time 
of whānaungatanga and manaaki. What is unique and fascinating about the Marae (as 
alluded to in chapter 1), was that to me, whānau knew what to do in preparing the 
Marae, whatever the occasion. Some prepared the whare moe (house where you 
sleep, beds were mattresses on the floor – being shown, how and which way to place 
the opening of the pillows), preparing the veranda for the tūpāpaku (deceased) and 
the whānau pani (family of the deceased). Certain whānau would do kaikaranga or 
whaikorero at the Marae. At the back in the whare kai (house where food is) whānau 
would prepare and cook kai. Within that whānau grouping some gathered kai, 
watercress or puha, while another made the best cakes, pavlova, or went out diving 
for kaimoana (seafood), making rewena bread, getting wood for the hangi. All these 
were whānau expertise and specialist skill sets. The Marae ran like a well-oiled 
machine (with no written operational manual). 
 
Present day 
We moved from the city to give our children the opportunity to experience the rural 
life and connect with their whakapapa. Tūranganui a Kiwa is their place, wherever life 
may lead them. We also wanted to have some time with my aging parents. 
Professional careers were unheard of in our “working class” whānau, so my parents 
were very proud of our whānau achievements. I wanted to put my skill set to use and 
help people in the community. And so, the family settled in, as we got on with life’s 
busy happenings (a frail parent with dementia, and we were blessed with baby 
number three and our first mokopuna). 
As a health practitioner in the community, what was noticeable was the absence of 
whānau in the community: kaumatua, kuia, pakeke, ringawera had died or moved for 
work (many to Australia). These were whānau who support and maintain the 
function of the Marae. Who in the community had the knowledge to carry out these 
 
47  
important roles at the Marae: kaikaranga38, whaikōrero39, ringawera? Was that 
knowledge lost, or was this handed onto other whānau? 
The challenge was to retain and maintain the integrity of mātauranga Māori, tikanga 
and whakapapa, and to transform that knowledge of kawa/custom and practice to 
best fit with contemporary times and our new generation of millennials. This has 
spurred broader questions on the sustainability of whānau, hapū and iwi; and the 
inanimate places of Marae, awa, maunga, whenua, Te reo Māori that interconnects 
whānau, hapu and iwi. 
As a health practitioner, you are often called upon for advice, advocacy and support 
on a myriad of health and non-health related issues and challenges. It is an organic 
process, and happened naturally, and I am happy to serve my community, it was like a 
return to the community, at the time I did not really understand what this meant. I 
felt it was a return of the love and nurturing we received as siblings while growing up, 
from those around us (our parents, grandparents, aunties, uncles, and cousins). I have 
been fortunate to “give back” to the community in many ways, supporting kuia from 
the Marae to the emergency department, walked alongside whānau when a loved one 
dies at home or sitting with whānau as they take their last breath, and watch our 
mokopuna take their first breath. 
As a community, they are proud and celebrate your achievements as one of their 
“own”. I was fortunate to secure employment as a Health Professional with an iwi 
Māori Health provider (Turanga Health) for many years, working fortuitously 
legitimises some of the work (not all) in the community and provides an opportunity 
to access additional services for whānau. With the multiple accountabilities, and a 
Health Professional potae, I am humbled and privileged to work with whānau, 
providing services in the communities of Tūranganui a Kiwa, for Turanga Health, an 
organization that practices within a holistic Māori Kaupapa framework. This reflects 
who and where I am grounded, and formulates the basis in which this research is 
embedded. The study is an accumulation of explicit and tacit learnings that have 
occurred over time during my own transformative change and continues to shape 
how I perceive and understand my worldview. 
 
 
                                                             
38 Kaikaranga – woman ceremonial call 




This chapter describes tikanga (values and practice) that are appropriate and relevant 
to the study, are grounded in the tikanga mo Te Hauora o Tūranganui a Kiwa and guide 
my research process. The chapter described how these tikanga are linked to my tūpuna 
and their characteristics. These have been discussed using examples in my story to 
illustrate these principles in practice and how they relate to the study. 
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This chapter provides background information on the topic of the thesis. It also 
describes existing research related to the topic. As noted in the earlier chapter (one) the 
focus of this thesis is Type 2 diabetes, rather than Type 1 diabetes. Type 2 diabetes 
accounts for approximately 90% of the diabetic population in the world, and has 
significantly greater consequences for indigenous populations around the world 
(International Diabetes Federation, 2017). 
The goal of diabetes treatment is to maintain good glycaemic control (that is blood 
sugar levels within the recommended parameters) (PHC 2012, MOH) to delay onset of 
complications. Clinical markers are one measure of the effective management and 
treatment of diabetes. Data has shown that improving clinical markers can reduce a 
patient’s risk of a cardiac event (UK Prospective Diabetes Study (UKPDS) Group, 
1998b). Clinical markers measure how well diabetes is managed. Diabetes that is not 
managed well creates a significant financial burden as well as additional mortality and 
morbidity. 
This literature reviews examines Māori specifically, but also other indigenous 
communities in other countries. In discussion with my supervisors, the author focuses 
the literature review on indigenous populations in Australia, Canada and the United 
States of America (USA). These countries had primarily been colonised by the British. 
In addition, the author reviewed literature on medicines use and access to medicines 
in rural areas. 
The methodology applied to identify relevant literature is provided for the reader, 
and followed by a description of the literature on Māori and diabetes; indigenous 
people and diabetes; Māori medicines use and access; indigenous medicines use and 
access; and rural medicines use and access. 
The goal was to produce a narrative literature review that describes relevant literature 
and important concepts related to the topic. It was not the intention to identify all 




This review includes published academic work (articles) and government publications. 
In all searches items such as letters, editorials, reviews, notes, meeting abstracts, and 
commentaries were excluded. 
Initially search engines; Scopus, Ovid, and Web of Science were used. Search terms used 
included: “Māori”; “Type 2 diabetes” and “medicines”. After reviewing the results of 
these searches, the remainder of the search were carried out in Scopus only. Scopus 
identified relevant material, and it had additional functions that allowed us to efficiently 
limit the search in useful ways. 
In order to identify literature on indigenous populations, Wikipedia was used to 
identify synonyms of ‘indigenous’. This produced “native”, “aboriginal”, “inuit”, 
“amerindian”, “indian”, “first nation”, “eskimo” and “metis”. These terms were used in 
searches for literature about indigenous communities outside New Zealand. The search 
was limited to countries of interest: Australia; Canada and the USA. These are similar 
to New Zealand, as far as they were settler colonies by European countries, and English 
is the primary language. The following thread was used to identify literature on 
indigenous people. KEY (indigen* OR native* OR aborigin* OR inuit* OR amerindian* 
OR american AND indian* OR first AND nation* OR eskimo* OR metis*). 
 
Subject areas were (medicine, nursing, social science, psychology, health professions, 
arts and humanities, economics and multidisciplinary). To search for articles on 
medicines, the following search thread was used (medicine* OR drug* OR 
medication*). To search for literature on access and use of medicine, the following 
thread was added (access* OR barrier* OR inequit* OR disparit* OR inequali* OR use 
OR consumption* OR utilisation*). The literature search on rural medicines use and 
access was not restricted to particular countries. The results were exported to 
Endnote and saved to an Endnote library. The search was extended by scrutinising 
the references of selected articles to identify additional studies that may have been 
missed. The abstract of each of the references was reviewed to identify whether it was 
relevant and discarded if not. To assist with summarising the key themes, the articles 




3.3 Māori and Diabetes 
There were 59 relevant papers. These are grouped into: 
 
• Prevalence 
• Management and treatment 
• Knowledge and attitudes 




High rates of diabetes among Māori have been reported since the early 1960’s (Prior & 
Davidson, 1966; Prior, Rose, & Davidson, 1964; Simmons, Gatland, Leakehe, & Fleming, 
1996), and there is a large body of evidence reiterating that Māori experience a greater 
prevalence of type 2 diabetes than non-Māori (Pacific Island, European and other 
ethnicities) (Sundborn et al., 2007). 
There are a number of cross-sectional studies in a variety of settings, such as GP 
practices (Joshy et al., 2009; Simmons, Kirkwood, et al., 1999), community (Simmons, 
Gatland, Fleming, Leakehe, & Scragg, 1994; Sundborn et al., 2007), urban (Simmons, 
Harry, & Gatland, 1999), rural (Tipene-Leach et al., 2004) and worksites (Scragg, Baker, 
Metcalf, & Dryson, 1991), that have assessed diabetes prevalence. 
These studies have found the prevalence of diabetes ranged from 5.2% to 10.6% for 
Māori (Simmons, Harry, et al., 1999; Tipene-Leach et al., 2004). The lowest diabetes 
prevalence was in an urban setting (Simmons, Harry, et al., 1999), and the highest 
prevalence of diabetes was in a community setting (Tipene-Leach et al., 2004). 
The prevalence in Māori compared to non-Māori was 2.8 to 3 times greater, and 4.1 
times greater for Pacific than European people over 40 years (Joshy et al., 2009; Joshy & 
Simmons, 2006; Sundborn et al., 2007). The overall prevalence increased with age, with 
the greater portion over 65 years (Sundborn et al., 2007). The risk increased for Māori 
aged 45-54 and 55-64 years (Simmons, Gatland, et al., 1994; Sundborn et al., 2007). 
The prevalence was greater for males (9.7%) than females (6.2%) (Joshy et al., 2009), 
and increased for those that were obese and living in high deprivation (Joshy et al., 
2009; Scragg et al., 1991; Simmons, Rush, & Crook, 2009). 
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These studies found the prevalence of undiagnosed/prediabetes was higher for Māori 




3.3.2 Knowledge and attitudes 
There was evidence that Māori patients with diabetes experience gaps in their 
knowledge of diabetes (Kenealy, Eggleton, Robinson, & Sheridan, 2010; Kirkwood, 
Simmons, Weblemoe, Voyle, & Richards, 1997; Lawrenson, Joshy, Eerens, & Johnstone, 
2010; Simmons, Shaw, Kenealy, Scott, & Scragg, 1994). A cross sectional survey of newly 
diagnosed whanau with diabetes aged 20-89 years in the region of Waikato, New 
Zealand (4- page questionnaire) was conducted (Lawrenson et al., 2010). Māori scored 
lower across the study in perceived knowledge. A survey of whanau with diabetes in 
South Auckland compared ethnic differences in diabetes knowledge and education (331 
European, 86 Māori, 123 Pacific Island participants) and a sub-sample of general 
practitioners (GP) (Simmons, Shaw, et al., 1994). Knowledge scores were higher in 
those who had received education at diagnosis. Europeans were least likely to want 
further education (Europeans 52%, Māori 69%, Pacific Islands 63%, p < 0.01). The 
preferred sources for ongoing education were the lay educator/diabetes nurse 
specialist service (Europeans 28%, Māori 37%, Pacific Islands 76%), and the hospital-
based clinic among Europeans (27%) and Māori (36%) (Simmons, Shaw, et al., 1994). 
Most of the education provided in the Lawrenson study (2010) is provided by their 
general practice from a GP/nurse. Simmons, however found that whanau with diabetes 
preferred ongoing education from the lay educator/nurse specialist service and the 
hospital clinic for European and Māori, while few of the whanau with diabetes preferred 
their education via their general practitioner. Patients wanting more education knew 
more than those who did not. The local delivery of diabetes education is uneven and 
diabetes services need to be better coordinated and integrated in primary care 
(Simmons, Gatland, et al., 1994). 
Lawrenson found that 93% received some diabetes education at diagnosis. The level of 
education received was the same between ethnicities although as noted above, Māori 
had lower levels of knowledge. Whanau with diabetes received the appropriate 
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information about diabetes at the time of diagnosis, but there was scope to highlight 
the importance of blood pressure and lipid control (Lawrenson et al., 2010). 
An earlier study in 1997 also found that knowledge of diabetes was limited amongst a 
rural Māori population. These authors stressed the importance of understanding the 
context and holistic view of health by Māori (Kirkwood et al., 1997). 
 
 
3.3.3 Experiencing diabetes 
There are very few qualitative studies exploring the lived experiences and views of 
Māori with type 2 diabetes. Handley et al., 2010 was a qualitative study that interviewed 
patients (n=9) in New Zealand (4=European, 4=Māori, 1=Samoan) to understand the 
day to day lived experiences of people with type 2 diabetes. They found similarities with 
international research: the impact of diagnosis of type 2 diabetes (T2DM); the 
difficulties adopting and adapting to complex self-care tasks; and managing chronic 
conditions on a daily basis. They also identified that primary support for self- 
management was enhanced by a person’s individual spiritual belief and their friends 
and family, rather than by health professionals. Self-management was more effective 
when patients had a stronger sense and understanding of their condition, but this was 
subject to their individual support mechanisms and systems. Future care and 
educational programmes should be tailored to the individual needs of the person and 
their support systems, which are culturally appropriate and reflect the principles of self- 
management (Handley, Pullon, & Gifford, 2010a). 
De Lore (1993) found participants in receipt of specialist diabetes services mostly 
named one or more complications, but hardly any knew about heart disease. While the 
majority were happy with the service received, a small portion would prefer Marae 




3.3.4 Management and treatment 
Studies (Agban, Elley, Kenealy, & Robinson, 2008) have shown that when the 
appropriate treatment and management of type 2 diabetes is implemented and 
monitored, positive clinical outcomes are achievable. However, a large body of evidence 
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(Ihaka, Bayley, & Rome, 2012; Marshall, Walker, Polkinghorne, & Lynn, 2014; McDonald 
& Russ, 2003a, 2003c; Simmons, 1998; Simmons, Clover, & Hope, 2007) concludes 
where diabetes is not effectively treated and/or managed, complications will manifest. 
This includes but is not limited to: loss of sight and or feeling and function of extremities 
and renal impairment. These complexities are a result of macrovascular and 
microvascular disease, the advanced progression of chronic disease. 
A range of studies show Māori are less likely to receive effective treatment and are less 
likely to have their diabetes well controlled (Atlantis, Joshy, Williams, & Simmons, 2016; 
Craig, Femia, Broyda, Llyod, & Howard, 2007; Daniels, White, Kyle, & Wong, 1997; Elley 
et al., 2008; Ellison, Elliott, & Moyes, 2005; Gentles et al., 2007; Ihaka et al., 2012; Joshy, 
Colonne, Dunn, Simmons, & Lawrenson, 2010; Joshy et al., 2009; Joshy & Simmons, 
2006; Keenan, Amey, & Lawrenson, 2013; Kenealy et al., 2008; Krebs et al., 2013; Mann 
et al., 2006; Marshall et al., 2014; McAuley et al., 2003; Sundborn et al., 2007; Tipene- 
Leach et al., 2004). 
An evaluation and review of aspects of the New Zealand primary care Diabetes Annual 
Review programme indicated that an evaluation of clinical measures indicated poor 
glycaemic control from baseline data for Māori and Pacific Island people (Agban et al., 
2008). Māori and Pacfic Island received a high rate of preventative drug therapy 
(cardiovascular and renal disease), compared to Europeans, but had a high prevalence 
of smoking, obesity and raised haemoglobin A1c (HbA1c) and albuminuria (Elley et al., 
2008). Non-Māori, people over 60 years, along with those that experienced more 
practice nurse than general practice time were shown to have a greater retention in 
programmes (Keenan et al., 2013). Improved clinical measurements (blood pressure 
and lipids management) for Māori and Pacfic Island participants, and an overall 
improvement with the management and treatment of diabetes coincided with the 
removal of restrictions on statin use (2002) and the introduction of Diabetes Guidelines 
2003 to improve management standards, possibly impacting on the clinical measures 
(Agban et al., 2008). 
The following studies show Māori are more likely to experience adverse outcomes from 
the complications of nephropathy, neuropathy and retinopathy (Bayley et al., 2008; 




1998; Simmons et al., 2007) (complications in eyes, kidneys, and feet). A household 
survey indicated the proportion of patients receiving no ongoing care or who were seen 
at least once by the diabetes services was similar across ethnicities, in an area with a 
high proportion of Māori and Pacific Island people, but there were significant ethnic 
differences in diabetes outcomes and their care (Simmons et al., 1996). 
A study (1983) at Middlemore Hospital found a high proportion of inpatient whanau 
with diabetes (Europeans 8%, PI 1%, Māori 28%) with chronic renal failure, while a 
further study (1995) of new patients (n=286) needing renal replacement therapy 
(RRT), identified 67% as Māori. This highlights the importance of diabetic nephropathy 
among Māori and Pacfic Island, while increasing the demand on RRT, as a result of the 
increasing incidence of type 2 diabetes. These characteristics of diabetic nephropathy 
differed, with proteinuria more common among Polynesians in five years of diagnosis. 
The numbers were European (5.4%), Māori (30.2%) and Pacfic Island (13%). It may 
also be attributable to the differences in glycaemic and blood pressure control 
(Simmons, 1998), and a later presentation and a progressive advanced disease state. To 
compare ethnic differences in diabetic retinopathy, participants with known diabetes 
were randomly selected from a household survey. Of those with type 2 diabetes, Māori 
had a 12.9% prevalence of moderate or more severe retinopathy, but overall, there 
were no significant ethnic differences in the prevalence of retinopathy or macular 
disease. This cross-sectional design study recruited participants with diabetes from two 
Māori Primary Health Organization’s (PHO’s), and despite their length of diagnosis and 
poor glycaemic management, there was no evidence of lower limb complications, and 
their knowledge of foot care was good. There was, however a high prevalence of pre- 
ulcerative lesions, that if undetected, may predispose the foot to ulceration, supporting 
the need to utilise appropriate podiatry screening and management, and mitigate risk 
factors for whanau with diabetes foot related complications (Ihaka et al., 2012). 
McDonald et al (2003) examined the Australia and New Zealand dialysis and transplant 
register over a nine-year period. The rate of end stage renal disease (ESR) was much 
higher for indigenous than non-indigenous populations. The average age of the 
indigenous population at the start of RRT was ten years younger than non-indigenous. 
The high rate of diabetic nephropathy among the indigenous population reflected the 




lung disease). Indigenous peoples receiving RRT were less likely than non-indigenous 
people to be on the transplant list or receive a graft, and the overall mortality outcomes 
for each of the RRT modalities was poorer for indigenous peoples (McDonald & Russ, 
2003a, 2003c). 
There is a high prevalence of peritoneal dialysis (PD) and home haemodialysis (HD) in 
New Zealand, particularly amongst Māori and Pacific Island populations. Another study 
investigated whether HD was associated with better survival than facility HD. Patients 
treated with PD and facility HD were similar, while patients on home HD were younger 
and healthier. There was a lower mortality risk for home dialysis patients than for 
patients receiving facility HD. Patients undergoing PD were associated with a lower 
mortality risk (20%) in the first three years, than those in the later three years of PD, 
where the mortality risk was greater (33%). This suggested better outcomes for 
patients in the first three years on PD (Marshall et al., 2014). Another study of prisoners 
(n= 438) (53% Māori) who were treated for diabetes showed that they had a high 
prevalence of previously unrecognised complications, and were admitted to hospital for 
diabetes-related health problems including self-induced hypoglycaemia or diabetic 
ketoacidosis (Braatvedt, Rowan, & Atherfold, 1994). 
Studies have reported high levels of diabetes-related hospitalisation and mortality 
amongst Māori (Jackson, Walker, Smith, Papa, & Field, 2009). Māori, Pacific Island and 
Indian patients were three times more likely to have a diabetes recorded admission 
than European, while the largest increase in admissions were amongst those aged 45- 
to 64-year-olds (Jackson et al., 2009; Jeffreys, Wright, Mannetje, Huang, & Pearce, 
2005). A study linking hospital discharge records and death records in New Zealand of 
whanau with diabetes compared to the general population, after adjusting for age and 
calendar period, found the mortality pattern of patients with diabetes was higher for 
both Māori women and men (Jeffreys et al., 2005). 
These studies found Māori patients experienced a higher risk of mortality compared to 
European whanau with diabetes and were more likely to die from cardiovascular 
disease, cancer and renal disease (Joshy et al., 2010). A study of whanau with diabetes, 
myocardial infarction or congestive cardiac failure between 1994 and 1999 found that 
Māori patients had 80% excess mortality, but if use of medicines (beta blockers, ACE, 
aspirin and statins) increased, risk factors improved (Kerr, Gamble, Doughty, Simmons, 
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& Baker, 2006). 
Structured programmes were found to be effective interventions to achieve positive 
clinical and psychosocial outcomes for Māori in some studies (Agban et al., 2008; Krebs 
et al., 2013; Mann et al., 2006; McAuley et al., 2003; Murphy et al., 2003; O'Grady, 
Simmons, Tupe, & Hewlett, 2001). Group-based programmes, specifically designed 
diabetes self-management education (DSME) programmes for the New Zealand 
population led to an improvement in diabetes care (Krebs et al., 2013). 
Lifestyle programmes are the way forward to resist the tide of type 2 diabetes and 
Māori are known for poor participation in mainstream programmes. Murphy describes 
the processes to successfully develop an acceptable and successful community 
programme for Māori (Murphy et al., 2003). This lifestyle programme demonstrated a 
risk reduction, in the short term for type 2 diabetes and cardiovascular disease for 
Māori participants (n=36) (McAuley et al., 2003). A diabetes support group in a rural 
community of New Zealand found an increase in the monitoring of care processes, and 
an increase in the number of people on insulin (15% to 22%), after the implementation 
of structured care and auditing. There was also a change in the delivery of care and the 
patients were more empowered (O'Grady et al., 2001). 
Those whanau newly diagnosed with type 2 diabetes or insulin resistance displayed 
similar risk factors and reduced their risk of diabetes with physical activity and a high 
fibre dietary intake. These results are for a predominantly Māori population (n=371) in 
New Zealand that completed a questionnaire and clinical data (Mann et al., 2006). 
Māori-centric initiatives were found to be effective in delaying or preventing the 
progression of type 2 diabetes (de Lore et al., 1993; Kirkwood et al., 1997; Simmons, 
Rush, & Crook, 2008). Strategies to prevent and control diabetes should be Marae-based 
and appropriate to those populations where diabetes is a high risk (Kirkwood et al., 
1997). Māori with type 2 diabetes acknowledged that Marae-based health care was 
preferable to hospital-based health care. This was from a small sample (n=51/77%) of 
Māori patients with type 2 diabetes attending a diabetes hospital clinic in New Zealand. 
They were happy with the overall service received and named one or more diabetic 
complications; however, heart disease did not feature high in complications (de Lore et 
al., 1993). A Randomised Control Trial (RCT) of intensive lifestyle change was 
commenced with non-diabetes whanau (n=5240) in rural and urban areas, with 
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baseline assessments completed, by Māori Community Health Workers (MCHW), as 
personal trainers, and found progression from Impaired Glucose Tolerance and 
Impaired Fasting Glucose to type 2 diabetes can be delayed or prevented through 
lifestyle changes. A pilot cohort (Vanguard study) (n=160) was established to receive 
and contribute to reducing the incidence of diabetes (Simmons et al., 2008). 
These findings of the management and treatment of diabetes literature described above, 
highlight the negative outcomes associated with poorly treated and or managed 
diabetes, however where the appropriate services and resources are engaged, positive 
clinical outcomes will manifest for whanau with diabetes. 
 
 
3.4 Indigenous people and diabetes 
There are 506 relevant papers found. These are discussed below under the 
following groupings: 
• Prevalence 
• Undiagnosed diabetes 
• Risk factors 
• Complications of diabetes 
• Interventions 
• Diabetes programmes 
• Gestational diabetes 
• Medication/treatment 
• Population screening 




The global prevalence of type 2 diabetes in 1980 increased from 4.7% to 8.5% in 2014 
(World Health Organization), with higher rates for indigenous populations compared to 
non-indigenous populations in: Australia, Canada and the United States of America. 
In Australia, during 2012–13, 11.1% of Aboriginal and Torres Strait Islander adults had 
diabetes. These were known diabetes (9.6%) and newly diagnosed diabetes (1.5%). 
Aboriginal and Torres Strait Islander people had a higher risk of diabetes with a high- 
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impaired fasting plasma glucose (4.7%) and this was twice as common for those 
Aboriginal and Torres Strait Islander people living in remote areas (20.8%) than those 
in non-remote areas (9.4%) (Australian Bureau of Statistics, 2014). 
Diabetes prevalence among Aboriginal and Torres Strait Islander people steadily 
increased with age, especially among those aged > 55 years (34.5%), with one in three 
of this age group having diabetes and 7.5% of this age group at high risk of diabetes 
(Australian Bureau of Statistics, 2014). 
The age pattern of diabetes was similar for indigenous and non-indigenous Australians, 
but tended to occur at an earlier age for Aboriginal and Torres Strait Islander people. 
The rate of diabetes for Aboriginal and Torres Strait Islander people aged 35–44 years 
(9.0%) was similar to the non-indigenous people at aged 55–64 years (8.2%). The rate 
for the 45–54 years (17.8%) was similar to those aged 65–74 years (15.0%) in the non- 
indigenous population, for both known diabetes and newly diagnosed diabetes 
(Australian Bureau of Statistics, 2014). 
In the United States of America, the rates of diagnosed diabetes in adults by race/or 
ethnic background are: 7.4% of non-Hispanic whites; 8.0% of Asian Americans; 12.1% 
of Hispanic; 12.7% of non-Hispanic blacks; and 15.1% of American Indians/Alaskan 
Natives (Centers for Disease Control and Prevention, 2017). 
In Canada, the Aboriginal Peoples Survey (APS), in 2012 found diabetes (excluding 
gestational diabetes) was reported by 5% of the total Inuit population, compared to 4% 
for the total population of Canada. Ninety seven percent of all cases of diabetes were 
type 2 diabetes (excluding gestational diabetes) (Statistics Canada, 2012). 
Researchers have used a variety of methods to determine the prevalence of diabetes in 
indigenous communities. Bruce (2000), for example, looked at the prevalence of type 2 
diabetes among Metis of Western Canada - using the APS of 2012. They found the crude 
prevalence of type 2 diabetes (6%) among Metis of Western Canada, is slightly less than 
Native American (NA) Indians (7%), but twice the general rate for Canada (3%) (Bruce, 
2000). Adler et. al (1994) found the Alaskan Inuit age-adjusted prevalence of diagnosed 
diabetes was 0.9% compared with 2.6% for the United States population in 1985. 
The prevalence of diabetes in Alaskan and Canadian Indians is higher than in Inuits, but 
is generally lower than other Indigenous tribes in which the prevalence may exceed 
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20% in adults (Adler, Boyko, Schraer, & Murphy, 1994). 
Indigenous people in Canada are more likely to be diagnosed with type 2 diabetes at a 
younger age, and consequently they have higher rates of diabetes in young people. A 
prospective study of the Canadian National surveillance found Canadian Aboriginal 
children <18 years of age have the highest incidence of type 2 diabetes. This is 
comparable to the United States, which reports an incidence of type 2 diabetes in 
American Navajo youth aged 10–14 years of 22.4 cases per 100,000 person-years and 
39.34 cases per 100,000 person-years in those aged 15–19 years. Type 2 diabetes in 
American Indian children <10 years of age is rare. However, in Canadian Aboriginal 
children, 11 cases (11%) of type 2 diabetes occurred in children <10 years of age 
(Amed et al., 2010). 
 
 
3.4.2 Undiagnosed diabetes 
The International Federation of Diabetes Atlas – 8th edition states that for every one 
adult diagnosed with diabetes, there are at least two adults with undiagnosed diabetes 
(212 million people in the world) (International Diabetes Federation, 2017). Of the 30.3 
million adults with diabetes, 23.1 million were diagnosed, and 7.2 million were 
undiagnosed (Australian Bureau of Statistics, 2014). 
Annis (2005) found rates of undiagnosed diabetes are high. In the US, for example, those 
with undiagnosed diabetes constitutes approximately a third (29.3%) of the total 
diabetes prevalence in the United States population (Annis, Caulder, Cook, & Duquette, 
2005), while the rates of undiagnosed diabetes are possibly even higher for the 
indigenous population. Twelve percent of Canadian aboriginal people compared to 6% 
of European Canadian were diagnosed as having new diabetes (defined as a fasting 




3.4.3 Risk factors 
Some risk factors for type 2 diabetes, such as genetics, ethnicity and age, are not 
modifiable. Other risk factors, such as being overweight or obese, eating an unhealthy 
diet, insufficient physical activity and smoking, are modifiable through behavioural and 
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environmental changes. Indigenous populations have higher rates of risk factors 
associated with developing diabetes. These include family history. 
Studies show the prevalence of obesity and other chronic conditions like diabetes is 
higher for First Nation (FN) populations living on reserves than for non-FN. The obesity 
prevalence for FN people in Sandy Lake, Ontario (BMI>30) was 50% in men and 65% in 
women. In Quebec, 91% of FN participants from a sample of 172 were abdominally 
obese, while the obesity prevalence was 55% among a sample of Alberta FN people and 
49% among a sample of Metis people (Chateau-Degat et al., 2009). 
In Canada, the Aboriginal Peoples Survey (APS) (2012) found that 30% of Inuit, aged > 8 
years were overweight and 26% were obese. Four in ten Inuit aged >18 (42%), were 
within the category of “normal weight” and 3% were considered underweight. Among 
Inuit aged >18, living within Inuit Nunangat (Nunangat is the name for the four regions 
of the Inuit people of Canada), 28% were overweight and 24% were obese, while 
outside Inuit Nunangat, 32% were overweight and 31% were obese. The differences 
between Inuit living inside and outside Inuit Nunangat were not statistically significant 
(Statistics Canada, 2006). 
Obesity is a recognised modifiable risk factor in the management and treatment of type 
2 diabetes, and contributes to the increasing incidence of this disease. Indigenous 
populations are at increased risk for pre-diabetes and type 2 diabetes with the rising 
global pandemic of childhood obesity. As people get increasingly overweight, they 
become less sensitive to insulin and insulin secretion, putting them at greater risk of 
type 2 diabetes. For those of Native American and Latino descent, ethnic disparities in 
obesity rates emerge early in life and have profound consequences on metabolic health 
as shown by their high prevalence of pre-diabetes and type 2 diabetes mellitus (T2DM) 
(Alderete, Toledo-Corral, & Goran, 2014). 
The Australian Aboriginal and Torres Strait Island Health Survey showed 39.8% of 
Aboriginal and Torres Strait Islander people were obese. In 2010-13, Aboriginal and 
Torres Strait Islander people who were obese were around seven times more likely as 
those of normal weight or underweight to have diabetes (17.2% compared with 2.4%). 
Around half (53.1%) of all Aboriginal and Torres Strait Islander people with diabetes 
had signs of chronic kidney disease compared to the non-indigenous population 
(32.5%). Aboriginal and Torres Strait Island people with diabetes (60.5%) with diabetes 
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had lower than normal levels of High-Density Lipids (HDL), good cholesterol, compared 
with 32.9% of those without diabetes (Australian Bureau of Statistics, 2014). 
Health status of indigenous populations, First Nations (FN), Inuit and Metis peoples in 
northern Canada varied particularly in the prevalence of chronic disease (obesity, heart 
disease, diabetes and respiratory illness) and risk factors (Bruce, Riediger, & Lix, 2014).  
The HEALTHY trial funded by the National Institute of Health assessed if school-based 
strategies reduced the risk of diabetes in four middle schools, two in Southern 
California, Texas, and North Carolina. At least 50% of minority students were recruited 
for the trial (Bobo, Schantz, Kaufman, & Kollipara, 2009). Bobo et al (2009) reported 
almost half the cohort of predominantly minority middle school-aged children, had a 
body mass index (BMI) greater than the 85th percentile, while 38% had fasting glucose 
levels in an abnormal range comparable with impaired fasting glucose; 36% had a high 
fasting insulin level. A pilot project observed insulin and glucose levels increased with 
an elevated BMI percentile, and fasting glucose was highest in Native American and 
Hispanic students. This highlighted the importance of screening youth at school and 
referring at risk children on to the appropriate services. 
In a Report of Surgeon General’s (2014) “The Health consequences of Smoking – 50 
years of progress”, smoking is causally linked to diabetes. The report cites that smokers 
had a 30-40% higher risk of developing diabetes than non-smokers. In 2015, 15.1% of 
all adults (36.5 million people or 16.7% males, and 13.6% females) in the United States 
of America were current smokers. In 2013, 43.8% of American Indian/Alaska Native 
adults, and 29.8% of African American adults reported current use of commercial 
tobacco (Lushniak, 2014). 
The 2012 Aboriginal Peoples Survey (APS) in Canada found 52% of Inuit aged 15 or 
older smoked cigarettes daily, more than three times the rate (16%) of the total 
population of Canada (Statistics Canada, 2006). 
The survival of indigenous Australians (adjusted for risk factors) was worse compared 
to Chinese and Arab participants in a group of patients with type 2 diabetes in Sydney, 
Australia (measured as Hazard Ratio of death (HR)). The prevalence of smoking and 
albuminuria40 was strongly associated with death (Alharbi et al., 2015). 
                                                             
40 Albuminuria – the presence of albumin in the urine, typically as a symptom of kidney disease 
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In New Zealand (2015/2016), the proportion of current smokers over 15 years was 
38.6% Māori, 25.5% Pacific Island, 14.5% European, 8.7% Asian (Statistics New 
Zealand, 2017). 
 
Native Alaskan youth were screened for cardiovascular disease (CVD) risk factors, and 
85% had three or more risk factors for CVD (diabetes, obesity and passive smoking). 
This is a group at significant risk, as the Native Alaskan adults have a prevalence of 
CVD and an increase in CVD related mortality (Botash, Kavey, Emm, & Jones, 1992). 
The traditional way of life, such as hunting and gathering of food and shelter for many 
indigenous populations has become something of the past, as indigenous people have 
become colonised over the years. As indigenous people have become more westernised 
and assimilated into a different way of living, such as eating processed and convenience 
foods, many people have lost traditional customs and practices. Adler (1994) speculated 
that the low prevalence of diabetes in Inuit might be a result of a diet high in co-3 fatty 
acids. Seal oil and salmon were the most frequently consumed by Alaskan Natives 
(Adler et al., 1994). Alaskan Natives traditionally consumed a diet high in sea mammals 
and fish high in fatty acids. However, as a traditional diet, this has decreased (for many 
reasons - limited skills to catch, food resource availability) while subsequently diabetes 
prevalence and glucose intolerance has increased. Adler (1994) suggests the Inuit’s low 
prevalence of diabetes may be due to a diet high in co-3 fatty acids, and the increasing 
prevalence of glucose intolerance in Alaskan Natives suggests the presence of an 
environmental factor affecting diabetes prevalence. Adler went on to study the 
association of these foods with glucose intolerance among the Yup'ik Inuit and 
Athabaskan Indians of the Yukon/Kuskokwim Rivers Delta. Adler speculated that the 
consumption of seal oil and salmon high in fatty acid appears to lower the risk of 
Impaired Glucose Tolerance (IGT), a potential modifiable risk factor to reduce the risk 
of type 2 diabetes among Alaskan natives (Adler et al., 1994). This is a potential 
framework for further study with similar indigenous populations. 
Food security is defined as the assured ability to acquire nutritionally adequate and safe 
food that meets cultural needs, and has been acquired in a socially acceptable way and 
known to lead to favourable outcomes. Food insecurity, conversely, is a measure of 
situations when, for example, the food purchased does not last, and there is not enough 
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money to buy more. Alternatively, a household that cannot afford to eat balanced meals, 
or household members cut the size of their meals or skip meals because there is not 
enough money for food is known to lead to adverse outcomes (Jernigan, Huyser, Valdes, 
& Simonds, 2017; Pal, Haman, & Robidoux, 2013; Reeds et al., 2016; Rudolph & 
McLachlan, 2013).In 2012, the APS cited 41% of Inuit aged 15 and older lived in 
households that experienced food insecurity in the prior 12 months, compared with 8% 
of the total population of Canada (Statistics Canada, 2006). 
Results of the longitudinal Survey of Families, Income and Employment (SoFIE) showed 
over 15% of the SoFIE population in New Zealand were food insecure in 2004-05. 
Prevalence of food insecurity was much greater in females (19%) than males (12%), 
and higher among Māori and Pacific Island populations. Māori and PIs have higher rates 
of poverty than the general population and suffer disproportionately from the burden of 
nutrition-related disease (Carter, Lanumata, Kruse, & Gorton, 2010). 
 
 
3.4.4 Complications of diabetes 
Untreated diabetes can damage the heart, blood vessels, eyes, kidneys, nerves, and 
increase the person’s risk of heart disease and stroke. Diabetes and its associated 
complications are major contributors to the comorbidities and premature mortality 
experienced globally by indigenous populations, and the greater prevalence and burden 
of disease (WHO). Indigenous populations experience poorer outcomes associated with 
type 2 diabetes related complications, comorbidities and mortality than non-indigenous 
populations. 
Arif (2016) found diabetes and obesity as common causal factors in the incidence rate 
of narcosis fasciitis (NF) associated deaths and had a greater impact on American 
Indian, black and Hispanic individuals compared to white individuals (Arif, Yousfi, & 
Vinnard, 2016). Broussard reported high rates of diabetes and obesity over a year, in 
a group of American Indian/Alaska Native outpatients seen for diabetes and 
hypertension at an Indian Health Service (IHS) compared to other ethnic groups in 
the US; however, blood pressure rates were lower (Botash et al., 1992; Broussard, 
Valway, Kaufman, Beaver, & Gohdes, 1993). 
Bruce (2011), found 75% of the FN population had at least one co-morbidity; 22% of 
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men and 43% of women aged 18 to 29 years had two or more chronic conditions (Arif 
et al., 2016; Bruce, Riediger, Zacharias, & Young, 2011). A further study by Bruce, in 
2014, found variable health status among indigenous populations: FN, Inuit, Metis 
populations in northern Canada. The prevalence of chronic disease (obesity, heart 
disease, diabetes and respiratory illness) and the many risk factors differed between the 
indigenous populations. The odds of having at least one chronic condition were 
significantly lower for the Inuit than the non-Aboriginal population, but similar for the 
FN and Metis populations (Bruce et al., 2014). 
Bertoni (2004) however, found in a national sample study of elderly Medicare claims 
(United States of America), the overall deaths related to diabetes increased with age and 
were similar across the ethnic groupings. The age adjusted relative risk (RR) associated 
with diabetes was similar for white (1.86) and non-white minorities (Hispanic 2.37, 
Asian 1.95, Native American 2.38, and Blacks 1.64) (Bertoni, Kirk, Goff Jr, & 
Wagenknecht, 2004). 
Microvascular diseases can be attributed to diabetes. Neuropathy is damage to 
peripheral nerves, for example in the eyes and feet. The Freemantle Diabetes study 
looked at changes in foot ulceration and the risk factors for community-based type 2 
diabetes. There was a strong association between foot ulceration and length of time 
people have diabetes, periphery sensory neuropathy, and clinically detectable 
peripheral vascular disease (PVD). Ethnicity (aboriginality) was an independent risk 
factor (Baba, Davis, Norman, & Davis, 2015). The Bruce (2008) study also found the 
prevalence of neuropathy high among First Nation populations; 22% had previous 
diabetes, and 14 % were new with diabetes or had impaired fasting glucose. The mean 
age was 40 years, presenting with undiagnosed diabetes and a high number with foot 
problems, increasing their risk of ulceration along with the low level of foot care in the 
community (Bruce & Young, 2008). 
Macrovascular diseases can also be attributed to diabetes, such as cardiovascular 
(heart) disease. Diabetes is a major determinant of cardiovascular disease (CVD) in 
Native Hawaiian people, with most of the CVD occurring in those with diabetes. For 
Native Hawaiians, CVD increased with age, and was higher for those with type 2 
diabetes, hypertension, and high-Low density lipids (LDL). The CVD rates were higher 
for men than women and increased four-fold with type 2 diabetes. Strategies to prevent 
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type 2 diabetes, manage hypertension, and lipid management should reduce CVD rates 




Studies find that community programmes that are culturally appropriate and 
responsive to need are effective in achieving positive outcomes for indigenous 
populations and their communities. The Diabetes Prevention Program (DPP) and 
Look AHEAD study are two large randomised clinical trials designed to look at 
different aspects of diabetes interventions. Both studies profiled diabetes 
demography (Bray, 2006; Bray et al., 2000). Adams (2005) also found children who 
participated in the Kahnawake Schools Diabetes Prevention Project (KSDPP) Mohawk 
community improved their lifestyle with increased physical activity, less TV viewing 
and good quality food (Adams, Receveur, Mundt, Paradis, & Macaulay, 2005). Barbeau 
(2015) showed growing potatoes and bush beans in subarctic Canada was sustainable 
and that this also benefits and contributes to the local food production and helps 
promote social capital, healthier lifestyles and food security for Aboriginal people in 
Canada who experience disproportionately high rates of diet related illness such as 
obesity and diabetes. (Barbeau, Oelbermann, Karagatzides, & Tsuji, 2015).  
In a programme that advocated a role for community health workers in a Canadian First 
Nations Diabetes Clinical Management and Epidemiologic (CIRCLE) study (phase II), 
Bhattacharyya (2011) surveyed 244 healthcare providers in 19 First Nations 
communities in 7 Canadian provinces, representing three isolation levels (isolated, 
semi-isolated, non-isolated). Patient factors had the largest impact on improving 
diabetes care, suggesting self-management strategies are suited in this context. This 
highlights that program planning should focus on training programs for community 
health representatives (CHRs) who provide a unique link between patients and clinical 
services (Bhattacharyya, Rasooly, et al., 2011). 
 
 
3.4.6 Diabetes programmes 
Evaluations of structured diabetes programmes show routine data can be helpful in 
measuring quality improvements of a programme. Acton (2001) concluded from an 
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analysis of Indian Health Services National Diabetes programmes data set, that data 
alone is not sufficient to effect change or a guarantee of improvement, but was helpful in 
measuring quality improvements in a programme (Acton et al., 2001). Agban (2008) 
studied the Diabetes Annual Review programme (DARS) in New Zealand over a two- 
year period and identified minimal improvements in health status and the management 
of diabetes. Māori and Pacific Island people had little improvement with glycaemic 
control. However, there was improvement in the treatment and management of blood 
pressure and lipid management in year two. During the study period, changes in statin 
restrictions use occurred in 2002 and the New Zealand Guidelines Group was formed in 
2003 (Agban et al., 2008). 
 
 
3.4.7 Gestational diabetes 
There is an increasing prevalence of gestational diabetes (GDM) among indigenous 
women in rural settings. Back’s (2012) study compared First Nation women who had 
gestational diabetes living in rural regions with First Nation pregnant and First Nation 
non-pregnant women living in urban areas, and found the levels of physical activity and 
nutritional intake need to improve for those women in rural remote settings (Back, 
2012). Azar (2015) found a third (30%) of American Indian women have some form of 
dysglycemia (broadly refers to any abnormalities in blood glucose levels that lead to 
disease), commonly associated with insulin resistance (IR), and this was a long-term 
risk for themselves and their baby (Azar et al., 2015). Over a 20-year period, Aljohani 
(2008) found the prevalence of gestational diabetes mellitus (GDM) increased by 2.9% 
for First Nation women over 35 years living in rural areas in Manitoba, and this was 
2.3% in 1985-1989 and 3.7% in 1999-2004 (p<0.01) (Aljohani et al., 2008). The 
prevalence of GDM continued to increase in Manitoba, despite major changes to the 




International studies maintain the recommended best practice guidelines for the 
treatment and management of diabetes are applicable to all ethnic groupings. Research 
supports that when diabetes is treated and managed effectively, positive outcomes are 
achievable (UK Prospective Diabetes Study (UKPDS) Group, 1998a). However, studies 
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illustrate treatment and management of type 2 diabetes are not always equitably 
distributed across ethnic groupings/populations. Aparasu (2008) found American 
Indian with diabetes were less likely to receive medicine than other patients with 
diabetes, and optimal blood pressure was observed in only a third of those with 
diabetes receiving medication for high blood pressure (Aparasu & Aparasu, 2008). 
 
 
3.4.9 Population screening 
Studies suggest screening of populations for the early detection of diabetes will enable 
the appropriate implementation of interventions and increase the likelihood of better 
outcomes (sooner rather than later) for indigenous populations (Azzopardi, 2012). This 
suggests screening is needed for Aboriginal and Torres Strait Islander youth living in 
remote areas, over 10 years old and overweight, who have a positive family history of 
diabetes (gestational diabetes), show signs of insulin resistance, dyslipidaemia and 
receive some type of psychotropic therapy. It is a challenge, particularly for indigenous 
youth living in rural remote settings, to access health related services and with 
individual limited resources. It is also a challenge at the health providers service level 
(Azzopardi et al., 2012). 
 
 
3.4.10 Knowledge and attitudes 
Patient-focused interventions and cultural competence training were the primary 
concern of providers delivering diabetes care in remote First Nation communities in the 
Sioux Lookout Zone (SLZ) of Northwestern Ontario, Canada (Bhattacharyya, Estey, et al., 
2011). The Nuxalk people (Bella Coola, Valley, British Columbia, Canada) reported that 
their challenges in dealing with diabetes were: i) understanding connection between 
diabetes and western and/or traditional medicine, ii) dietary changes, exercise, weight 
loss, iii) how Health Providers communicate and the relevance of what is said, iv) 
having life choices and the responsibility to choose, and v) a belief in living day by day 
and an awareness of life cycles that need to be broken (Barton, Anderson, & 
Thommasen, 2005). First nation youth (n=28) (7-18 years) with type 2 diabetes and 
their parents completed a quality of life (QOL) questionnaire. Overall, the youth had a 
higher QOL than their parents perceived, and this may be a reflection of living in remote 
 
69  
communities, family experiences with complications of diabetes and clinical factors 
(high HbA1c, oral medication - not insulin) that may be modified to reduce the 
psychosocial burden of illness (Allan, Flett, & Dean, 2008). 
 
 
3.5 Māori Medicines access and use 
Literature shows inequitable medicine use across ethnic groupings in New Zealand. 
Māori are less likely to receive appropriate medicines for the management and 
treatment of a condition. There are many reasons why and where this might occur. The 
following studies highlight Māori medicines use and support my argument for doing 
this doctoral research. 
There are 54 relevant papers found. These are discussed further under the 
following groupings: 
• Optimal medicine use leads to positive outcomes 
• Medicines access – barriers 
• Attitudes and views to medicine use 
• Alternative medicines and therapy use 
 
Metcalfe et al (2013) looked at all medicines used for the general population 
in a year (2011) using data from the Pharmaceutical collection. A later study 
(Uniservices, 2018) also found similar findings. They found the rates of 
prescription medicine use amongst Māori; Pacific Island people and other 
New Zealanders were similar. However, when adjusted for disease burden, 
the medicines use amongst Māori was considerably lower than for 
European and overall dispensings were lower (19% - 37%) for Māori than 
non-Māori. Māori were less likely to access medicines, and had fewer 
subsequent dispensings (Metcalfe, Laking, & Arnold, 2013). 
The Equity in prescription medicine use (EIPMU) study (Horsburgh & Norris, 2013) in 
Tairāwhiti found lower rates of medicine use. This study used data from dispensing 
computers in pharmacies in Gisborne and looked at several therapeutic groupings 
(antipsychotics, antibiotics, gout/allopurinol, statins, and diabetes). The following 




inequitable treatment in the type of medication but also the amount of medication for 
the condition. 
Norris et al (2011), paper on dispensed psychotropic medicines showed that Māori over 
65 were less likely than non-Māori to be dispensed psychotropic medicines. The rate of 
use for antipsychotics, anxiolytics, hypnotics and sedatives, and antidepressants was 
particularly lower for Māori. A third of the population over 65 year were dispensed one 
or more psychotropic medication, and the usage by women was high and increased with 
age. Those in the most deprived areas were least likely to be dispensed psychotropic 
medicine (Norris, Horsburgh, Lovelock, et al., 2011). 
In the general population, antibiotic medicines use was high. However, Māori were less 
likely to receive a prescription for antibiotic medicine than non-Māori. On average, 
Māori also received a lesser quantity of antibiotics than non-Māori. Also disconcerting 
were rural Māori, particularly children living in rural areas who received fewer 
prescriptions and lower quantities of antibiotic medicine compared to other population 
groupings (Norris, Horsburgh, Keown, et al., 2011). 
Although the Equity in Prescription Medicines use study found lower use of some 
medicines in Māori, the use of allopurinol and statins was higher in Māori. The study 
(Horsburgh et al., 2014) found allopurinol used in the treatment and management of 
gout with a greater prevalence of allopurinol in males (6%) than females (1%), and in 
Māori (5%) than non-Māori (3%). However, the pattern of adherence measured as 
medication possession ratio (MPR41< 0.80) show non-Māori (54%) were less likely to 
have sub-optimal adherence compared to Māori. Māori may have received allopurinol 
treatment as noted in the greater prevalence use than non-Māori, but many were not 
taking the allopurinol as measured consistently over the study period. 
Norris et al (2014) found statin use increased with age to 75 years, and there was a 
higher use among Māori than non-Māori, particularly in middle age (45-54yrs, 11.6% 
Māori vs 8.7% non-Māori), where Māori have a higher risk of cardiovascular disease. At 
the time of the study a national campaign by PHARMAC (pharmaceutical management 
agency, a crown agency responsible for the procurement of medicine, devices etc. in 
New Zealand) to increase statin use may have contributed to the increased use in high- 
risk groups in New Zealand (Norris et al., 2014). Grey et al (2014) studied patterns of 
                                                             
41 MPR – medication possession ratio 
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statin use over a 3-year period following acute coronary syndrome (ACS), and found a 
third of patients were not adequately maintained on statins over the 3-year study 
period. Māori (55%) had poorer statin maintenance compared to European (68%) 
/others and Indians (71%) over the 3 years of follow-up (Grey et al., 2014). A review of 
the treatment and management of heart failure guidelines used during patient 
admissions found no difference between Māori and non-Māori use of echocardiogram 
and discharge medications for patients, and no difference between Māori and non- 
Māori adherence to management guidelines for first admission heart failure patients. 
However, a larger number of cases is needed for the study to see if there has been a 
difference between Māori and non-Māori treatment and management (Wall, Bell, 
Devlin, & Lawrenson, 2013). 
Additional studies found disparities in the dispensing of blood glucose test strips (not a 
medicine but a related device used in the management and treatment of diabetes). 
Metcalfe et al (2014) looked at all the dispensings for blood glucose test strips in 2011, 
and relative to the guidelines for diabetes treatment, blood glucose test strips were 
under dispensed particularly for those on insulin aged 25 to 44 years and Māori and 
Pacific Islanders, and there were high dispensings for blood glucose test strips for 
those on metformin or no medications. Adherence may improve efficacy and outcomes 
for those using insulin and reduce pain, anxiety and disruption for those using 
metformin or diet alone for managing their diabetes (Metcalfe, Moodie, Norris, & 
Rasiah, 2014). 
New Zealand studies suggest approximately two-thirds of patients who present with an 
acute coronary syndrome (ACS) are maintained on a statin/aspirin post-discharge (a 
follow on to the 2014 Grey study). This is possibly due to sub-optimal initiation or poor 
longer-term adherence. This study looked at the pattern of aspirin/statin following ACS 
from initial prescription to 3 years post discharge. Most people in the study were 
prescribed a statin on discharge within 3 months, decreasing in the preceding years 1 
and 3. Independent predictors of inadequate maintenance in the third year are: age< 45 
years; no prior statin; ethnicity (Māori and Pacific Island). Longer-term maintenance of 
evidence-based secondary prevention medications after ACS is sub-optimal despite high 
levels of initial prescribing and dispensing. Understanding the barriers to longer-term 
maintenance is required to improve patient outcomes (Kerr et al., 2016). 
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Wheeler et al studied antipsychotic prescribing in the treatment of schizophrenia. 
Monotherapy was lower for Māori than other ethnic groups. The rates of oral second-
generation medicine use for Māori were lower compared to European (59% vs 67%), 
and the maintenance dose use for first generation depot (long-acting injection) was 
more likely for Māori compared to European (36% vs 22%) (Wheeler, Humberstone, & 
Robinson, 2008). A study by Dey et al (2016) also found prescribing high for 
antipsychotic polypharmacy (33.7%) and Māori were prescribed more clozapine than 
non-Māori (24% vs 13%). Clozapine rates on discharge were low (20%), but the rate for 
Māori was nearly twice that of non-Māori (24 % vs 13%), which aligned with existing 
guidelines (Dey, Menkes, Obertova, Chaudhuri, & Mellsop, 2016). 
 
 
3.5.1 Optimal medicine use leads to positive outcomes 
Studies show people that receive active assessment and treatment, and appropriate 
medication have better medication adherence and benefit from significant 
improvement in clinical measures, and that this is particularly true for Māori and Pacific 
Island people (Agban et al., 2008; Elley et al., 2008; Gu, Warren, Kennelly, Neuwelt, & 
Harwood, 2014). Initial baseline data from a review of the DAR42 indicated poor 
glycaemic control for Māori and Pacific Island people. However, after review at year two 
significant improvement was seen for Māori and Pacific Island people. Appropriate 
management and treatment reduced disparities (Agban et al., 2008). 
Gu et. Al., found the proportion of Māori patients with high cardiovascular risk, 
treated with oral antidiabetes medication (42%) was lower than Pacific 
Islanders (50%), but higher than non-Māori/non-Pacific Islanders (33%). The 
proportion of high-risk cardiovascular patients treated with antihypertensive 
and cholesterol-lowering medication was similar across Māori and non-Māori. 
Māori patients with high cardiovascular risk had the poorest adherence with 
cholesterol-lowering and antidiabetes medication (Gu et al., 2014). 
Smith et al (2011) studied the use of oral hypoglycaemic agents, insulin and a number of 
individuals with an HbA1c > 8 % not on insulin therapy, by ethnicity, at visit 1 and visit 
5. Māori use of oral hypoglycaemic agents at visit 1, increased by visit 5 (73.5% vs 
86.9%). Insulin use also increased for Māori (10.4% vs 18.8%). Māori on no insulin use 
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and HbA1c >8 % decreased (82.2% vs 69.1%). Overall statin use was initially low 
(Europeans 23%, Pacific Island 7%), but after 5 years, statin prescriptions increased 
from 20 to 61%. Māori had the highest statin use (66%) (Smith et al., 2011). 
Wheeler (2008) and Dey (2016) found similar antipsychotic medicine use by ethnicity 
and within the recommended best practice guidelines for the maintenance and 
treatment of schizophrenia (Dey et al., 2016; Wheeler et al., 2008). However, Wheeler et 
al reviewed antipsychotic prescribing use in schizophrenia over two time points and 
found at the first audit, baseline differences in the prescribing rates for antipsychotic 
medicines. The overall monotherapy rates increased for all ethnic groups (Māori, 
European and Pacific Island people), with no ethnic differences at the second audit (85- 
86%). The use of oral second-generation antipsychotics (SGA) across the ethnic groups 
increased (83-87%). The use of depots (14-19%) and oral first-generation 
antipsychotics (FGAs) decreased (5-8%) for the ethnic groups. The use of clozapine 
increased for all ethnic groups at the second audit, with a significant difference between 
European, Māori and Pacific Island people (33-39%) (Wheeler et al., 2008). 
Peiris et al (2008) found substantial gaps between guidelines and practice in the 
appropriate prescribing of cardiovascular medicines and meeting recommended targets 
in a 12-month study examining an electronic assessment programme in general 
practice. Prescribing rates (for pressure lowering, lipid lowering, anti-platelet 
medication) demonstrated improved management of patients at high CVD risk, but 
modest achievement in treatment targets. Those with diabetes or established 
cardiovascular disease did not achieve the recommended targets for blood pressure and 
lipid lowering as recommended in the Primary Health Care Handbook 2012. There were 
few disparities in prescribing rates and achieving target levels by ethnic group (Peiris et 
al., 2008). 
The use of blister packs for people with type 2 diabetes on multiple medicines were 
found to be effective for glycaemic reduction, but not so much with blood pressure 





3.5.2 Medicine access – barriers 
Pharmaceutical Management Agency (PHARMAC) is the crown entity charged with the 
procurement and the subsidising of medicines in New Zealand. Most medicines are 
subsidised in New Zealand. However, access to medicines is a challenge for vulnerable 
populations (such as Māori) requiring medication as part of their care and treatment. 
Universal access to medicines is not an occurrence for everyone, particularly Māori. 
Babar et al (2014), discussed priority medicines with a number of stakeholders, and 
most were satisfied with the availability of subsidised medicines. However, there are 
numerous challenges with access to medicines for vulnerable populations. These 
include financial barriers – such as increasing costs, increased prescription fees which 
lead to people deferrd buying some medicines, particularly for Māori and Pacific Island 
than New Zealand European. In addition, other challenges include access to prescribers, 
budget constraints, cultural and health literacy, patient affordability, evidential 
documentation required for subsidy medicines, also those living in rural remote areas, 
or having 2 or more comorbid conditions (Babar & Francis, 2014; Jatrana et al., 2011). 
Norris et al (2016) identified Māori with low income had reasons not to collect their 
medicine. These included financial barriers – having to choose some medicines and 
leave others, like medicines for mental health but not medicines for physical health; 
reducing food intake or eating less healthy food in order to pay for medicines; or 
prioritising medicines for children and leaving medicines for adults. They also reduced 
the dose, which meant the medicine lasted longer and delayed collecting medicines. 
This led to sub-optimal dosing or interrupted treatment (Bassett-Clarke, Krass, & 
Bajorek, 2012; Norris et al., 2016). 
 
 
3.5.3 Attitudes and views to medicine use 
Bassett-Clarke et al (2012), found ethnic differences in medicine and medicine taking. 
These included the concept of medicine, self-management of medication, medicine- 
taking behaviour, seeking further support and medicine information. Māori utilised 
traditional medicine (rongoa - native plants) alongside prescribed medicines. Some felt 
they had no choice to use the prescribed medicine. Traditional medicine knowledge was 
lost. Māori were sceptical and resistant to the use of aides, devices or foils/blister packs 
for medication self-management. There were concerns about the adverse effects of 
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medicines (Bassett-Clarke et al., 2012). 
Cost of medicines was a deterrent for Māori (some people missed their medications for 
3 months). Māori wanted more information about the prescribed medicine and 
preferred their doctor as a reference source, but were often less likely to ask for further 
advice or help. Even if they had sourced information themselves off the internet or had 
hard copies, they were not likely to challenge or ask questions of the health provider 
(Bassett-Clarke et al., 2012; Jatrana et al., 2011). 
Māori mostly managed their medicine and regimes, but some lacked insight into the 
purpose of the medicines and how they helped with a condition, leading to a lack of 
perceived need to take the medicine. Māori were concerned poor communication 
between different ethnic groups, lack of cultural understanding, and their own 
unwillingness to confront or question health professionals had led to decreased 
standards of care (Bassett-Clarke et al., 2012). Māori preferred verbal communication 
within a communal non-clinical (termed as nonthreatening) environment to written 
information. 
Te Karu et al (2013) studied medication use by Māori patients with gout. They found 
medicines were poorly understood and not used properly. Participants felt 
overwhelmed and believed their gout was inevitable, blaming themselves and others. 
Māori had poor knowledge of gout and lacked an understanding of the disease process 
and the management and treatment of the gout. Having taken medicine for 
symptomatic relief for many years, patients had little awareness of what gout 
medicines are for and either delayed their treatment because of the adverse effects 
experienced or did not understand how to take the medication. Barriers encountered 
included the cost of medicines, time, attitudes and cultural fit. Māori were less likely to 
ask questions during the consultation, where the environment was not education 
friendly. Whānau were a source of information and support, a place where sharing 
medicines often occurred. Regardless of the information provided, Māori did not 
understand it and felt they were not understood (Te Karu, Bryant, & Elley, 2013,). 
Nikora et al (2011) carried out a qualitative study that explored medicines in the home 
and the important meanings of medicines for people and their lives. Medicines enabled 
them to manage illness and control their own health. Medication is seen as more than a 






3.5.4 Alternative medicines and therapy use 
The use of traditional medicine is common in many cultures, and there are a wide 
variety of complementary and alternative medicines (CAM). Rongoa43 practice lies 
within the traditional Māori values and traditions. Rongoa Māori includes herbal 
remedies, physical and spiritual elements in healing. Rongoa connects not only the 
physical, but also spiritual, whenua, and environment in a holistic approach. 
Evans et al (2008) studied the use of traditional, complementary and alternative 
medicines and therapies (TCAM) amongst inpatients at Gisborne Hospital. Overall 
TCAM use is similar between Māori and non-Māori. Of those interviewed 84% used an 
average of 6.4 alternative modalities. However, Māori had a greater use of rongoa 
Māori than non-Māori (59% vs 27%) (Evans, Duncan, McHugh, Shaw, & Wilson, 2008). 
Nicholson (2006) found that 1 in 3 people surveyed in a large tertiary emergency 
department (New Zealand) had used CAM. Most were female aged between 20 and 60 
years. More than a third had told medical staff that they used CAM and a quarter used 
conventional medicine concurrently with CAM. Most respondents believed CAM was 
beneficial (Nicholson, 2006). 
Te Karu et al (2013) found Rongoa (traditional medicine-rongoa rakau/wai rakau) 
played a role in the lives of rural but not urban participants, with the use of traditional 
plants for healing (Te Karu, Bryant, & Raina, 2013). 
  
                                                             
43 Rongoa – Traditional māori medicine 
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3.6 Indigenous medicines use and access 
There are 303 relevant papers. These are discussed further under the following 
groupings: 
• Medicines use 
• Medicines misuse 
• Multiple medicines use 
• Medicine management 
• Medicine adherence 
• Funding access to medicine 
 
There is a large body of literature which shows that indigenous people have poorer 
access to healthcare than non-indigenous people in Australia, Canada and the United 
States of America (Barnabe et al., 2015; Davis et al., 2016; Harris et al., 2006; Harrold, 
Randall, Falster, Lujic, & Jorm, 2014; Lau, Lin, & Flores, 2012; Law, Oraka, & Mannino, 
2011; Leslie et al., 2012; Liao et al., 2011; Olver, Marine, & Grogan, 2011; Pleis & Barnes, 
2008; Randall et al., 2013; Tuttle, Carrington, Stewart, & Brown, 2016; Wardman & 
Khan, 2004; Washington et al., 2002). 
Many authors argue that culturally appropriate programmes and health service delivery 
strategies are required to meet the needs of those populations (Betancourt, Corbett, & 
Bondaryk, 2014; Callaghan, Tavares, & Taylor, 2007; Croff, Rieckmann, & Spence, 2014; 
Elton-Marshall, Leatherdale, & Burkhalter, 2011; Guadagnolo et al., 2011; Hotson, 
Macdonald, & Martin, 2004; Novins et al., 2011; Novins, Croy, Moore, & Rieckmann, 
2016; Rothe, 2005; Smylie, Kaplan-Myrth, & McShane, 2009; Stewart, May, & Muneta, 
1980; Tarrant & Gregory, 2003). 
 
 
3.6.1 Medicines use 
Overall research suggests that indigenous people have poorer access to medicines than 
non-indigenous populations, but this varies by locality, medicine type and or condition. 
For example, Couzos (2005) found in Australia the average spending under the 
Pharmaceutical Benefits Scheme (PBS) scheme, for an Aboriginal person averaged 33%  
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of that for a non-Aboriginal person in 1998-1999. All Australians have access to 
medications through the PBS, which subsidises the cost of medicines under Section 85 
of the National Health Act (1953) (Couzos, 2005). Crighton (2010) identified where 
people lived and their Aboriginal identity impacted significantly on the use of asthma 
medication (inhalers) use. Those living on reserve or rural locations were least likely to 
be diagnosed, and there was poorer access to health care in these remote locations 
(Crighton, Wilson, & Senécal, 2010). In Canada, although smoking rates for aboriginal 
people are double the rate of the rest of the general population, they were less likely to 
see a general practitioner and use patches for smoking cessation although they were 
interested in cessation. However, they were less willing to use drug therapy (Wardman, 
Quantz, Tootoosis, & Khan, 2007). 
Similar patterns are found for immunisation coverage. Hull et al., (2004) found 
Aboriginal and Torres Strait Islander children had 17% lower immunisation coverage 
than other children. The biggest gaps were in urban areas. Coverage at 12 months (72- 
76%) and 24 months (64-73%) was considerably lower than other non-Aboriginal and 
Torres Strait Islander children (90-94% and 81-88%, respectively) (Hull, McIntyre, & 
Couzos, 2004). In the US, Buchwald (2001) reviewed medical records of older urban 
American Indian/Alaska Native primary care patients and found that their use of 
vaccines and other preventative measures (mammograms, faecal occult bloods, 
audiometry, visual acuity test, smoking cessation, pneumococcal vaccine, influenza 
vaccine) was suboptimal (Buchwald, Furman, Ashton, & Manson, 2001). 
In contrast, Anderson (2000) found that overall utilisation of the central nervous 
system drugs amongst First Nations people in Canada is moderate and similar to the 
non-First Nations population (Anderson & Mc Ewan, 2000). 
 
 
3.6.2 Medicines misuse 
Some studies have explored the misuse of prescription medicines amongst indigenous 
people. Anderson (2000) found that a small percentage of First Nations residents (in 
four western provinces of Canada) registered to a Non-Insured Health Benefits 
programme were excessive users of paracetamol with codeine and/or benzodiazepines 
(Anderson & Mc Ewan, 2000). Wardman (2002) surveyed aboriginal participants who 
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accessed addiction treatment services in Calgary, Canada. Sixty nine percent completed 
the survey, aged between 31 and 50 years. Forty-eight percent responded that they 
used prescription medication inappropriately, 8% indicated appropriate medication use 
and the remainder indicated no medication use. Sedatives or relaxants were the most 
frequently used inappropriately. Common sources for those who used medication 
inappropriately included medication given by a friend or a stranger (52%), medication 
bought on the street (45%), and medication prescribed by a physician (41%) 
(Wardman, Khan, & El-Guebaly, 2002). 
 
 
3.6.3 Multiple medicines use 
Literature shows indigenous people often have multiple medicines, difficulty with 
medication management, and do not understand their medicine, the purpose, and how 
to use their medications. 
Swain et al (2013) found that patients at Aboriginal health services had multiple 
medications, which they found difficult to manage and worrisome. Patients needed 
more information – both verbal and written. Swain also recommended that 
communication between health professionals and patients about medication 
indications, mechanisms, side effects, drug interactions and duration of treatment be 
improved (Swain & Barclay, 2013). Taylor et al (2016) found that a group of Torres 
Strait Islanders with poorly controlled DM had low knowledge especially about insulin. 
Insulin uptake might improve with better education about glycaemic control and with 
exchange of experiences about medication with peers (Taylor, Thompson, & 
McDermott, 2016). In another study of Torres Strait Islanders with diabetes, attitudes 
and practices related to oral and injectable treatments varied, possibly due to levels of 
understanding. Participants wanted more education and personal support in all areas of 
diabetes care (within their family and community environment) (Wong, Haswell-Elkins, 
Tamwoy, McDermott, & d'Abbs, 2005). 
 
 
3.6.4 Medicine management 
A 2004 survey of service providers by Kowanko et al (2004) on medication 
management by Aboriginal people with mental health disorders found the quality use of 
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medications (this included safe handling, storage, transport and administration) was 
difficult for Aboriginal clients, their carers or family members. In addition, Aboriginal 
clients were influenced by drug and alcohol misuse, the cost of medication, their 
feelings about the value of medicines, sharing of medications and unwanted side effects. 
Many workers providing services to Aboriginal people with mental health disorders 
lacked adequate training and/or resources on mental health and safe medication 
management (Kowanko, de Crespigny, Murray, Groenkjaer, & Emden, 2004). Kowanko 
et al (2004) noted the limited research in the areas of Aboriginal mental health and 
Aboriginal medication management. 
Evidenced based best practice guideline recommendations for the management and 
treatment of conditions can result in positive outcomes. Key to this process is 
engagement and effective, mutual communication. 
 
 
3.6.5 Medicine adherence 
There is little literature about medication adherence in indigenous populations. Cooke 
et al. (2006) looked at statin therapy in American Indian/Alaskan Native (AI/AN) 
patients with coronary artery disease. Approximately 40% of 65 to 79-year-old patients 
were non-adherent. Men were more adherent than women. Patients in this age range 
were more adherent than younger patients (Cooke, Bresette, & Khanna, 2006). In 
Australia, Davidson et al (2010) used the WHO adherence model which looks at 
healthcare team/system, socioeconomic factors, therapy, patient, and condition, to 
explore determinants of adherence amongst Aboriginal and Torres Strait islander 
people. Davidson et al argues the ingrained socioeconomic disadvantage aggravates 
challenges to medication adherence (Davidson, Abbott, Davison, & Di Giacomo, 2010). 
 
 
3.6.6 Funding access to medicines 
Attempts have been made to improve Aboriginal people’s access to medicines in 
Australia. In 1999, special arrangements were made so medications can be supplied 
through community pharmacists to Aboriginal Health Services (AHS). This 
arrangement, referred to as Section 100, extends to all remote area AHSs to improve 
Aboriginal access to the Pharmaceutical Benefit Scheme (PBS). As part of this 
 
81  
agreement, pharmacies supply eligible Aboriginal primary health care services with PBS 
listed drugs on a bulk supply basis and are reimbursed directly by the government. The 
Aboriginal health service then supplies the medications to individual clients, with the 
support of the community pharmacist (Davidson et al., 2010). However, Couzos (2005) 
estimated that the Section 100 improved access for approximately a third (36%) of 
Aboriginal and Torres Strait Islanders. Some Aboriginal Health Services were unable to 
access this scheme, even though Aboriginal peoples in these regions experience 
substantial barriers to accessing medication. In 2004, Section 100 arrangements were 
extended to all Aboriginal Health Services, regardless of location (Couzos, 2005). 
Similarities in barriers to medicines access for Aboriginal people across remote, 
regional and urbans sites and the underuse of medicines are identified in the 1997 
Keys-Young review. The PBS lacked medications for conditions that were highly 
prevalent conditions in the Aboriginal and Torres Strait Islander population but 
uncommon in the non-indigenous population. Additional funding in 2004-2005 
expanded the list of medications to include treatment for endemic skin infections and 
chronic suppurative otitis media, conditions particular to Aboriginal and Torres Strait 
Islander populations. Glitazones were also added to the PBS list in 2004, an additional 
therapy before commencing insulin in type 2 diabetes, particularly relevant to 
Aboriginal and Torres Strait Islander peoples as they are often on maximal tolerated 
doses of conventional oral hypoglycaemic therapy. The addition of a glitazone can 
improve glycaemic control and perhaps delay the need for insulin treatment (Couzos, 
2005). 
The Quality Use of Medicines Maximised for Aboriginal and Torres Strait Islander 
People Program (QUMAX), introduced in July 2008, aimed to increase medication 
compliance and improve the use of medicines. It was funded by the Commonwealth 
Government Department of Health and Ageing as part of an agreement with the 
Pharmacy Guild of Australia and developed in collaboration with the National 
Aboriginal Community Controlled Health Organization (NACCHO). The program 
complements Section 100 and focuses on appropriate management of conditions, 
choosing suitable medicines as necessary and the safe and effective use of medications. 
This included training for staff, cultural awareness training for community pharmacists, 
on-call pharmacist assistance to the Aboriginal community-controlled health services 
(ACCHS) for urgent medication queries or after hours dispensing of medicines; and 
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transport support for the delivery of prescriptions or medicines between the ACCHS 
and the local pharmacy. This improved recording of PBS safety-net entitlements for 
ACCHS clients, and Medication Access and Assistance Packages (MAAPs) for patients 
with a high level of need (Couzos, 2005; Davidson et al., 2010). 
The financial burden of medicines for those travelling from rural areas for cancer 
treatment is highlighted in one study. The personal cost for those living more than 
100km away from the Townsville hospital receiving cancer treatment ($7752), 
including radiation ($5135) was significantly greater (mean - $4311, median - $2263) 
than those receiving cancer treatment in the regional areas (Gordon, Ferguson, 
Chambers, & Dunn, 2009). 
Although there are many studies about indigenous people and healthcare, there is 
comparatively little research specifically on access to and use of medicine amongst 
indigenous people. Literature indicates that indigenous populations in this study 
received some medication for their condition’s issues of equity of treatment, and 
medication management remain. 
 
 
3.7 Rural and medicines use and access 
There were 394 relevant papers found. These are discussed further under the 
following groupings: 
• Knowledge and adherence 
• Complementary alternative medicine 
• Interventions 
• Rural workforce/health professionals 
• Other 
 
Access to healthcare, including to medicines, can be challenging for people living in 
rural or remote regions. Literature shows access to health care services for these 
populations can be poor, not just because of geographical distance, but also because 
health systems may not be appropriate or sufficient to meet the needs of rural or 
remote populations. People living in rural areas can face additional barriers to accessing 
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and using medicines in addition to those barriers experienced by people living in urban 
areas. 
Some studies found lower rates of medicines use for some conditions in rural and 
remote areas. For example, Caldwell (2004) found that there were only small regional 
differences across rural, remote and metropolitan areas for the rate of psychological 
problems and prescriptions for mental health medications per 100 GP-patient 
encounters. However, rural and remote residents visited GPs less frequently than their 
metropolitan counterparts, so their level of medication use for mental health was lower. 
The residents of remote areas were prescribed mental health medications at half the 
rate of those in the capital cities (Caldwell et al., 2004). Calver et al (2007) found the 
rate of stimulant prescription use in the treatment of ADHD44 was 2.3 to 5.3 times 
greater in major cities in Western Australia compared with remote and very remote 
parts of the state (Calver, Preen, Bulsara, & Sanfilippo, 2007). Henshaw claimed that 
transdermal opioids were underutilised in rural north-Northwest Tasmania, Australia 
(Henshaw, Walker, & Geraghty, 2013). 
A survey by Clarke (2007) found general practice patients in rural areas were less likely 
to receive the recommended diagnosis and management for congestive heart failure 
(CHF). Prevalence of CHF was higher in rural areas than in urban, but the prescribing 
rates of angiotensin-converting enzyme inhibitors was lower (51.4% vs 60.1%) (Clark 
et al., 2007). Warfarin medication was underutilised by patients with atrial fibrillation 
(AF), in the rural areas. In 1992 in Australia, an estimated $100 million per annum in 
direct hospital costs was spent on warfarin related adverse events. Jackson et al (2004) 
illustrates the practical use of point-of-care INR45 monitoring in rural and remote 
communities in three case studies, resulting in potentially safer and more effective use 
of warfarin (Jackson, Peterson, House, & Bartlett, 2004). Rucker et al (2011) found 
remote dwellers (in the study) with diabetes living further than 50 km from a 
nephrologist specialist in Alberta, Canada, were significantly less likely to receive an 
angiotensin converting enzyme inhibitor or receptor blocker medication or have their 
annual bloods and urine reviewed (Rucker et al., 2011). 
  
                                                             
44 ADHD – Attention deficit hyperactivity disorder 
45 INR – International normalised ratio (laboratory test of how long it takes blood to form a clot) 
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An earlier study by Shaw et al (1994) showed lower prescribing of prophylactic 
medications and a greater severity of asthma in Māori children (8 to 13 years old) living 
in Kawerau, New Zealand. They experienced passive exposure to tobacco smoke 
comparative to stored serum collected eight years previously. Although passive 
exposure to tobacco smoke was more common among Māori children, this only partially 
accounts for the greater asthma severity in Māori children. The lower prescribing of 
prophylactic medications may have contributed (Shaw et al., 1994). Similarly, as noted 
above, Norris et al (2011) found rural Māori children in New Zealand received fewer 
prescriptions and lower quantities of antibiotics compared with other population 
groups (Norris, Horsburgh, Keown, et al., 2011). 
In contrast, Sadowski (2009) found that the highest overall analgesic use amongst older 
Manitobans was in the most rural/remote regions. Greater access and defined daily 
dose (DDD) use for all classes of analgesics use was associated with being female, 
increasing age and a cancer diagnosis, when standardised for age-sex access and DDD. 
The lowest use for opioids, and multiple-prescription-program opioids was among 
residents lacking a cancer diagnosis (Sadowski, Carrie, Grymonpre, Metge, & St John, 
2009). 
Chong (2011) showed that Australian community pharmacies recommended the use of 
generic substitution medication less in the remote areas (91.6%) followed by rural 
(98.0%), and urban (98.7%) areas. Patients accepted the generic medication more in 
the remote areas (84.5%) than the rural (78.6%), and urban (73.3%) areas. Use of 
generic medication reduced the cost to patients by 21% (Chong et al., 2011). 
Cutts et al (2003) found more than half the general practitioners surveyed in the rural 
and remote settings of Queensland (n = 258), agreed that their prescribing was 
influenced by practice location, isolation of patient home location, limited diagnostic 
testing and the need for increased drug monitoring (Cutts & Tett, 2003). In contrast 
Hider et al (2007) compared patients that attended non-rural and rural general 
practices in New Zealand and found patients seen in rural practices were provided with 
prescribed prescriptions and non-drug treatments slightly less often, and follow-up 
appointments were arranged less frequently (Hider, Lay-Yee, & Davis, 2007). Mackenzie 
et al (2010) also found little differences in prescribing between general practitioners 
from 'urban and rural' practices in the Scottish Highlands. Overall general practitioners 
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were confident to initiate standard heart failure drugs, with the exception of beta- 
blockers. Differences between urban and rural localities suggest that models of care 
derived from evidence-based practice in urban areas may not be directly transferable 
to remote areas (MacKenzie et al., 2010). 
In contrast, other studies found similar patterns of treatment for urban, rural and 
remote areas. Goldney (2007) used the Accessibility and Remoteness Index of Australia, 
and found that depression was no more prevalent in less accessible regions of South 
Australia. When it was present, the treatment, in terms of antidepressants, was similar 
to treatment in more accessible areas (Goldney, Taylor, & Bain, 2007). Basu & Steven 
(2009), compared rural and urban rheumatoid arthritis populations in Scotland. The 
Disease Modifying Anti-Rheumatic Drugs (DMARDs) were prescribed in 77% of rural 
patient’s vs 70% of their city counterparts, a mean of 5.4 and 4.0 years respectively. 
Similar proportions of patients were exposed to prednisolone therapy and 
musculoskeletal procedures (Basu & Steven, 2009). Vanasse et al (2010) compared 
urban and rural disparities across chronic conditions, and found a common pattern 
across myocardial infarction, osteoporosis, and diabetes. Mortality rates and drug 
utilisation rates were very similar among regions (rural and urban). With the exception 
of hormone replacement therapy in women, the utilisation rates were higher in small 
towns and rural areas compared with metropolitan areas (Vanasse, Courteau, Cohen, 
Orzanco, & Drouin, 2010). Jordan et al (2011) studied rural and urban women (aged 77- 




3.7.1 Knowledge and adherence 
Sundararajan et al (2013) identified barriers to malaria control within the tribal 
populations in malaria-endemic Gadchiroli district, Maharashtra, India. The tribal 
adherence with antimalarial medications was poor. Surveillance by Community Health 
Workers was thwarted by the remoteness of villages, lack of transport and the high 
costs of malaria treatment outside the villages (Sundararajan, Kalkonde, Gokhale, 




Although 59% of parents of children with asthma on Thursday Island, Queensland, 
Australia, knew the dose of the medication prescribed for their child’s asthma, 80% had 
minimal knowledge of their child’s asthma medications. The children’s asthma 
management improved by 88% with the introduction of an appropriate spacer, device 
and changes to the dose and type of medications prescribed (Chang et al., 2000). 
Rheumatic fever (RF) and rheumatic heart disease (RHD) participants in rural Australia 
(Kimberly), participated in a Mincham et al (2003) study that linked medication 
compliance closely to positive patient–staff interactions. Compliance with medication 
sometimes came second to other priorities such as sporting commitments. Participants 
also had variable levels of understanding about RF/RHD, often related to the need for 
secondary prophylaxis and described living in a remote location as a negative influence 
(Mincham, Toussaint, Mak, & Plant, 2003). 
Twenty-nine adults from five remote Torres Strait Island communities in the Torres 
Strait region, with an HbA1c ≥ 8.5% (69 mmol mols) who were not taking insulin, 
participated in a survey using Insulin Treatment Appraisal Scale (ITAS) and Barriers to 
Insulin Treatment Questionnaire (BITQ). Overall, 34% had poor glycaemic control, 
compared to those with HbA1c levels ≥ 8.5% and taking insulin (n=37). Those in the 
group not taking insulin were more obese, more likely to smoke and drink alcohol, had 
lower mean HbA1c and fewer years with diabetes. Among this group, those with higher 
‘barriers’ (BITQ scores) were older and had lower formal education than those 
reporting fewer barriers. Participants consistently scored low in ‘knowledge’, especially 
those related to insulin initiation (insulin improves glucose control and prevents 
complications (Taylor et al., 2016). 
 
 
3.7.2 Complementary and alternative medicine (CAM) 
Poor access to conventional medical care appears to have influenced the increased use 
of CAM by women surveyed by Adams et al (2011), however this was not consistent 
across rural and remote areas. Users of CAM had a high prevalence of hypertension and 
skin cancer amongst the rural and remote residents (Adams et al., 2011). Traditional 
CAM providers were essential for rural healthcare in Canada, as they were accessible 




Lytle, Walji, & Cooley, 2013). Meurk et al (2013) found women with certain conditions 
had to travel to access adequate medical care, and it was clear that CAM was not a 
suitable substitute for orthodox medicine in cases of severe injury, accident or serious 
illness. They tended towards using CAM therapies as a preventative for the treatment of 




Studies suggest the use of “tele” programmes and interventions are enablers to access, 
support and specialist services, including advice for people servicing these areas and 
demonstrate positive outcomes for people and communities living in rural remote areas 
who would otherwise not have access to these resources. 
The Royal Flying Doctor Service (RFDS) in Australia has provided telemedicine 
consultation services since 1942 and this is supported by a tele-pharmacy program 
known as the Medical Chest Program. More than 85 items, including medications and 
equipment can be prescribed during a telehealth consultation, to cover both emergency 
care and treatment for less serious conditions. The most common categories of 
dispensed medications were: antibiotics (26%), analgesics (23%) and gastrointestinal 
medications (12%). The most common clinical diagnostic categories for the 
consultation resulting in dispensed medications were respiratory (17%), skin (15%) 
and abdominal conditions (13%). The RFDS medical chest program is a successful 
large-scale provider of medications to those living in remote Australia, enabling early 
access to medications for both emergencies and definitive care, while minimising the 
need for mail-order pharmacy or patient travel (Margolis & Ypinazar, 2008). 
The tele pharmacy programme at the Community Health Association of Spokane (CHAS- 
United States) allows for the dispensing of low-cost medications through participation 
in the federal government's 340B program, and the use of remote dispensing and 
counselling via a two-way interactive videoconferencing system to patients at six urban 
and rural clinics. Results from a questionnaire indicate overall, 75% patients seen at the 
remote sites were satisfied with their video conference interactions with the 
pharmacist. Of those seen at base sites 66% were satisfied with the time required to 
obtain medications and counselling. Patients seen at both sites mostly had no health  
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insurance and agreed they would have difficulty affording their medications without the 
programme (Clifton, 2003; Davis, Howard, & Brockway, 2001). Peterson et al., (2004) 
described telepharmacy in the rural areas of North Dakota, and found remote 
telepharmacy sites dispensed 15-55 prescriptions per day (average ∼35) and serviced 
communities with populations ranging from 498 to 1,367 people (average ∼799) 
(Peterson & Anderson Jr, 2004). 
Dharmar et al (2013) conducted a retrospective chart review of seriously ill and injured 
children presenting to eight rural EDs, with access to paediatric critical care physicians 
from an academic children's hospital. The study found that telemedicine was associated 
with a significantly reduced risk of physician-related ED46 medication errors among 
seriously ill and injured children in rural ED. Patients receiving telemedicine 
consultations also had significantly fewer physician-related errors, than patients who 
received telephone consultations or no consultations (3.4% vs 10.8% and 12.5%, 
respectively; P < .05) (Dharmar, Kuppermann, et al., 2013; Dharmar, Romano, et al., 
2013). 
The telestroke system successfully introduced safe thrombolysis and early specialist 
review of acute stroke patients in rural Victoria by providing remote access to 
neurologists via videoconferencing systems. This has the potential to bridge the gap of 
rural-metropolitan inequality in acute stroke care. The Nagao et al (2012) study found 
that of participants in an intervention group (54) and a control group (36) who were 
eligible for thrombolysis47, 24 patients in the intervention group had telestroke 
activated. Eight patients underwent thrombolysis. There was no thrombolysis in the 
control group (Nagao, Koschel, Haines, Bolitho, & Yan, 2012). 
Wang et al (2004) and Hess et al (2006) described the Remote Evaluation for Acute 
Ischemic Stroke, REACH and telestroke programme for outreach system as an enabler 
for remote stroke physicians to direct the local ED staff to administer thrombolytic48 
medicines for stroke presentations in rural settings where thrombolytic medicine was 
not previously used. REACH is a rapid consult tool that provides the same quality of 
stroke care to patients in rural hospitals as is given in tertiary stroke centres and 
                                                             
46 ED – Emergency department 
47 Thrombolysis - breakdown of blood clots formed in blood vessels 
48 Thrombolytic – drug used to break up or dissolve a blood clot 
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endeavours to bring stroke expertise to rural community hospitals (Hess et al., 2006; 
Wang et al., 2004). 
Hilty (2006) found individual primary care providers (PCPs) and clinics in rural areas, 
significantly improved medication dosing over time, when utilising tele psychiatric 
services. Comments included “normally, we do not get to discuss the rationale for 
medication and how to target symptoms” and “it was challenging to focus on decision 
making rather than just learn which drug would work for a disorder” (Hilty, Yellowlees, 
& Nesbitt, 2006). 
Davidson et al (2010) and Lu (2007) highlighted the adverse health outcomes 
associated with poor medication adherence for those indigenous populations in rural 
remote regions of Australia. They emphasised the need for strategies to have multiple 
approaches and initiatives (e.g., subsidised medicines), to improve the quality use of 
medicines for populations in rural remote areas (Aboriginal Torres Strait Islanders) 
(Davidson et al., 2010; Lu, 2007). 
 
 
3.7.4 Rural workforce / health professional 
Working as a health professional in a rural area requires specialised skills. To ensure 
the sustainability of a competent rural workforce requires the recruitment and 
retention of rural health professionals with a robust teaching health system, continuity, 
commitment and funding (Murray & Wronski, 2006). In Australia, courses are 
established specifically to increase the workforce in rural and remote areas. Young 
(2016) examined the views of beginning Medical students in a rural-focused medical 
course, such as on the rural lifestyle, rural doctor’s role and rural practice. These were 
mostly positive, such as the doctor’s role, views of doctor, impact on community, 
broader work and skills knowledge, and better relationships with community and 
patients. Challenges identified included doctor’s health, pressure on doctor, family 
problems, greater workload, privacy and confidentiality issues, cultural issues, isolation, 
limited resources and financial impacts (Young, Lindsay, & Ray, 2016). 
The sustainability of the rural workforce area is vital to ensure the most appropriate 
services are available to those populations. Dedicated resource to ensure the 
sustainability and continuity of service delivery in these areas is crucial. Working with  
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the local communities to find fit for purpose solutions that meet the local needs is also 
important (Baker, Eley, & Lasserre, 2005; Gorsche & Woloschuk, 2012; Kitto, Peller, 




McCarthy et al (2003) found in the smaller rural and remote Queensland facilities, the 
majority of chemotherapy administered was relatively simple in terms of 
administration and toxicity such as 5-FU, methotrexate and cyclophosphamide, and it 
was not uncommon for more potent cytotoxic (vesicant drugs cisplatin and carboplatin) 
medication to be administered. This required a higher degree of knowledge and skill to 
administer safely, posing potentially higher risk to nursing staff and poorer patient 






3.8.1 Māori and diabetes 
The prevalence of type 2 diabetes is greater for Māori than non-Māori. The 
manifestation of the disease is also greater in severity for Māori. Presentation and 
diagnosis are often delayed, and more likely to occur at a younger age, and increase as 
people age. The incidence of diabetes is increasing, particularly for those living in rural 
remote areas. There is a strong association between diabetes and low socioeconomic 
status. The number of people with undiagnosed diabetes is said to be more than twice 
that of those diagnosed. 
Māori experience a far greater burden of disease than non-Māori, particularly for 
diabetes related comorbidities and premature mortality. Poor diabetes management 
and treatment contribute to these poor outcomes, which Māori experience far greater 
than non-Māori. Māori also experience a greater prevalence of risk factors like obesity, 
smoking, family history, ethnicity and complications associated with diabetes, such as 




Māori centric, group-based programmes and interventions have been found to be 
effective. Studies indicate gaps in diabetes knowledge are greater for Māori than non- 
Māori, especially for those living in the rural areas. There are multiple complexities 
associated with the self-management of diabetes with no single solution. Primary 
supports (family and friends) of similar or the same belief system was found to be 
effective, then those health professional’s biomedical practice. 
 
 
3.8.2 Indigenous populations and diabetes 
Literature indicates a similar pattern of diabetes prevalence for other indigenous 
populations. Indigenous populations were more likely to have a greater prevalence for 
all risk factors (modifiable and non-modifiable) and the complications associated with 
diabetes, especially for those in the younger age group. Interventions responsive to 
need and an understanding from an indigenous population perspective of the 
connection between diabetes and western and/or traditional medicine were found to be 
effective and more likely to achieve positive outcomes. Population screening of 
indigenous populations was used in early detection and diagnosis of diabetes. 
Culturally appropriate management and treatment of diabetes are effective when 
tailored for indigenous populations. However, disparities are evident between 
indigenous and non-indigenous populations. 
 
 
3.8.3 Māori medicines access and use 
Several studies of medicine use in the management and treatment for some conditions 
show disparities between Māori and non-Māori (such as antibiotic used by children in 
rural areas). Disparities also continue in adherence patterns for some conditions 
indicating sub-optimal treatment, and some conditions over treated, like gout. However, 
other studies found appropriate medicines use and adherence for some conditions. 
Literature shows the challenges and barriers to the access and use of medicine for 
Māori. These challenges and barriers are also observed across other indigenous 
populations in the literature reviewed. Common barriers included: cost of medicines, 
access to prescribers, and physical locality. They may have a perception that the 
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medicine was no longer needed, and stop taking the medicine. 
 
Attitudes to medicines differed across ethnicities, impacting on the use and access of 
medicines for people’s conditions and outcomes. Māori had a different definition and 
understanding of medicine to non-Māori, and were not averse to the use of traditional 
medicines alongside western medicine. 
 
 
3.8.4 Indigenous medicines use and access 
Indigenous populations have poorer access to medicines than non-indigenous 
populations, depending on location, condition and medication. Comparing population 
measurements of treatment and management like immunisation coverage or 
preventative measures, they were poorer for indigenous populations (as they are for 
Māori). Access to appropriate treatment and care was an issue for many indigenous 
groups, particularly for those in rural remote areas. They received sub-optimal 
treatment for some conditions while other conditions were over treated. Preventative 
measures were less likely to be accessed by indigenous populations and this 
contributed to poor outcomes. 
The use of medication was particularly challenging for many indigenous people, as they 
were likely to have multiple medications. However, improved communication between 
the consumer and the health professional would increase their knowledge and 
education about the medication, improving medication adherence. 
Culturally appropriate programmes are effective and best suited to meet the needs of 
indigenous populations. Despite strategies like “tele” services to increase access to 
medications, inequity in access to treatment, medication and the use of medication for 
indigenous populations remains an issue, comparative to non-indigenous populations. 
 
 
3.8.5 Rural and medicines use and access 
Problems with access of medicines and use of medicines in rural areas included: access 
to transport, medicines and specialist services; the degree of rurality or remoteness; the 
cost of medications; patient/practitioner relationships; level of education; knowledge 
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about medication use; the practice of complementary and alternative medicine. 
Regardless of country studied, all agreed that rurality was a factor in the access and use 
of medicines for rural populations. There were a number of factors that impacted on 
medicines use and access, including: fewer visits to the doctor, hence less medicines use 
than urban/metro counterparts, particularly for some conditions (antibiotics, mental 
health) but not others. People living in rural areas were less likely to visit a GP, and 
fewer visits to the GP could account for less medications use and in some conditions 
overuse of medicines (analgesics). 
Positive relationships between staff and patients were linked to medication compliance; 
however, medication was not always a priority for some patients. Medication 
knowledge was not consistent across the studies reviewed. The use of specialist 
medicines was restricted due to a required higher level of knowledge and services. The 
use of complementary alternative medicine was common practice, especially by women, 








There is a high prevalence of diabetes in Tairāwhiti, as outlined in chapter one. 
Following global trends, the incidence of diabetes is predicted to increase, as people 
become fatter and more sedentary in lifestyle. In this chapter the author utilises data 
from the EIPMU (2005-2006) study to examine the pattern of diabetes medicines use in 
Tairāwhiti and whether the medicine use matches the pattern of diabetes. The EIPMU 
study described in this chapter was part of a wider Health Research Council (HRC) 
funded project, titled Equity in Prescription Medicines Use (EIPMU).  The EIPMU study 
(2005-2006) explored demographic variation in medicines use in Tairāwhiti, New 
Zealand, by utilising pharmacy dispensing databases, which contained records of all the 




The main aim was to investigate and determine any patterns of diabetes medicines use 
and if these matched the pattern of known diabetes in the population. Further 
explorative questions were; what, if any disparities of diabetes medicines use exist in 
Tairāwhiti; and examine any differences in the distribution of diabetes medicines 




• To assess if the pattern of diabetes medicines use is equitable according to the 
prevalence of type 2 diabetes. 
• To examine the distribution pattern of diabetes medicine use, by age band and 
ethnicity during the study period. 
• To assess if there is a difference in the type of diabetes medicines used by 







The data from the Equity in Prescription Medicines Use (EIPMU) study (Horsburgh et al., 
2010) was used to examine dispensings of diabetes medicines in Tairāwhiti. At the 
time, the EIPMU dataset was the most comprehensive source of medicine dispensing 
data for Tairāwhiti. 
In New Zealand, the National Pharmaceuticals Collection database (known as ‘Pharms’), 
is a source of medicine use maintained by the Ministry of Health and the Pharmaceutical 
Management Agency (PHARMAC). The Pharms database is a record of all medicines 
dispensed, that the New Zealand government has contributed to the cost of (or 
‘subsidised’). There are some exceptions where medicines are not recorded in the 
Pharms national database; where a medicine is particularly cheap, and the patient’s 
payment has covered the cost of the medicine and the government contribution was 
zero; or where the government does not contribute at all to the cost of the medicine. For 
the purposes of the study, the Pharms database, was incomplete and limited as a data 
source. Hence, data from the Equity in Prescription Medicines Use (EIPMU) 2005/2006 
study was utilised. Diabetes-specific data is now available in the Virtual Diabetes 
Register (VDR established in 2007) described in chapter one. Retrieved October 3, 2019, 
from  https://www.health.govt.nz/our-work/diseases-and-conditions/diabetes/about- 
 diabetes/virtual-diabetes-register-vdr   
 
The analyses were restricted to people aged 25 or over, as the Tairāwhiti District Health 
Board49 population counts did not include people with type 2 diabetes who were 
younger than 25 years. 
 
 
4.3.2 Data sources 
 
4.3.2.1 The EIPMU study    
The EIPMU study was undertaken to examine and explore the utilisation of medicines 
among population groups in Tairāwhiti using data downloaded directly from the 
                                                             
49 Tairāwhiti District Health Board – governing crown agency for health services in Tairāwhiti 
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dispensing databases of community pharmacies. Early phases of the EIPMU project 
included initial engagement with local pharmacies to gauge their interest and 
agreement to provide data, and to explore any concerns they had. Consultation 
occurred with local stakeholders and interested community groups. 
Ethical approval from a Ministry of Health accredited ethics committee was obtained. 
The research group implemented strict protocols to maintain and ensure patient 
privacy. Ngāti Porou Hauora50 and Tūranganui Primary Health Organization51 were 
supportive of the study. The study was funded by a Health Research Council project 
grant (07/139). 
Pharmacy dispensing data were collected from all nine community pharmacies located 
within Gisborne for the period 1 October 2005 to 30 September 2006. It is likely that 
nearly all prescription medicines for people in Tairāwhiti were dispensed from these 
nine pharmacies; the nearest pharmacies outside the region (Opotiki and Wairoa) were 
at least an hour drive via a winding road. Dispensings possibly not captured were for 
people that travelled outside the area (on holiday, for example). 
Tairāwhiti was selected for the EIPMU study for the following reasons: 
 
• The region was geographically isolated, and the next closest pharmacy was at 
least an hour’s drive outside the region. 
• A high proportion of Māori compared to the national average (44% vs 30%) 
(Ministry of Health, 2013) live in the region, and 75% (Māori) lived in Quintile 
552 (most deprived) areas (Ministry of Health, 2016) 
Data for all medicines dispensed from the nine pharmacies - eight community 
pharmacies and the hospital pharmacy (outpatients only) were collected for the period 
1 October 2005 – 30 September 2006. Patients in inpatient hospital care dispensed 
medicine were not included in the study as these medicines were at no cost to the 
patient and the patient and medication details were not in electronic format and thus 
not easily retrievable. 
A series of computer programs were developed to match individual patients across the 
different pharmacies and all their dispensings (Horsburgh et al., 2010). Address data  
                                                             
50 Ngati Porou Hauora – Māori Health provider and Primary Health care agent 
51 Tūranganui Primary Health Organization – Primary Health care agent 
52 Quintile – measure of deprivation; 1 (least deprived) to 5 (most deprived) 
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from the pharmacy dispensing computers was geocoded and used to determine each 
individual’s New Zealand Index of Deprivation (NZDep 2006) score (Salmond et al., 
2007). 
Dispensing records (total of 619,264) were matched to an individual. After data 
cleaning and linkage, 561,223 (91%) dispensing records for 38,027 individuals with 
complete person and medicine information were available (Horsburgh et al., 2010). 
Medicines were classified according to the Anatomical Therapeutic Chemical (ATC) 
classification system, an internationally recognised system that classifies the active 
ingredients of a drug, according to the organ and body system they target, and their 
pharmacological and chemical structure (WHO, 2009). 
To examine variations in medicine use by ethnicity, people were coded as Māori or non- 
Māori, based on their self-identified ethnicities recorded in the Ministry of Health’s 
National Health Index (NHI) collection (Ministry of Health, 2009). If a person self- 
identified as Māori for any of their recorded ethnicities, they were coded as Māori. 
Otherwise, they were coded as non-Māori. People with no ethnicity data were included 
in the non-Māori category. Other demographics, such as age and gender, were either 




4.3.2.2 Population counts  
The population counts for diagnosed diabetes type 1 and 2, aged over 25 years, for the 
study period were sourced from the Tairāwhiti District Health Board. These data are 
estimated at the time of the study from the “Get Checked” programme53  (Ian Diamond, 
Planning and Funding Tairāwhiti District Health Board). Data provided included 
ethnicity and age, but no gender or socioeconomic deprivation data. The analyses below 
therefore do not address the latter two demographic variables. 
Tairāwhiti population figures for calculating the prevalence of type 2 diabetes overall 
by age group and ethnicity were obtained from the New Zealand Census (2006). To
                                                             
53 These figures are a count of all people in the year recorded as having a hospital discharge diagnosis of 




determine the proportion of people with type 2 diabetes receiving medications, the 
figures provided by the Tairāwhiti District Health Board for the type 2 diabetes 
population in Tairāwhiti were used as the denominators and broken down by age group 
and ethnicity, and it was assumed that all these people receiving antidiabetes 
medication were to treat type 2 diabetes. 
 
 
4.3.2.3 Medicines analysed 
The main focus was on the primary pharmacological treatments for type 2 diabetes 
in New Zealand – biguanides (ATC A10B) (Metformin), sulphonylureas (A10BB) 
(Glipizide, Gliclazide, Glibenclamide) and insulins (ATC A10A) (New Zealand 
Guidelines Group, 2012). At the time of the study, thiazolidinediones (ATC A10BG) 
and Alpha glycosidase inhibitors – acarbose (ATC A10BF) were very rarely used and 




A descriptive statistical analysis, was used to describe diabetes medicine use by age 
and ethnicity. Population counts supplied by the Tairāwhiti District Health Board for 
type 2 diabetes (see section 4.3.2.2), by age and ethnicity, were used to examine 





4.4.1 Type 2 diabetes in Tairāwhiti 
According to figures provided by the Tairāwhiti District Health Board, in 2006 1,748 
people, or seven percent (7%) of the region’s population, had been diagnosed with type 
2 diabetes in Tairāwhiti. The greater proportion of people with type 2 diabetes were 
Māori (1,090 or 62%). The prevalence of type 2 diabetes was greater for Māori 




Figure 13 shows the prevalence of type 2 diabetes by age group and ethnicity in the 
Tairāwhiti population. The overall prevalence increased across the age groups to 65-74 
years, and then slowly declined. Across all age groups, the prevalence of type 2 diabetes 
was substantially greater for Māori than non-Māori. The increase in prevalence 
occurred much earlier for Māori than non-Māori. The greatest prevalence was Māori 
aged over 65-74 years, and the lowest prevalence was in the 25-34 age group for both 
ethnicities.  
Most of the people with type 2 diabetes were in the middle to older age group (55 -85 





Prevalence of type 2 diabetes in Tairāwhiti 
 
 
Figure 13: Prevalence of type 2 diabetes in Tairāwhiti 1 October 2005 – 30 September 2006.  
 (Data source: Tairāwhiti District Health Board) 







Table 4: Prevalence use of diabetic medicines for type 2 diabetes: by medicine class, age and ethnicity 
 
Biguanide Sulfonylurea Thiazolidinedione Insulin Combined 
  type 2    type 2    type 2    type 2   type 2 
 diabetes N diabetes N diabetes N diabetes N              diabetes 
 
Age Group 
          
25-34 49 63% 7 9% 0 0% 22 28% 67 86% 
35-44 117 53% 44 20% 4 2% 50 23% 149 67% 
45-54 227 54% 91 21% 13 3% 63 15% 279 66% 
55-64 310 71% 177 41% 12 3% 91 21% 393 90% 
65-74 247 70% 169 48% 11 3% 80 23% 336 96% 
75-84 115 58% 96 48% 2 1% 49 25% 199 100% 
85 and over 19 49% 21 54% 0 0% 4 10% 36 93% 
Ethnicity           
Māori 614 56% 324 30% 20 2% 171 16% 772 71% 
Non-Māori 439 67% 267 41% 22 3% 179 27% 649 99% 
Unknown 31  14  0  9  38  
Total 
 




2% 359 21% 1459 83% 
 





Table 4 shows the people in Tairāwhiti who were dispensed a diabetes medicine by age 
group, ethnicity and diabetes medicine class. Eighty three percent of the people with 
type 2 diabetes received one or more antidiabetes medication. Biguanides were the 
most commonly used class of diabetes medicine (62% of people with type 2 diabetes), 
followed by sulphonylureas (35%) and insulins (21%). Thiazolidinediones were hardly 
used at all (2%) and not considered in the remainder of these analyses. More non-Māori 
were dispensed a diabetes medicine (99%) compared to Māori (71%). The 35 to 54 age 
group received the lowest proportion of medicine dispensed (67% and 66%). People 
receiving insulin in the 25 to 34 age group were likely to be people with type 1 diabetes. 
Nearly all those >55 years received at least one diabetes medicine class. Biguanide 
use peaked between the 55 - 74 age groups, as expected, given that metformin is the 
first line pharmacotherapy for the treatment of type 2 diabetes (New Zealand 
Guidelines Group, 2012). Sulphonylureas use increased as people aged, consistent 
with recommended treatment guidelines. Insulin use was reasonably consistent 




Prevalence use of diabetes medicines in Tairāwhiti 
 
 
Figure 14: Prevalence of diabetes medicine use, by age group and ethnicity in Tairāwhiti.  
(Data sources: EIPMU Study [diabetic medications use] and Tairāwhiti District Health Board [population counts for people with 




The prevalence use of any diabetes medicine by age group and ethnicity (Figure 14) was 
calculated to determine if there were any differences in medicine use by ethnicity and 
age. The prevalence of diabetes medicine use was consistently lower for Māori than 
non-Māori across all ages, especially at the younger and older age groups where the 
difference is markedly greater. Where the prevalence is greater than 100% (non-Māori 
25-34 years), it is likely to be due to including those receiving treatment for type 1 





















































Figure 15: Proportion of people taking diabetes medicine, by class of medicine, age and ethnicity.  
 
(Data source: EIPMU Study) 
 
106  
To clarify further if there were any differences in the class of diabetes medicine use by 
age between Māori and non-Māori, the proportion of people who were taking a 
biguanide, sulphonylurea or insulin by age group and ethnicity in those people taking at 
least one antidiabetes medication, was calculated (Figure 15). People can take a 
combination of these medications, and the proportion for each age group can total to 
more than 100%. When compared, the patterns of diabetes medicine use were broadly 
similar for Māori and non-Māori. The increased use of insulin in the younger age group 
for non-Māori was consistent with the prevalence of use seen in the same group in 
















































Figure 16: Percentage of people who received one or more class of diabetes medicine in the study year, by age and ethnicity.   
 
(Data source: EIPMU Study)
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In the study period, over half the people dispensed with diabetes medication 
(60% or 877 people) received one medication class, while 534 (37%) people 
received two classes of antidiabetes medication. Three percent (48 people) 
received three or four classes of antidiabetes medication. Of those people 
receiving multiple diabetes medicine, most (376 people, or 65%) received a 
combination of biguanide and sulfonylurea. Twenty-one percent (125 people) 
were dispensed a biguanide and an insulin. 
Receiving multiple classes of diabetes medicine was slightly more common in 
Māori than non-Māori (44% vs 36%). For ages 25 – 64 years, Māori were more 
likely to receive multiple diabetes medicine (Figure 16). This pattern is 
consistent with Māori developing type 2 diabetes at an earlier age and a greater 
severity of condition than non-Māori, requiring more intensive pharmacological 
treatment to achieve glycaemic control. In addition, young Māori have a higher-
than-average BMI (Body mass index) compared to non-Māori, a known risk 




Māori experience a greater burden of disease compared to non-Māori, 
particularly for diabetes and diabetes-related co morbidities in Tairāwhiti 
(described in chapter one). Figure thirteen highlights the prevalence of type 2 
diabetes is far greater for Māori than non-Māori. Were the treatment of type 2 
diabetes equitable, you would expect the proportion of people receiving diabetes 
medicines to be the same, if not at least similar in pattern, with some variance 
due to clinical parameters. These findings however indicate inequity and 
disparity in the prevalence of diabetes medicines use. Māori had lower medicine 
use across all ages and then non-Māori (Table 4 and Figure 14). 
This begs the question – “What might the reasons be for these findings”? People 
who develop type 2 diabetes earlier are likely to have a greater severity of 
disease and a number of risk factors. These include immediate whānau with 
diabetes, and a higher risk of diagnosis at a young age. Younger Māori have a 
higher average BMI compared to non-Māori (Lascar et al., 2018; Ng et al., 2014).  
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People aged < 40 years diagnosed with diabetes have a higher risk of mortality, 
cardiovascular disease, chronic kidney disease and retinopathy than older adults 
with diabetes, or type 1 diabetes of a similar age, and have been shown to have a 
more aggressive progression of diabetes leading to more advanced 
complications (Beig et al., 2018; Elley et al., 2008). This is because having 
diabetes longer exposed people to more risk (Al-Saeed et al., 2016; Dabelea et al., 
2017; Huo et al., 2016). The differences in the use of medicines (and limited 
clinical parameters) are consistent for people diagnosed with diabetes at an 
early age and experiencing a progressive disease state. Improving glycaemic 
control can prevent microvascular complications, and reduce macrovascular 
complications long term (>8 to 10 years) (McNamara, 2019). These and other 
possible drivers, for example differential attitudes and beliefs of diabetes and 
medicines, and communication and relationships with health professionals, are 
explored further in chapter five. How people access medicines in rural areas is 
discussed in chapter six. 
This difference in medicine use is consistent with multiple medicines use by 
Māori, particularly at a younger age (Figure 16), suggesting an early onset of 
diabetes and the likely presentation of an advanced progression of the disease. 
The Ministry of Health, Virtual Diabetes Register identified the incidence of 
people with diabetes aged 30 – 39 years has nearly doubled between 2005 to 
2017 (Cundy & Drury, 2018). This highlights the need to initiate pharmacological 
therapy early. Increasing the need for optimal diabetes management and 
treatment, in this age group, studies indicate this age group have poor glycaemic 
control and sporadic contact with healthcare services (Beig et al., 2018; Huo et 
al., 2016). Excess weight is also prevalent in people with type 2 diabetes earlier 
in life (Beig et al., 2018). As expressed earlier, New Zealand has one of the 
highest rates of obesity in the world (Ng et al., 2014). 
The incidence of type 2 diabetes in children and adolescents in New Zealand has 
been observed to be increasing, particularly for Māori and Pacific Island 
populations (Hotu, Carter, Watson, Cutfield, & Cundy, 2004; Jefferies et al., 2012; 
Jefferies & Owens, 2015; Scott et al., 2006). The prevalence in Figure 13 included 




Potential areas for future discussion are of quality improvement, and a review of 
the system and processes for diabetes data collation and collection regionally 
and nationally. 
Multiple medicines are more common for Māori than non-Māori (Figure 16) and 
this may suggest poorer diabetes management and control, requiring a more 
intensification of treatment. Therefore, we assume this group required tighter 
control and management of their diabetes (individual clinical data was not 
available), by way of more intensive medication. A likely result, of the degree and 
severity of diabetes and the advanced progression of the condition along the 
disease continuum. 
It is important to note that medicines dispensed are not medicines prescribed, 
collected, picked up or delivered from the pharmacy; nor is dispensed indicative 
of people’s adherence and or compliance with their medicine; nor the efficacy of 
medicine dispensed. Medicines dispensed are affected by people’s access to 
medicines and health services, explored in chapter six. The New Zealand Health 
survey (2006/2007) (Ministry of Health, 2010), found Māori were one and a half 
times more likely to have uncollected prescriptions than non-Māori aged >15 
years. During the study period, Tairāwhiti were funded Very Low-Cost Access 
(VLCA54). This funding provided people with subsidised doctor visits and 




Data analyses were at a population level, rather than individual level. The 
analyses were based on the assumption that all those who received diabetes 
medicine had type 2 diabetes. Individual data related to diabetes status and 
diabetes medicine use were not available. However, those who did receive 
diabetes medicine could potentially have type 1 diabetes and/or be treated for 
polycystic ovarian syndrome (PCOS) or gestational diabetes. PCOS is an 
endocrinological condition known to cause infertility, and affects approximately 
4-12% of women in New Zealand. The prevalence of PCOS increases for women  
                                                             
54 VLCA - funding stream administered by Primary Health organizations to general practice 
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who are either obese, insulin resistant, have diabetes or have a family history of 
PCOS (Farquhar & Johnson, 2008). 
General practices are eligible for Practitioner Supply Order (PSO) medicines 
which are commonly used by rural general practice. Data for PSO medicines 
were not included in the collation and analysis because they do not contain 
information on the person receiving the medication. These medicines were not 
evident in the dispensing data and potentially may contribute to the 
underreporting of medicines for the region. 
The data does not inform the reader of the levels of medication adherence, and it 
was difficult to determine over the study period, as people may have started 
their medication at any time point during the study. For example, a person who 
received a bolus amount, or an increase or decrease in medication during the 
year (dependent on clinical need, medication titration is common practice to 




This chapter highlighted that Māori have greater prevalence of type 2 diabetes in 
Tairāwhiti than non-Māori. Māori experience a disparate use of diabetes 
medicines for the treatment and management of type 2 diabetes. Non-Māori 
were the greater users of diabetes medicines. Māori (<35 years) were the greater 
users of multiple medicines, indicative of a likely advanced disease state, and 
necessary treatment intensification. Evidence clearly indicates early intervention 
and treatment can limit the disease state and associated comorbidities. 
This study provides evidence of the untenable and inequitable use of diabetes 
medicines in Tairāwhiti between Māori and non-Māori for the treatment and 
management of diabetes. This ignited my interest and provided the impetus to 
investigate further the reasons for these findings in the study. These analyses 
also further inform the qualitative studies of the thesis. Preceding chapters 
orient the reader to an overview of Te ao Māori that underpins the study; 
contextualises the region – Tairāwhiti; and gives a comprehensive literature 
review of other indigenous populations and diabetes and medicines use and 
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access. The following chapters describe the lived experiences of whānau with 





“Turanga mua, Turanga tika, Turanga muri, Turanga he” 
 
The lens we gaze through shapes our understanding, knowledge 
and gives meaning to our world. 
 
This research is through a Kaupapa Māori lens that also looks to 
the future by looking to the past. 
5 Chapter 5: Exploring the views and experiences of Māori 
with type 2 diabetes living in Tairāwhiti 
 
“Ehara taku toa i te toa takitahi, engari he toa takitini” 
 
 
“Success should not be bestowed onto me alone, 







The aim of this study was to explore the participants’ (referred to in this chapter 
as whānau) feelings about diabetes and identify what living with diabetes means 
for whānau. It aims to assist health professionals understand the meaning of 
diabetes from a te ao Māori perspective. The majority of diabetes management 
and treatment has traditionally been in primary health care: a brief meet and 
treat, one on one consultation. However, not all people live in isolation from 
either their whānau or community. Therefore, it is important to understand a 
person’s worldview and understand their context of whānau life and community, 
in order to identify achievable strategies that best support and awhi (to 
surround and be with) whānau in their management of type 2 diabetes to ensure 




It is important to detect and diagnose diabetes early, treat and manage 
appropriately to minimise the impact of diabetes and ensure positive outcomes. 
If left undetected, diabetes can result in microvascular and macrovascular 
damage that is not always visible or felt by the individual. 
Findings from chapter four explored the patterns of diabetes medicine use, and 
clearly identifies that the prevalence of type 2 diabetes is greater for Māori, and 
Māori were less likely to receive diabetes medicine than non-Māori. This is an 
alarming result for a region where Māori make up half the population (Brady, 
2007; Director General of Health, 2006; Green & Collins, 2005b). These findings 
have generated more questions than answers, as to the reasons why these 
inequities and disparities have occurred for Māori. This chapter focuses on the 
voice of Māori with diabetes (type 2) living in Tairāwhiti, their views and 
experiences. It is hoped that these findings will provide some insight and 
understanding, and potentially illuminate reasons for the pattern of diabetes 
medicines dispensed found in chapter four and possible ways to reduce these 
differences of inequity, and improve outcomes for Māori. 
The literature review (chapter three) identified that indigenous populations are 
disadvantaged compared to non-indigenous cultures in many aspects of diabetes 
and medicines. Globally, indigenous populations have the highest incidence and 





This study aims to explore the views and experiences of Māori, with type 2 
diabetes in Tairāwhiti. This will provide a Māori perspective of diabetes and an 
understanding of the realities for Māori living with diabetes; what diabetes 
means for them and their whānau; and what those experiences mean for whānau 




Key questions were: 
 
• What are the views and understandings of Māori with type 2 diabetes? 
• What does diabetes mean for Māori? 
• How do Māori with diabetes feel about taking diabetes medication? 







As described earlier in chapter two, the thesis is grounded within a Kaupapa 
Māori worldview. The researcher is Māori and the participants are Māori. The 
study locality is Tairāwhiti, where nearly half the population are Māori. 
Traditionally Māori were renowned for their oratory and storytelling prowess, a 
practice that was applied during these interviews; this was to allow the 
opportunity for the sharing and transfer of matauranga (knowledge, information, 
whakapapa, tikanga). 
The study is informed by grounded theory as described by Strauss and Corbin 
(Strauss & Corbin, 1998), applying an inductive approach. This best describes 
the essence of everyday experiences or individual’s life worlds. Findings from 
data has been systematically gathered and analysed through the research 
process. This approach allows for themes or commonalities to emerge from the 
data and provides an opportunity to explore local tacit knowledge in the context 
of the study. 
This study is an example of insider research, where the researcher is part of the 
context and known to the whānau interviewed, either as a colleague, health 
professional or whānau member (Smith, 2012). Therefore, the researcher had a 
pre-existing relationship prior to the commencement of interviews. This 
knowledge and relationship provided a level of comfort and safety for whānau 
interviewed and whānau were readily engaged. Being of the same ethnicity and 








5.3.2 Sampling and recruitment 
A stratified purposive sampling approach was used to recruit twenty (20) 
whānau to the study. Māori who lived in Tairāwhiti with type 2 diabetes were 
invited to participate in the study. The researcher endeavoured to capture a 
broad sample, representative of whānau with type 2 diabetes in Tairāwhiti. A 
significant period of time was required to recruit a diverse sample that was 
representative of people living in rural and urban areas, included people of 
varying duration of diabetes (recently diagnosed and long-term diabetes) age 
and gender (Liamputtong & Ezzy, 2005). Excluded from the study were those 
with acute mental illness or an intellectual disability, or in hospital, or under 
25 years. 
The most appropriate strategy to recruit whānau for the study was a kanohi ki te 
kanohi (face-to-face). The researcher referred to the “interviews” as inviting 
whānau to have a “korero about diabetes”, and explaining the purpose of the 
interviews. Most of the those interviewed had whakapapa links to the researcher 





The method of data collection was semi structured, in-depth interviews using 
open-ended questions to explore whānau views and experiences of diabetes. In- 
depth interviews are to understand the whānau perspectives of their lives, 
experiences and/or context as expressed in their own words (Taylor & Bogdan, 
1998). Semi-structured interviews refer to interviews where the content focuses 
on the crucial issues of the study (Burns, 1997). 
Participants received an information sheet and were asked to complete a 
                                                             
55 Whakaaro – understanding, idea, plan 
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consent form (Appendix: 1.1, 1.2). The School of Pharmacy, University of 
Otago, approved the study, including the participant sheet and consent form, 
under delegated authority from the University of Otago Human Ethics 
committee (Appendix: 1). In addition, the study was submitted to and 
discussed with the Ngāi Tahu Research Consultation Committee, to ensure 
Māori obligations are met, and Māori are not being unduly coerced or taken 
advantage of during the study. 
An interview schedule (Appendix: 1.3) guided the researcher to explore the 
participant’s views, understanding and experiences of having diabetes. The 
interview questions focused on four broad areas of diabetes: 
• Diagnosis: how did whānau find out they had diabetes, what information 
were they given at the time about diabetes and any other health issues. 
• Knowledge of diabetes: understanding and knowledge of diabetes, what 
strategies whānau used to manage their diabetes. 
• Change: changes made and challenges faced since having diabetes 
• Medication: changes and/or challenges related to diabetes medication 
 
Twenty-one interviews were completed; one interview was accidentally taped 
over and lost. Twenty interviews were transcribed and coded. Time taken for the 
interviews ranged from 24 minutes to 1 hour 57 minutes. The number assigned 
to the whanau interview for example Whānau #45 in this chapter, relates to the 
Dictaphone recording number. The duration of diagnosis ranged from 2 years to 
more than 30 years. All interviews were completed at a place of whānau 
choosing. Three quarters of the interviews were in the whānau whare. The 
whare space was a locality where whānau could just “be”, where the balance of 
power or “mauri” (life force) is with the whānau. As the researcher, you are 
manuhiri (visitor) to their whare. In the whare space whānau appeared 
comfortable and engaged, and open and free in their korero. 
The notion and practice of reciprocity applied during the interviews – expressed 
as gratitude and sharing, giving and receiving korero. Most of the interviews 





5.3.4 Reflexivity – my role in the research 
In some models of research, the ability for the researcher to whakapapa to the 
participants and their prior knowledge of the whānau could be deemed a 
limitation of the study, potentially creating bias in the data collection, analysis 
and results. However, within a Kaupapa Māori approach, whakapapa is a 
strength of the study. The ability to whakapapa to some of the participants aided 
in recruitment. This connection between the whānau and researcher formed a 
common kinship and lent an element of trust to the relationship. Therefore, 
whānau were more engaged and receptive to the interview process, creating the 
opportunity for whānau to express their views and experiences of diabetes and 
to share in their whakairo (story/experiences). 
As the researcher, I walked the journey with whānau during their story telling. 
Whānau knew my whānau and I knew their whānau; we were part of the 
community we lived and worked in. Allocating time for whānau to reflect and 
express their experiences was a necessary part of the interview process. I sensed 
whānau had not had the opportunity to korero about their feelings, diabetes and 
discuss the psychological aspects of diabetes. Time was allotted for initial chat, 
prior to the interview’s questions. 
Active listening, being present before, during and after the interviews were 
critical. Demonstrating and expressing empathy also ensured whānau were 
comfortable to share their stories, which was important, regardless of 
disruptions like phone ringing, someone at the door, people coming home or 
coming into the room, partner sitting in and contributing to the interview, 
animals, mokopuna, television or radio. 
To instil the trust and confidence of whānau, maintaining integrity as the 
researcher and health professional was critical throughout the study. It was 
important to also remain non-judgemental and impartial when the practice of 
whānau did not fit within the recommended “best practice” guidelines. When 
information disclosed compromised the health and safety of whānau 
interviewed, (for example whānau who choose not to take their insulin) or was a 
perceived risk for the researcher, this was an ethical dilemma as a health 
professional; as such, it was important whānau made their informed decisions 
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based on appropriate information and knowledge. This entailed “courageous 
conversations” about their situation, graciously and honestly with whanau of the 
risks they may encounter. Another risk was whānau who provided answers they 
felt the researcher wanted to hear. The researcher affirmed with whānau that 
there were no right or wrong responses or korero. 
It is important to maintain the tikanga and mana of the whānau. Reassuring and 
maintaining their anonymity, trust. Confidentiality was an imperative aspect of 
the interviews. 
 
5.3.5 Transcribing and capturing meaning 
A critical aspect of transcribing is clearly identifying the level of detail required 
for the analysis. This is subject to the aims and objectives of the research 
question and type of methodology applied in the research (Taylor & Bogdan, 
1998). The transcribing for this study was verbatim, that is word for word text. 
Processing and transcribing the interviews was initially arduous. However, as a 
novice researcher this was an opportunity to get a feel for the interview 
objectively, critique the interview process, amend questions and interview 
technique, and make any adjustments for further interviews. 
External out-sourcing of transcribing expedites the transcription process of 
interviews. Clear expectations of terms and conditions is essential between 
contractor and researcher to save valuable time and resource. Conditions 
include: expected time frame for turn around and return of transcribing; the 
level of detail; what to include and exclude for example slang, colloquial words, 
swearing and non-verbal cues like sighing, laughing, heckling. The use of 
specialist language and knowledge may require specific skill sets in transcribing. 
For this study, the interviews included the use of te reo Māori, medical and 
medication terms. After transcribing the initial interviews (3), it became 
apparent that there was a potential risk to whānau anonymity if a local person 
undertook the transcribing. In discussion with my supervisor, and to ensure 
whānau anonymity and integrity of the study; the completion of the remaining 







5.3.6 Challenges and learnings from transcribing 
There were issues with the early transcriptions, a result of poor communication 
in relation to the terms and conditions of transcribing, between the researcher 
and the external contractor. Fortunately, issues were identified early and 
rectified promptly and was a timely reminder of the importance of field notes. 
Transcribing for this study was demanding because it required a knowledge of 
local te reo Māori and tikanga, familiarity with medication and medical 
terminology and jargon, and the ability to produce credible timely transcripts 
within budget. This was especially difficult because we also needed a transcriber 
who was unlikely to identify the participants in the study. Fortunately, we found 
a person ably suited and the transcriptions were completed for all interviews. 
The reading and coding of the transcriptions was fraught with challenges. As the 
researcher had “local” tacit knowledge and insight to the “local” linguistics, this 
aided in interpretation and analysis of text where the “local” language and use of 
double negatives or positives were transcribed. Earlier transcriptions had 
discrepancies in the text, subtle euphemisms, and local colloquial sayings were 
omitted, for example the use of “yeah/nah” responses were appropriate and 
relative to the interview. After reading the transcriptions, I found including the 
use of non-verbal comments was as important as the verbal comments. The 
mutterings, sighs or laughter were not always included in the earlier 
transcriptions but were in context, and supported the meanings during the 
interviews. 
There were often differences between the written (transcriptions) and what 
whānau verbalised (communicated) during the interviews. This was not an 
uncommon finding for Māori, who traditionally use oratory as a source or tool to 
share knowledge and information (Barnes, 2000). Nearly all transcriptions had 
examples of half-finished sentences during the interviews. This in part reflected 
the established relationship between the researcher and whānau. However, it 
became a challenge when reading and interpreting the transcripts. 
The use of humour and laughter was common during the interviews. Holmes et 
al. describe humour as a boundary marker in ways that do not occur for pakeha 
and ways of knowing. Many situations where someone made a comment and 
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laughed, or made a joke of a bad situation, or of something as they brushed it 
off, when in fact that had meaning for them. For example, one participant 
described admission to hospital for an excision and drain of a breast abscess. 
During the post-surgery visit by the doctor, she was told you’re a “diabetic”. Her 
response was, “Nah shut up!” (hahahaha she laughed), the irony of being 
admitted for breast surgery, then told you have diabetes, did not go unnoticed 
as she (jokingly) laughed (Holmes, Stubbe, & Marra, 2003). Laughter and joking 
had an impact on the meaning of the interviews and was captured in analysis 
(Stubbe, 1998). 
In addition, some Māori words were difficult to translate to English verbatim. 
Potentially their meaning was lost in the translation. The use of analogies to 
articulate and describe feelings or events was challenging. For example, “T” 
described” …. a crocheting hook ….” to recount an incident; using a crochet hook 
that gets busier, the crochet item gets bigger and bigger and out of proportion 
sometimes. A similar analogy to a fisherman’s catch - the bigger the story, the 
bigger the fish (Metge & Kinloch, 1978). 
Stubbe and Holmes (2000) states the differences in Māori and pakeha ways of 
communicating stem from the differing cultural norms of behaviour. Listening 
and re-listening to the audio was more helpful than reading the transcripts when 
thinking about the themes that emerged. The conversational style of Māori is 
strongly based on shared knowledge and consensus, with the affective meaning 
of conversation being as important as its referential content, in contrast to the 
more individualist orientation of Western cultures (Holmes et al., 2003; Stubbe & 
Holmes, 2000). 
Articulating the tone of the speaker was very important to the meaning of the 
conversation. The emotional intensity and feelings of whānau were difficult to 
convey in a meaningful way. Local cultural gestures were also an aspect to the 
interviews that communicated a message or subtext of the interview, like a raise 
of the eyebrows or shift or nod of the head. These were recorded in the field 
notes and informed the analysis. Māori have more emphasis on non-verbal 
signals and less on verbalisation. When Māori korero kanohi ki te kanohi, silence 
is not seen as a negative, as in Western culture, but rather it is a natural part of 
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the flow of the conversation or interaction (Stubbe & Holmes, 2000). Silence also 
forms a polite negative response; it avoids imposing on to others, and indicates a 
willingness to keep listening until he or she wishes to comment. Silence is 
expressed as a nonverbal signal to substitute for words, and context is crucial in 





The NVivo software programme was utilised to assist with data analysis, 
management and coding. It was a challenge to utilise the software programme 
with the volume of data in the context of the study, and not be overly 
prescriptive with the use of codes and coding, in order to allow the conversation 
and data to organically unfold and meanings to emerge from the data. To pre- 
empt and be too prescriptive with the coding potentially risks the loss of 
meaning from the interviews. Annotations were an important factor to capture 
the use of colloquial language (yeah/nah), kupu hou (the use of Māori words in 
the context of the interview), local nuances and non-verbal activity. 
Deconstructing the text from the transcriptions when coding for analysis was a 
challenge of too much and not enough detail, and it was a constant balance 
between content of the conversation, and allowing the themes to emerge 
organically from the data. Manual inductive coding, thematic analysis and 
constant comparison was applied to assist with the analysis by the author and 
my two supervisors. Themes generated were checked and rechecked until a 




5.4.1 Whānau characteristics 
Table 5 describes the characteristics of the whānau interviewed. Ages of 
whānau that participated ranged from under 40 years to over 70 years, and 
each gender was equally represented. A greater portion lived in the urban area. 
Throughout the results section are shaded text boxes, each of which describes 
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excerpts from whānau who participated in the study (each whānau are 
identified by #). Whānau stories provide insight for the reader to the realities 
for Māori with type 2 diabetes. This is a qualitative aspect to the thesis, to form 
a picture and narrative of the person as a whole and their whānau, rather than 
compartmentalised and dissected by conversation. 






Participants age range   
Age Bands  <40 years of age to >70 years of age 
Under 40 2  
40 to 49 4  
50 to 59 4  
60 to 69 6  
Over 70 4  
Gender    
 Male 10 
 Female 10 
Geographical locality   
Urban 12 
Rural 8 
Living status   
Living on their own 5 
Living with spouse or 15 
whānau  















Length of interviews  24 minutes to 1 hour 57 minutes 
Diabetes history   
Length of diagnosis  Range = from 2 years to 30+ years 
<10 years 9  
Male 6  






Male 7  
Female 4  
Familial History   
Known whānau history of 15 
DM  
No known whānau history 5 






Told by GP/nurse they had  
DM 12 


















Pharmacological   
intervention  
Whānau on medication 20 
Oral hypoglycaemic (OAD) 13 
Insulin & OAD 7 
 
<10 years diabetes (9) 
 
Male (6)  
Insulin 2 
OAD 4 
Female (3)  
Insulin 0 
OAD 3 
 10+ years diabetes (11)  
Male (7)  
Insulin 3 
OAD 4 










Most of the diagnosis for type 2 diabetes was made by the GP, after a visit to the 
GP with presentations unrelated to diabetes. These included: routine general 
check-up, flu symptoms, blurred vision, routine blood tests, supporting their 
spouse to get a prescription, getting repeat prescription for a medication, feeling 
generally unwell, and a review for hypertension. One person was advised by the 
community nurse to see a doctor. Two people were diagnosed during community 
screening for another condition, and one person was diagnosed post-surgery. 
 
 
5.5.1 Positive encounter 
The context and how whānau are told they have diabetes set the pathway for 
their journey with diabetes. Nine whānau had a positive encounter with a new 
health practitioner (HP)56 or HP who they had an established relationship with 
(sometimes over generations). The remaining whānau (n=11) experienced a less 
than positive encounter with the HP. 
Whānau who had a positive encounter shared a mutual understanding and 
bantering style of conversation with their HP. What whānau liked was that the 
HP was known to them, and familiar with their whānau history. They did not 
have to repeat and tell their story several times to different HPs. This connection 
and relationship were based on truth, mutual respect, trust and honesty. 
Whānau in turn were more likely to ask questions to gather further information. 
 
 
I went to my doctor and I said to him “oh there’s something wrong with me” and 
he…run all the tests and everything and he said … “oh you got diabetes and quite… 
bad”. One of the things was … I knew my doctor so well, and I knew…the seriousness 
in which he spoke and I … knew that he wasn’t just saying that to me, you know, to 
make me ease up a bit. You know he just said to me straight, straight out, he said 
“D*** you’re not going to reach 50“. “So I’m telling you now” he said “if you don’t do 
nothing about it you’re not going to reach 50”. You know it kind of frightened me. 
  
                                                             
56 HP – health practitioner (nurse/doctor) 
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Straight away when he said, I knew he was … being serious, I knew he was being 
honest (Whānau #45) 
I just go and see the nurse and she does my pills. Cause I been with him (GP) for 
about 36 years. Better, the devil you know then … aye? (Whānau #41) 
 
 
The HP are trusted confidantes; they provide expertise and knowledge on 
diabetes. There was no reason to question or doubt their expertise. Whānau 
acknowledged they had to make changes, and dialogue with their HP indicated 
they were comfortable discussing their concerns or worries. They felt heard, 
when changes were slow and challenging. 
 
 
Then I’ve got a GP who is really awesome. I think the world of my GP and he’s 
turned around and said, “no, you get that mind-set out of your head.” (Whānau 
#29) 
Actually, it was great the second time I went back. I had a good doctor. He 
explained it to me, so that’s been a lot better … that approach is great … that 
approach was by one of the doctors. But no one sort of told me, … until that doctor 
talked me through, … just said that simple thing and then I got it (Whānau #43) 
 
 
5.5.2 Negative encounter 
Whānau who experienced negative feedback or a poor relationship with their HP 
were more resistant to change than those who had a positive experience. 
Whānau who experienced poorer outcomes were less likely to be adherent with 
their diabetes management and treatment. They were passive and not actively 
engaged with their HP and their diabetes management. 
 
 
Well she was treating me like a kid … probably the worst thing you could do. So … 
you know when she was talking to me … “you’re not doing very good” … sort of like 
a kid … don’t never treat me like a kid cause I’m not. You just straight up with me  
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… talk to me kei te pai. But I think that was part of the problem …it’s like I’m a 
dumb Māori. … sort of suggests along those lines I’m not saying that’s it (Whānau 
#43) 
Well just an inkling but …when I mentioned it …if you told him (GP) … you know he 
don’t like you to tell them what you think you got. Just feels like I’m strong diabetic 
... GP goes no you’re not … (Whānau #30) 
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# 30 M 
M is a quietly spoken 70 + year old, living on her own in a small council flat. 
We sat in her kitchen over a cuppa and cake, as M shared her stories. M and 
her husband lived for many years in a small rural community. They raised 
three children who attended the local school, while working on the family 
farm. M began to feel unwell, and visited the doctor. After going backwards 
and forwards to the doctor, M was told she had diabetes. M recounts life was 
busy, cutting thistles in the paddock or constantly cooking (always “meat and 
veg”). The family relocated out of the district for work, returning as retirees. Ill 
health fell upon her husband, M became a full-time carer to her husband for 
many years, until he died from complications of his chronic illness. M says, he 
has left a huge gulf of emptiness in her life and she misses him very much. 
Supportive whānau live close by and afar, keeping in regular contact usually by 
landline telephone (M has no cell phone or internet). 
Keeping good health is important to M. She is extremely independent (despite 
being unable to drive a car), and regularly attends her doctor appointments for 
her medications and check-ups. M has been able to walk to the shop for basic 
needs, such as milk and bread. On occasion, she catches the bus to town. 
Lately, she has been doing less walking as it takes a little bit longer and she is a 
lot slower now. Whānau pick her up and drop her off to her appointments and 
shopping (the shopping list was on the table). M does enjoy being out 
participating in the various community activities, and often travels away to 
stay with whānau out of town. 
A pastime M enjoys is embroidering and painting (flowers) pillowcases. These 
were displayed in the lounge, bright and bold, awaiting her attention, and 
destined for her Marae. M expressed frustration with her failing eyesight and 
diminishing dexterity of fingers, as this has meant less time spent on these 
activities. She enjoys attending kaumatua programme57, korikori tinana58, and 
Tai Chi59, and has a small close network of friends, and whānau. 
 
  
                                                             
57 Kaumatua programme - Lifestyle programme for older people – Turanga Health 
58 Korikori tinana - Line dancing group 






M gets by on her pension and states she does not have “flash” meals, sticking to 
simple fare, and not always bothering to cook a kai every night for herself, but 
does try to eat healthy, and an exercycle sits in the bedroom, hardly used. 
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5.5.3 Pathway to diagnosis 
Three pathways emerged from the data about how whānau came to know of 
their diagnosis: i) those with diabetes related symptoms, ii) those with non- 
diabetes related symptoms, and iii) those who were asymptomatic. Similarly, 
Peel et al., (2004) describes three main “routes” to diagnosis of diabetes as 
“suspected diabetes route”, “illness route” and “routine route”. 
Whānau (n=3) who experienced classic signs and symptoms of diabetes were 
genuinely unaware their symptoms (thirst, fatigue, weight loss, weight gain, 
dizzy, blurred vision) were associated with type 2 diabetes. These symptoms led 
whānau to seek medical advice; others required additional testing and 
examinations, to inform a definitive diagnosis of type 2 diabetes from their HP. 
 
 
All I can remember … very clearly was … urinating … you know always wanting to 
go. Yeah regular ... it was starting to concern my wife … every time we went 
somewhere, we’d stop near a shop. I needed a drink always and to have a drink … 
soft drink or water (Whānau #36) 
I was losing weight … I couldn’t quench my thirst … drinking lots and lots of 
water…all sorts of stuff, … milk, fizzy drinks which is the worst. But then I didn’t 
know. (Whānau #43) 
 
 
More than half the whānau (n=15) who experienced symptoms and or received 
treatment for non-diabetes ailments (mental health, acute surgery) from their 
HP experienced negative feedback. 
 
 
He saw my psychiatrist … can he go off these things … that’s what spiked my sugars 
… in the end it was up to me. It was the only medication … that worked for me … so 
I stayed on them … bear with the diabetes and keep it under control, but stay on the 




I went to the doctor and they sent me to hospital, I had an abscess in my tit. That’s 
how I found out … they took blood tests … the doctor … said to me. Do you know 
you’re a diabetic? I said “nah, shut up”. I didn’t have any idea (Whānau #33) 
I wanted something for the flu … came out of the blue … “I’ll take your sugar” … 
“What do you mean by take my sugar?” Nah … sweet as, Yeah arggh! (Whānau 
#38) 
I was sweet as … he never said to me oh it’s all in your blood or whatever (Whānau 
#41) 
(Question - So you had no idea? “Nah”. (No?) No idea, no symptoms, no nothing … 
just got picked up in a blood test. “Yeah” (Whānau #37) 
 
 
Whānau (n=2) who were asymptomatic presented opportunistically and/or 
serendipitously were told they had diabetes by a HP, and experienced a negative 
encounter with the HP. 
The three distinctive pathways to diagnosis did not determine whānau 
understanding, knowledge and management of diabetes. More importantly, 
factors that had a significant difference and impact for whānau and their 
diabetes related outcomes included: the interface and quality of experiences 
with the HP at the time of diagnosis; and where and when the initial encounter 
occurred. The increased treatment burden can trigger and push whānau past 
their coping threshold and reduce their ability to adhere to therapies; for 
example, managing a heart condition or ulcerated wound. Studies found 
treatment burden escalates with an additional disease and the subsequent 
treatment and/or related tasks, such as additional medication, tests and 
appointments; and negative interactions between disease states. For example, 
medications and their drug interactions or converging specialist appointments 
(Gallacher, Montori, May, & Mair, 2016). 
Their experience made the difference for whānau in their understanding and 
internalising the korero from the HP, making the change for them and their 




always happen the first time. Some whānau struggled and took several 
encounters or a different HP to korero with, before whānau grasped an 
understanding of diabetes. 
 
 
It was great the second time, I went back I had a good doctor. He explained it to me 
… a lot better actually that approach is great … by one of the doctors. No one … told 
me until that doctor talked me through ... simple … then I got it (Whānau #43) 
 
 
5.5.4 Response to the diagnosis of diabetes 
Diabetes unlocked diverse and emotive memories and feelings for whānau. 
These reactions and responses occurred while face-to-face with the HP and are 
grouped into: responsive whānau, less responsive and non-responsive whānau – 
not ready. 
Some whānau were open and comfortable with being “told” they have diabetes, 
and had a very pragmatic approach to diabetes, wanting all of the relevant 




They say you’re a diabetic … hey let’s treat it. I’m not into … recriminations … oh if 
…only done this. You know … it’s a done deal. Now … what do … you need to do. 
Yeah, really haven’t any issues since I’ve been tagged … diabetes (Whānau #40) 
 
 
Some whānau were resistant to the autocratic way they were told they had 
diabetes. Whānau struggled to process and conceptualise information, and 
became overwhelmed with the inflexibility and rigidity of the treatment and 




What I found hardest was … told … I couldn’t have this and I could have that and I 
looked at the list of things I couldn’t have any more and thought I might as well go 
like that (gestured to cutting her throat) (Whānau #31) 
 
 
Whānau became overawed with the knowledge of having diabetes and the 
barrage of information. It was all too much to cope with and they were not ready. 
 
 
She tried to show me but it was a blur … I didn’t really take much notice … I was 






J lived and worked for many years in a rural community. He and his wife 
relocated to town because his wife had a long-term chronic illness and needed 
access to health services. J stopped working full time, to be a fulltime carer to 
his wife, until she passed a number of years later. J reflects on the later years 
he shared with his wife, her declining health and increasing demands placed 
on him. J describes this time as lost (not in anger but rather regret, and an 
acknowledgement of that time that passed), putting his life on hold, while he 
cared for his wife. Since his wife’s passing – J is asking himself - where he fits 
in the world? J finds himself having to re-engage and reconnect with the world, 
after being socially disconnected from everyone. Managing on a reduced 
income has been a challenge; with no extra money for basics, jobs around their 
whare are on hold. They often travelled out of the area to secondary and 
tertiary care hospitals to attend specialist appointments and tests (a five hour 
drive to Waikato Hospital). J wants to work, a difficult task for most people, but 
made even more difficult for J because of being out of the labour market for 
several years. His age and decreased physical capacity leave him with limited 
options. 
We chatted in the kitchen, while mokopuna were in the lounge watching TV or 
wandered in to talk with their papa. J felt in reasonably good health attending 
the Hauora programmes60 and enjoyed the camaraderie being with like- 
minded people. He also kept busy doing different activities with whānau from 
these programmes. 
J was familiar with accessing health services, having accompanied his wife to 
her many appointments and tests for problems, some related and some not 
related to her chronic illness. It was during one of these visits that he was 
given a prescription for medication from the doctor. Bemusedly he asked 
“what’s this for?” He was promptly told, “for your diabetes –to keep you alive 
to look after your wife.” Prior to this experience, J never took any regular 
medication. Now he assures me he takes his medication regularly no matter  
                                                             






what, to keep himself well. Ironically, the trials and tribulations of living with a 
chronic illness continue for J and his whānau. 
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5.6 Feelings about diabetes 
The pathway to diagnosis and the quality of the encounter whānau experience 
during their initial diagnosis does not appear to be associated with nor 
determine how whānau react to knowing they have diabetes. A common theme 
identified was how whānau were told they have diabetes, and is discussed 
further in the analysis. Being diagnosed with a chronic illness is an emotional 
and traumatic time (Wilkinson, Randhawa, & Singh, 2014). Negative emotions 
can disrupt the memory, resulting in an inability to retain information. This is a 
response that is not ethnicity-specific. The following are excerpts of whānau 
responses to having diabetes. 
Some whānau, with insight into their wellbeing, felt unwell, and actively sought 
advice from their HP. Whānau #25 was worried about her weight loss and 
thought she had cancer, and was shocked to find she had diabetes. 
 
 
I wasn’t feeling well … I had lost weight … I thought gosh something’s happening. 
Then I went to see (GP) … I was worried I thought … the big C. You know, losing 
weight and tired, those symptoms … Diabetes it was ... it’s a shock. Yeah it is. 
Because you know … you don’t want to be ill … you want to live longer that’s the 
thing for me. That’s why I gave up that smoking. Aye! (Whānau #25) 
 
 
Similarly, whānau#45 knew something was “not right” after experiencing an 
episode of dizziness and fainting. He sought medical advice and was surprised to 
find from his HP that he had diabetes. The relationship with the HP made the 
diagnosis of diabetes more believable. 
 
 
I had blacked out ... and said (to his wife) gee I blacked out down there (in a 
paddock), and … never thought about it. Then a couple of weeks later I got out of 
bed and I felt the house and everything going around and round so I went to my 




there’s something wrong with me … he told me run all the tests … he said to me … 
oh you got diabetes and quite bad (Whānau #45) 
 
 
At the initial diagnosis, whānau questioned and doubted themselves, discrediting 
the HP’s knowledge of diabetes. Uncertain and frustrated, whānau were in 




When I … got diagnosed as a diabetic … I thought what the heck do they know, 
what do doctors know, what does anybody know, this is my body. I’ve heard people 
say … you be responsible for your own body … I thought yeah that’s right (Whānau 
#36) 
I was pissed off big time when I first … was told. That was initially my reaction and 
I thought et. you fellas don’t know what you’re talking about I’ve had good (results) 
(Whānau #31) 
You know when you’re 60 you’re gonna have a stroke … heart attack. Oh shut up 
A**** (laughter) cor. I don’t know what I’m doing sometimes … I think I’m doing 




Whānau with no known familial history of diabetes expressed their anger and 
frustration. This fuelled their denial and non-acceptance of the information and 
diagnosis of diabetes. 
 
 
I think the hardest part at the start was just trying … was ah accept that that was 
the case. You know, that I had diabetes. For me hard to accept cause there’s no 
history. There’s no you know doesn’t line up with either or but and yet if I don’t 




When I first heard … it really pissed me off. Because I thought well why all of a 
sudden you know I've had all these things and then just out of the blue. You know 
I’ve got diabetes (Whānau #32) 
Oh I heard it. I heard it but I didn’t want to accept it. I didn’t … want to face that 
reality that’s what it comes down to (Whānau #39) 
 
 
Other whānau were not concerned about diabetes and had a pragmatic approach 
to diabetes; others were nonchalant about the diagnosis. 
 
 
just get on with life … activities and those things. I shouldn’t have that … no one else 
gave it to you but yourself. The thing is to just look after … yourself that’s all it is. 
Mmm nothing else … just look after yourself cause no one else will. You’re the one 
carrying the maemae (sickness), no one else. It’s really about how you manage it 
though aye. Yeah ... like I say take your pills get on with life. Well to me … I just 
don’t worry about it, man knows you got it and that’s it. Like … get along with life 
(Whānau #26) 
Initial response to diagnosis. Oh fairly blasé really. Just ho hum yeah. Ok no it’s no 




Whānau with a familial history of diabetes and/or had experienced first-hand 
the stark realities of the damaging effects of poorly managed diabetes expressed 
their fear and anxiety knowing they had diabetes. Some whānau felt that getting 
diabetes was inevitable and just a matter of time. 
 
 
Apparently, I got become diabetic the same age as my mother. Yeah nah ... So I 
always think about that. You know I’m gonna end up like my Mum. Yeah I don’t 
think I really worry about it … if I’m being honest it’s in the back of my mind. It’s 
always gonna be there with my Mum (Whānau #34)  
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Yeah I didn’t know what to eat, didn’t know what to do, and didn’t know anything. 
For about 4 months … didn’t know what to do I just kept on walking. But mum said 
“what’s wrong baby?” and I just broke down to mum … I don’t know what to do. 
Diabetes … I know heaps of people that have died from this thing. So I just stopped 
eating (Whānau #37) 
I look like my mother, but I don’t want to have the same sort of checking out the 
same way she did. But I’m going there … not at the pace that she did, but … 
eventually. It’s like … I’ve had these doctors and specialists telling me that this is 
where I’m going. I used to blame my parents and my grandparents that I got it … 
until this GP came along … that’s been an excuse for far too long. I can’t use that 
excuse anymore (Whānau #29) 
 
 
Diabetes became normalised into the activities of daily life for whānau over time, 
similar to other long-term chronic conditions (Kelleher, 1988). Treatment 
regimes fitted into the activities of daily living. 
 
 
“I've been a diabetic too long … I’ve sort a grown with it. Diabetes has become part 
of life … a part of … daily living” (Whānau #30) 
 
 
Complacency becomes embedded among whānau, resulting in the “same same” 
mentality and attitude. HPs treat presenting symptoms and not the person 
(Khunti et al., 2015), fail to initiate or intensify treatment (clinical inertia) 
(Strain, Cos, Hirst, Vencio, Mohan, Voko, et al., 2014), as diabetes is acculturated 
and immersed into the lives of whānau. Ministry of Health (NZ) endorsed 
guidelines and algorithms for the treatment and management of diabetes, and 
provided recommendations to support and guide the HP with their clinical 
reasoning, as to what best meets the needs of whānau. To bring about change, 
active engagement is needed between the clinician, whānau and community to 
improve diabetes outcomes and reduce the disparities of diabetes management 
for whānau.  
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After a while it becomes same old same old. So, you … not too worried about it. You 
become complacent I suppose (Whānau #39) 
It doesn’t worry me to tell you the honest truth. Long as I take my medication. I’m 
cool as … I don’t even think about it … I don’t even think about it now (Whānau 
#33) 
You know it’s part of my life … just a normal thing. I think I just got used to it … it’s 






Widowed for over 10 years, E has lived in a kaumatua61 flat on the fringes of 
the city, for a number of years, and seen people come and go. With good 
neighbours, they keep an eye out for each other, but still “mind our own 
business”. E has a number of conditions including diabetes. She discovered she 
was diabetic during a routine blood test. E describes herself as healthy most of 
the time; she has not monitored her blood sugars, “not for ages” and is not 
bothered about it. She is very particular with taking her medication, and 
attends her regular check-ups with the doctor. She gets “by” on her pension, 
and does not have any of that “flash” kai, just the basics, she does not go 
hungry. One thing she is particularly proud of is being smoke free for a number 
of years, which has meant a few extra dollars in her bank account and even 
better still, being able to taste her kai62. 
E has a supportive whānau and a network of friends. Her daughter lives within 
walking distance and visits regularly. Her mokopuna63 visit after school most 
days. She used to walk up and back to her daughters with the aid of a walking 
stick, but “slowed up a lot”. Her mobility is not as good as it used to be. She 
gave her car to her whānau; it became too expensive to run and they needed a 
car. Whānau take her to town or to her appointments when needed. 
E enjoys being a volunteer of the local Māori Wardens. This keeps her fairly 
busy, attending different hui in and around the community at various activities 
and events and she is a regular attendee at the Hauora programmes64 in the 










                                                             
61 Kaumatua – older person 
62 Kai - food 
63 Mokopuna – grandchild/ren 
64 Hauora programme – Lifestyle programmes at Turanga Health 
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5.7 Inevitability and whānau history 
Diabetes is a part of whānau life. Whānau confidently articulated the breadth of 
their diabetes knowledge and were “experts”, for example clear understanding 
and workings associated with a dialysis machine. Whānau demonstrated 
insightfulness, and awareness of change when personal circumstances shifted 
outside the “normal” prescribed parameters by the HP. Whānau described the 
common manifestations of poorly managed diabetes, such as the amputation of 
limbs, debilitating loss of eyesight, a heart attack or stroke, kidney problems, 
poor circulation, numbness and tingling in their feet and hands (peripheral 
vascular disease). Some whānau just knew they were going to have diabetes, or 
had an “inkling” they might be diabetic eventually, while other whānau were 
unaware of diabetes. 
Research shows lengthy and constant exposure to a negative behaviour or 
attitude is detrimental to your wellbeing and has psychological implications. This 
repeated attitude and behaviour permeates and is modelled by other groups or 
people. To enable and create change, HP and whānau need to be in a position to 
challenge that behaviour or attitude (Handley, Pullon, & Gifford, 2010b). Whānau 
were exposed to the negative impacts of diabetes, such as a parent’s daily 
dressings to an (diabetes) ulcerated leg wound, or parts of limbs amputated; or 
whānau transitioning to a life of haemodialysis. However, when equipped with 
the appropriate resources and knowledge, whānau can position themselves to 
challenge and change these behaviours and attitudes. Interventions that increase 
whānau knowledge about diabetes are enablers to support whānau with making 
informed choices for wellbeing. 
There were some whānau who genuinely had no idea they had diabetes. 
However, once prompted, they reported that they were not feeling right in 
themselves. They sought medical advice because they were worried or 
concerned with how they were feeling. Vermeire, Van Royen, Coenen, Wens, and 
Denekens (2003b) found health beliefs, the quality of the doctor/patient 
communication and the quality of information patients received are important 




No, absolutely no idea at all, in fact didn’t even know anything about diabetes. 
Furthest thing from my mind you know. Yeah no … I didn’t know. (Wife - till you 
had problems aye dear?). Yeah I knew something wasn’t right (Whānau #45) 
(Question: So you had no idea?) Nah. No idea, no symptoms, no nothing. Just got 
picked up in a blood test. Yeah! (Whānau #37) 
 
 
There were other whānau who were “tip toeing” around the edges and on the 
fringes of diabetes. They sort of knew or had an idea they might have diabetes 
from their whānau history. They often referred to diabetes as “borderline” or 
“verging on”, “inkling”, but not a definitive diagnosis from the HP. 
 
 
Although Dr had always sort ah implied … was a case for diabetes. I was borderline 
diabetes and she sent me for full bloods … results came back … I was diabetes. Dr 
always sort of implied … he would say things like … diabetic, you’re on the 
borderline (Whānau #31). 
Well just an inkling, but when I mentioned it (referring to his GP) ... he don’t like 
you to tell them what you think you got. It just feels like I’m strong diabetic … he 
(referring to GP) goes no you’re not (Whānau #30) 
Well put it this way, I showed signs … but my diabetes and heart problems ... is 
hereditary. Yeah symptoms … I was verging on, but … like most know all’s don’t 
wanna listen (laughter) (Whānau #39) 
 
 
Whānau clearly recounted diabetes in their whakapapa, and believed it was 
inevitable they would have diabetes, acknowledging diabetes was their destiny 
or fate. Whānau appeared more receptive and emotionally prepared to the 
notion of diabetes. There was an assumption whānau who had a familial 
history of diabetes were more informed and knowledgeable about their 




I just thought well, being here in my whānau, I would naturally have it. But I knew I 
must have had it, I had it in my own mind (Whānau #28) 
I know it was gonna come. Cause my Dad’s family have it ... my Dad’s brother … his 
older brother … heart and diabetes … he got gangrene in his legs. I seen too many 
people die from this, I’ve already seen the ugly side. It’s going to get me (Whānau 
#37) 
My sisters … girl you should go to the doctor you might be a diabetic … my father 
was a diabetic (Whānau #33) 
 
 
Whānau who presented with symptoms were too afraid to find out the reason or 
cause of why they felt the way they did. Expecting the worst: “cancer” not 
“diabetes”. This fear and uncertainty led to whānau delaying their decision to see 
a HP for advice and support, delaying a diagnosis, and likely leading to advanced 
disease state and poor outcome. 
 
 
We were expecting something worse to be wrong, instead of just taking it as it 
comes or f** might be cancer or something. I think I was scared … there might be 
something else wrong with me (Whānau #28) 
And I used to see him and he saw my psychiatrist and said look can he go off these 
things and I think that’s what spiked my sugars up. In the end it was up to me. It 
was the only medication that I found that worked for me. It was that simple so I 
stayed on them and it was, bear with the diabetes and keep it under control, but 
stay on the other ones as well (Whānau #27) 
 
 
5.8 Meaning of diabetes 
Whānau who had diabetes for more than ten years had internalised diabetes, as 
part of their normal activities of daily life (Kelleher, 1988). Diabetes is “normal” 
and they were desensitized to the disease state. Creating a sense of complacency 
became evident.  
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After a while it becomes same old same old. So you … not too worried about it. You 
become complacent I suppose is how you put it (Whānau #39) 
It doesn’t worry me to tell you the honest truth. Long as I take my medication. I’m 
cool as. It doesn’t worry me ... I don’t even think about it. Na I don’t even think 
about it now (Whānau #33) 




Diabetes meant death and dying for some whānau. Whānau history and 
experiences influenced how whānau viewed life, diabetes, death and dying. 
 
 
I’m gonna die … no I’m not (laughter) … my Mum she was a perfect diabetic … 
honestly, she listen to the doctor, she did everything. Yet ... it just did away with all 
her systems … her kidneys everything just failed (Whānau #34) 
 
 
The loss of life affects not only the immediate whānau but also the wider 
community (hapu and iwi), and the loss of whakapapa, and matauranga 
(knowledge). 
Some whānau were philosophical in their approach to diabetes, but still wanted 
to be free of diabetes. 
 
 
I don’t like it (diabetes) … to me it means death … it means stress … It’s reversible … 
you want to do the things that you are able to do. I do know its life threatening … I 
don’t want it anymore (Whānau #35) 
 
 
The notion of being stereotyped, with a label or tag “diabetes” attached to your 
persona invoked a negative connotation of shame and disgrace (stigma) for some  
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whānau. This stereotyping could lead to perceived and/or unwarranted barriers 




So that’s your tag. You’re a diabetic. You have a label put on you (Whānau #40) 
 
When I got told – and I was … oh well there’s another disease you got and that’s it 






S and her elderly widowed mother live in their whānau home, in a rural 
community. S and her large extended whānau are active participants at their 
local Marae. S has a good support network that enables her to “get to town”, to 
attend appointments, pay her bills and shopping, usually all on the same day. 
She is providing carer support to her mother – preparing meals and domestic 
household chores. 
S talks about a healthy diet, but struggles with the kai side of things. But feels 
she does a “pretty good job” most of the time, sticking to the basics and not any 
of the fancy stuff. She tries to walk every day up and down the road. S enjoys 
having her mokopuna after school and some weekends, and is one of the 
reasons to getting moving and out on the road. 
Lots of her whānau have diabetes, but she never thought she would end up 
with diabetes. Ironically, she recounts her feelings of being thirsty and 
“drinking heaps” and not being able to satisfy or quench that thirst (the classic 
signs and symptoms of diabetes). S was surprised to find she had diabetes, 
after receiving treatment for an unrelated condition. Fortunately, her whānau 
support was a good advocate, with experience in diabetes, and proved 
invaluable in helping to process information and ask questions, when the 
myriad of information was given. Admittedly, it’s easy to say “you shouldn’t do 
this” and “you shouldn’t do that”, but S comments that it is much harder to do 
in true life. Agonising whether to cut the fat off the meat, and then–, “oh what 
the hell”. If it’s not about kai, it’s about losing weight. S felt stranded in no 
man’s land; you could hear her frustration - you’re doing really well in one 





Effective communication and therapeutic relationships are critical elements to 
achieving successful outcomes for whānau, hapu and iwi (Relationships around 
health and wellbeing are not static; they constantly evolve as people and their 
environment change). A study by Sheridan et al (2012), found whānau did not 
have the opportunity to converse with clinicians about their needs as often as 
they would have liked. Positive outcomes for whānau are achievable when 
whānau feel valued and are able to discuss their needs in relation to the context 
of their lives (Sheridan et al., 2012). 
 
 
5.10 Whānau Centric 
Some whānau preferred to dialogue face to face about diabetes, about their 
particular challenges and needs, with a HP or someone else. This tailored 
approach is recommended as best practice in national and international 
literature (New Zealand Guidelines Group, 2012). Face to face communication 
gives an opportunity to reiterate diabetes information. HP are not always the 
most appropriate source for additional information. Whānau had several visits to 
their HP (not always the same HP) before they really understood and accepted 
diabetes, and knew what this meant for them in the context of their lives. 
 
 
They put me into hospital and I had someone come in to talk to me at the time. 
Talking to them I … realised … people are giving advice, to help me. Not to try and 
deny me from having this thing … they were able to sort of like calm me down. Be 
more accepting to the fact that I’m diabetic. I need to take certain steps to help 
myself so that was my experience (Whānau #34) 
Go and learn about it, and actually, it was great the 2nd time I went back I had a 
good doctor… He explained it to me … He says it’s … sugar … it’s kind of like rust to 
a car … So you don’t take care of it … It’s gonna start doing damage to your organs 
… “… a lot better actually that approach … I get the whole rust thing that makes 




… but no one sort of told me that until that doctor talked … you know just said that 
simple thing and then I got it (Whānau #43) 
 
 
5.10.1 Mixed messages 
Mixed messages from the HP provoked uncertainty. When whānau were 
simultaneously praised and chastised, they became confused and indecisive. 
These mixed messages influenced how whānau managed their diabetes or not. 
 
 
Went for … blood tests … you’re doing really really well. Then she said but … now 
it’s your weight (laughter). Yes I know … it’s my weight. I don’t know what I’m 
doing (Whānau #33) 
 
 
Alternatively, whānau felt bewildered and perplexed when they may have 
diabetes “borderline” – then yes, you do have diabetes. 
 
 
Well she (GP) did say … you on the borderline for diabetes. I went back in about a 





Nearly all whānau were provided with the standard/obligatory “folder”. This 
folder contained the traditional written information provided at diagnosis in 
primary care or general practice. The HP would check in with whānau and ask if 
they had any questions or if they understood the information and resources. 
Folders were stowed away for future reference, whilst others had limited or no 
recollection of the contents or material in the folders. 
The relationship between whānau and HP is key to positive outcomes. Ensuring 
the health literacy needs are met will help in reducing the knowledge gaps 
around diabetes. Keeping an open mind and having courageous conversations 
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are needed between whānau and HP, to identify strengths that best support and 
assist whānau towards positive change. This whānau reflected on the literacy 
abilities of some whānau and their preference to have a conversation, and 
someone to “sit down and have a talk”. 
 
 
As you say earlier … did I get brochures? Sort of thing you know. Question: Would 
that of helped? (Whānau #45) Yes to some and no to quite a lot I’m talking 
culturally again. Cause a lot of our Māori hardly reads. We need somebody to … sit 
down and have a talk about, a little script of these things … what do you think of 




In the Peel et al. (2004) study, participants wanted more information about 
diabetes management at the time of diagnosis. However, in this study, whānau 
confronted with a barrage of written information and verbal instructions during 
the initial diagnosis, were not ready to listen or hear all the information about 
diabetes. Allowing time at initial diagnosis is a key element to positive outcomes 
and supports the mana and tino rangatiratanga (self-determination) of whānau. 
 
 
They gave booklets on it, but it was like I just went into shock really, it was like 
“why me?” Why is it always me? Got brochures … finally mum managed to talk me 
around to going to the doctor you know to get some help (Whānau #37) 
Hang on, she can’t give those up straight away she’s just diagnosed a couple of days 
ago and you want her to give up those things straight away. The doctor he used to 
say “well, it’s for her own good”. Yes, I know what you’re trying to say doc, but hang 
on let her… think first (Whānau #33) 
Time to process and synthesize information; I have diabetes, what does this mean? 
It was just getting my head around it all. You know getting rid of all those barriers 
that I put up when they told me I had diabetes. Now I realise … them letting me 
know … those tests must of shown … the light sort of went on … they wouldn’t tell  
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you that for nothing. So, adjusting my life to thing with that. But it’s been the 
hardest thing, just getting your head around it. Adjusting, but just gradually over 
time I have been able to just make those little changes that affect me and not them 
(whānau) (Whānau #31) 
It took me ages … to let it sink in my head. Took me forever … oh bout 3 years … 
before I realized I got to do something. Well here I am still doing something. 
Chugging along slowly (laughter) but hey you know I feel good … I still get out 
there. Mow my lawns, do my gardens, walk down the road (Whānau #33) 
 
 
5.10.4 Usefulness of written information 
There is an immense volume of written material about diabetes and diabetes 
related conditions. Written material came in lots of different shapes and sizes, 
which some whānau found informative, while others did not. 
 
 
They were good, they were really good, heaps of information. What to eat and what 
not to eat and stuff like that while I was in hospital. Yeah, those young nurses tell 
you all about it and the one at (GP) gave me the same stuff also (Whānau #28) 
Excessive amounts of information. Yeah, I got one of those thick folders that they 
normally hold and give to patients. They said take that one cause we’ve ordered 
some more. So if there is anything that you need to find out about then you can just 
refer to it. And that folder did have everything (Whānau #29) 
 
 
Whānau acknowledged receipt of the information; whānau knew they should 
read, but it was a waste of resource, as they were not going to read it, and they 
described how they stored their information. 
 
 





Whānau were not bothered or not ready for any information. 
 
 




5.10.5 Diabetes language/jargon 
Diabetes has its own peculiar vernacular: blood sugars, highs, lows, insulin, 
hypos, blood glucose monitoring, HbA1c, podiatry and glucose tolerance test. 
Some whānau were familiar with the language whilst others were a little 
bemused. 
Understanding the language associated with diabetes will improve whānau 
knowledge and contribute to their outcomes. The use of biomedical markers, 
such as HbA1c65, GFR66, micoralbumuria67, BMI68, waist circumference, and 
cardiovascular risk are objective clinical measures used to identify how well a 
person is managing their diabetes. 
Whānau were supported by the HP to make sense of these measures, in terms of 
their diabetes management. For other whānau, the HP had a lesser role in their 
understanding of diabetes. As discussed earlier, the pathway to diagnosis for 
whānau is influential to understanding diabetes. 
Whānau were more reluctant to visit the HP when they knew something was 
wrong or they felt unwell. Accepting advice from the HP was subject to the 
individual’s situation and the relationship they had with their HP. Where whānau 
and HP converge is not always equal, but usually where the “upper hand” is with 
the HP, this can put whānau at a disadvantage, and make them feel not heard, 
inept and overwhelmed. While other whānau sought affirmation of their 
wellness from their HP. 
  
                                                             
65 HbA1c - A test that measures your average level of blood sugar over the past 2 to 3 months 
66 GFR - Glomerular filtration rate 
67 Micoralbumuria - Albumin present in urine 
68 BMI - Body Mass Index 
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I soon find out … when I go to my own doctor if I’m doing everything right 
(laughter) (Whānau #33) 
Yeah it must be all good if the doctor’s saying it’s good (Whānau #40) 
 
 
Whānau who were less engaged with the HP saw themselves as being “done to 
rather than with”, and were less likely to actively participate in their own care 
and management of diabetes, potentially contributing to poor outcomes. 
 
 
I don’t know what I’m doing sometimes. I think I’m doing alright, next minute I 
come see you (doctor) … I’m not doing alright; well I can’t win (Whānau #33) 
 
 
The level of education whānau had little influence on their experience or 
encounter with a HP; nor had it made them more likely to engage with their HP; 
or influence their ability to access care and treatment or achieve positive 
outcomes. Whānau did not always disclose their concerns during a consultation 
with the HP. They often told the HP what they (HP) wanted to hear, not what the 
HP should know. This situation was dependent on the relationship of whānau 
with the HP, and the level of comfort discussing the realities of their lives. 
 
 
I came home that day I told my wife … and I haven’t drunk or smoked since … I 
thought I was normal to anybody else he said (doctor) to me how much do you 
drink and I said oh a couple of jugs … Yeah (Whānau #45) 
… he said (doctor) how often and I said umm oh every night excepting Fridays and 
Saturdays … oh what do you do on Fridays and Saturdays … I said I drink 12 jugs 




5.11 Whānau engagement 
The challenge for many HPs is to engage in a way that keeps whānau connected 
to their health and wellbeing. Many whānau were disengaged, passive, and not 




I use to do that … I just couldn’t be buggered doing it anymore (monitoring BSL) 
(Whānau #41) 
Yeah just read … parked it to the side. I mean, life wise there was no change … I 
mean, I didn’t feel any different (no changes) (Whānau #40) 
Nah and it was ... Sweet as. Yeah arggh (frustration) (Whānau #38) 
 
 
There were whānau who “got it”, during a second or third visit with a HP. In this 
excerpt, a different HP resonated for this whānau. 
 
 
Go and learn about it. Actually, it was great the second time I went back I had a 
good doctor. He explained it to me. That’s been a lot better actually, that approach 
is great … by one of the doctors. But no one … told me that until that doctor talked 
me through … that simple thing and then I got it (Whānau #43) 
 
 
5.11.1 Power and control 
The power balance has traditionally sat with the HP. Unintended or not, whānau 
stories articulate their perception that the power sat with the HP. The medical 
model has traditionally been “the doctor knows best”, and is based on the 
hierarchical class system, that only the “privileged”, smart professionals went to 
medical school and university, and ordinary people did manual jobs like 
labouring, or service employment. Whānau in a position of “doctor knows best” 




observer role, rather than an actively engaged participant. This behaviour was 
not related to any age, gender or duration of diagnosis. 
The feeling whānau had of disempowerment exacerbated the power imbalance. 
Whānau expressed their dissatisfaction and annoyance at the use of patronising 
and disparaging language from the HP. This behaviour fostered a negative 
experience and whānau disengaged. 
 
 
She was treating me like a kid … that’s probably the worst thing you could do. You 
know when she was talking to me … “you’re not doing very good” … it was sort of 
like a kid. Never treat me like a kid … I’m not. Just straight up with me, up front, tell 
me … talk to me, kei te pai. I think that was part of the problem …. it’s like I’m a 





Strategies and behaviour the HP used with whānau were questionable. To 
chastise and reprimand whānau in this quote, when asked in a jovial manner 
about their health and wellbeing, made whānau feel vulnerable and confused. 
 
 
They say (GP) “do you want to die when you’re 60?” ....... “Shut up” When you’re 60 
you’re … have a stroke … heart attack. Oh, shut up A**** (laughter). I don’t know 
what I’m doing, sometimes …I think I’m doing alright, next minute I come see you 
fellas I’m not doing alright, well I can’t win (Whānau #33) 
 
 
Having an understanding and knowledge of whānau history would assist the HP 
to develostrategies with the whānau that best work for them; this whānau was 




Lot of my family died of it … this other doctor now *** he was gonna put me on the 
insulin, I said I’m not doing that. I just got up and walked out … and she (nurse) 





M, is a physically active, Māori male, married with a supportive whānau living 
in an urban area. He was born and raised in a rural farming community. M 
prides himself on being fit and healthy, enjoys surfing and finds this activity 
therapeutically healing. 
Diabetes has been a real shock; he and his wife are perplexed as to how and 
why he came to have diabetes, especially as his mantra is to live life healthy, 
active and fit, after a history of drug and alcohol in his youth. 
Initially presenting at his doctors with blurred vision, the GP referred him to 
the hospital emergency department, where, after further tests, found he had 
diabetes. 
M has spent time reading and researching diabetes, its management and 
treatment. He received the standard lifestyle (nutrition and activity) 
information and started on medication. He was frustrated; no one listened to 
him and his story; he was made to feel like a scolded child; told what to do, as 
if he knew nothing; and felt like a “dumb idiot”. Not surprisingly, M stopped 
taking his medication, (he experienced some side effects from the medication) 
and presented unwell at his general practice. The diabetes had spiralled out of 
control. It was during one of these visits to the general practice that he 
connected with a locum doctor who sat and talked with him about diabetes. 
From here, they developed a plan that M could self-manage and tweak in 
discussion with the medical team. The process has been trial and error, as he 
became familiar with the medication that worked for him and discovered it 
depended on what he was doing at the time, like surfing. 
He has great support from his whānau and constantly asks questions about 
diabetes and treatments. His negative experiences earlier on in his diagnosis, 
with some of the health professionals has left him weary and battle-scarred. 
Fortunately, that one positive encounter made a significant difference for M, 
and it was a turning point to his understanding of diabetes and his approach to 




5.12 Living with diabetes 
It is important that HPs have an insight of Te ao Māori, so they can understand 
and best serve Māori to achieve positive outcomes. Te ao Māori is a way of being 
and is integral to whānau wellbeing. To broaden the lens of the HP, and lift the 
gaze from condition - disease and presenting symptoms, to being whānau 
centered (Strain, Cos, Hirst, Vencio, Mohan, Voko, et al., 2014). Examples of this 
include one whānau who linked their diabetes to their spirituality. 
 
 
Then I realised … it’s … not just looking at solely diabetes. It’s about looking at my 
Māori spiritually. The whole being (Whānau #36) 
 
 
Diabetes is a financial burden for many whānau. The financial constraints 
associated with being well is real for some whānau. 
 
 
And the meat that I buy is more, … the lean meat instead of the fattier meat. It 
becomes more expensive. That’s the other problem. It’s expensive being sick. It’s 
expensive being healthy (Whānau #29) 
Plus see I was only on the dole. We were getting bugger all, look at our whare, I 




5.12.1 Diabetes knowledge 
Diabetes knowledge was not consistent across the whānau, and the level of 
diabetes health literacy was variable across the disease continuum and appeared 
to have no correlation to duration of diagnosis, age, gender or physical locality. 
Studies have shown that those who have a chronic condition for a number of 




(Doctor) He gave me some tablets. And I thought “oh yeah I’m all better now” 
(laughing). I don’t have to go back and get a repeat or I didn’t ask. (giggling) dumb 
b *** aye? (Whānau #28) 
Well really put it down to nuts and bolts. I don’t really know much about diabetes 
… (Whānau #41) 
 
 
The UKPDS study showed a 1% decrease in HbA1c can make a significant 
reduction in risk (UK Prospective Diabetes Study (UKPDS) Group, 1998a). This 
was a difficult concept for whānau to understand, considering the manifestations 
of uncontrolled diabetes are not always visible or felt, and it was a challenge for 
whānau to make this connection with diabetes. 
 
 
We were struggling alone trying to understand what diabetic itself was stuff is. All 
we know was just the sickness, we couldn’t, and we couldn’t see or weren’t told the 
dangers that were in in it (Whānau #44) 
 
 
Whānau clearly articulated their diabetes knowledge. To understand diabetes 
meant knowledge, autonomy and wellbeing. 
 
 
I think it’s just knowing that all that sugar in your system that doesn’t get used is 
going through every part of your body. It’s going through your liver, your kidneys, 
your heart, your brain and all that kind of stuff. It’s just going everywhere and it’s 
not just that, that spot of blood on your finger where you test. It’s all in here sort of 
thing yeah. Just knowing that if my blood sugar levels are high what it’s doing to 
insides. Yeah ok doing some damage. I know you can have complications later on if 
they’re too high for too long that sort of thing too often (Whānau #27) 
 
 
Some whānau were not confident with their knowledge and understanding of 




I didn’t know what the hell they were, you know all these big words I didn’t know 
what the hell they were talking about (Whānau #33) 
 
 
Access to the appropriate knowledge and information is needed to assist whānau 
in making informed decisions and choices. In this quote, a whānau reflects that if 
the previous generation had had more knowledge, they may have lived longer. 
 
 
Yeah. The information. Maybe dad and them would have been you know ... around a 






D has been living with diabetes for over 20 years, is semi-retired, and lives in 
the whānau home, in a rural community. D is a respected and knowledgeable 
local, born and bred in the area with whānau, hapu and iwi connections to the 
area. He is an active leader in the community, and a committed hāhi69 member. 
D keeps good health, taking his medication and having regular check-ups with 
his GP. 
D works occasionally as a part time driver, which he enjoys, as it gets him out 
and about meeting different people. He likes to keep busy and the extra money 
is always helpful. 
Leading up to his diagnosis, D led a healthy and active lifestyle, and worked full 
time in various primary industries. He became concerned after experiencing 
several episodes of unwellness that were unfamiliar to him. This led to a visit 
to his GP. After several tests, his GP said he had diabetes. He was initially 
mystified with this news and uncertain about what being having diabetes 
entailed. 
What resonated for D, his GP (known for generations) said he needed to make 
a change or he would not not be around to see his mokopuna grow up, or 
reach the age of 50. This was serious and the message really hit home for him. 
D stopped drinking. He stopped going to the pub after work, a habit he had for 
many years. It was not without its challenges for him or his family. D avoided 
situations and events where there was alcohol. When he did attend, he would 
not stay long, or he would share a meal, and leave not long after. He worries 
about his immediate whānau with diabetes and encourages them to get 








                                                             
69 Hāhi – church, religion 
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5.12.2 Busyness of diabetes 
Diabetes is hard work and high maintenance; it takes consistency and effort to 
keep well, as explained by: 
 
 
I work on it (diabetes). All the time (Whānau #45) 
 
 
Diabetes involves attending a myriad of tests, examinations, and appointments 
such as outpatients, dietetics, podiatry, ophthalmology, laboratory-blood tests, 
clinical nurse specialists, physicians and specialists in secondary care services, 
visits to the doctor or nurse in primary care. Access to tertiary health care 
services for whānau in Tairāwhiti, is a five-hour drive each way. Increasing the 
treatment burden withmultiple specialist appointments and polypharmacy, can 
lead to the diminishing coping mechanisms of whānau and their reduced 
adherence to therapies, contributing to poor outcomes (Gallacher, May, Montori, 
& Mair, 2011). 
 
 
I had to have that Glucose Tolerance test. It came out borderline. I don’t know the 
result. I had to go to those appointments … eyes checked … podiatrist ... I had all 
those done … and … the dietician up at the hospital. I have been through all those 
appointments (Whānau #25) 
 
 




Just morning and nights now, it was 4 times a day when I first started. I got hōhā70 
with it (Whānau #36) 
  
                                                             
70 Hōhā – bored, fed up with 
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If I don’t listen … my family … get on my back … They doing it … out of love … they 
don’t want to lose you. You get all ach71 (laughter) … and we wonder why we end 
up where we are (Whānau #39) 
 
 
Equitable access to services was not evident across whānau interviewed. Not all 
whānau experienced the same “busyness” associated with diabetes nor were 
they recipients of all the services described above. Some whānau received little 
service, while others received no service. Poor access to diabetes related services 
is likely to contribute to an increase in hospital admissions for advanced chronic 
disease states, a poor quality of life and poorer health outcomes for whānau 
(Jansen, Bacal, & Crengle, 2008). 
  
                                                             





L is a Māori woman, living in a small rural community. Her immediate whānau 
(tamariki and mokopuna) are nearby and overseas. L has active contact with 
her immediate whānau and extended whānau in the community. L works full 
time, and has diet-controlled diabetes (previously on diabetes medication). 
L returned home to care for her elderly parent whose health was failing with 
diabetes. The role of carer included preparing and cooking, what she thought 
were healthy meals at the time, including pudding. Reflecting on this time, she 
wishes she had known more about the food side of diabetes and wouldn’t have 
had so many puddings. 
L gained some knowledge about diabetes from her life experience of caring for 
someone with diabetes. It has taken her a considerable amount of time to 
grasp and understand diabetes, when diagnosed with diabetes herself, many 
years later. 
L had a very active and busy social lifestyle during the weekends and was 
shocked she had diabetes, and immediately set about making changes to her 
lifestyle. L stopped smoking, electing to go “cold turkey”, an incredible 
achievement in light of the social environment, where nearly all her friends 
smoked. The difficulty of maintaining these changes led L to her social 
isolation. She avoided people, events and venues that would be a temptation to 
have a cigarette. This meant limited contact with her friends and social 
networks. L kept good control of her diabetes and was conscientious of 
monitoring and measuring her blood sugar levels, and carried snacks with her. 
Over the years, her confidence waned, as she continued to stay home and 
isolated from her circle of friends and whānau, and she was diagnosed with 
mild depression. Diabetes became secondary as L received treatment: 
medication, counselling and good support from her GP. 
L has strong community relationships and networks, and is active on the local 
Marae. Mokopuna72 and mokopuna tuarua73 often stay in the weekends or 
holidays, and L is involved with their activities. Overall, she keeps good health,  
  
                                                             
72 Mokopuna - grandchild 
73 Mokopuna tuarua - Great grandchild 
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tries to walk most days (harder in the winter, when it’s dark), eats the right 
kai74 and keeps herself well. L encourages her whānau and whānui75 to make 

















































                                                             
74 Kai - food 




The concept of self-management is a westernised non-pharmacological 
intervention recommended as best practice for the management and treatment 
of diabetes in New Zealand (New Zealand Guidelines Group, 2012). The notion of 
one’s “self” in terms of Te ao Māori, is foreign, whereas the term “whānau” has a 
more important role in health and wellbeing and is not dissimilar to other 
indigenous populations. The term self-management also places a significant 
personal burden on the individual, as one whānau participant said: 
 
 
If you bugger it up or stuff up it’s your own fault. The blame rests at your door. As 
one whānau member said “my own stupidity”. You’re the one carrying the 
mamae76, no one else (Whānau #26) 
 
 
Although the focus of the interviews was individual whānau experiences of 
diabetes, all of those interviewed talked about and connected to their respective 
whānau, during their journey of diabetes. 
 
 
5.12.4 Drivers for positive change: whakapapa - whānau, hapu, iwi 
A major driver for change of lifestyle and behaviour was whānau, tamariki and 
mokopuna. Whānau wanted to live longer, continue to work and be there for 
their mokopuna and whakapapa. Having an understanding of your genealogical 
connections or whakapapa establishes who you are and how you move in the 
world. This mum was not worried about herself or her diabetes, but was afraid 
her daughter would get diabetes. 
 
 
My next dread is if she does get diabetes. I don’t want her to. If I can make it better 
for my girl I will. She can be quite stubborn. She knows that her nannies and … her 
 
  
                                                             
76 Mamae - pain, sore, hurt 
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friend have died because of this. I don’t want my daughter getting it (Whānau 
#37) 
I see her in me … and I see me in her. Mum … she’s a diabetic too, she knows what 
it’s like. She’s actually having a better picture. It’s not just … easy … changing 
everything. It’s not as easy as that. That’s it for me *** yeah. I just … really get 
scared for my girl (Whānau #37) 
You know you want to be here longer. Keep going out to work. You know what I 
mean. So that’s why I changed. Made that big change (Whānau #25) 




Positive changes to whānau lifestyle can have an immediate impact on quality of 
life, and the wider context of whānau, hapu and iwi (in terms of whakapapa, 
matauranga), and economy (whānau ability to work, your social contribution to 
the community (worth). This whānau made changes to their kai: 
 
 
We eat a lot more greens and salads than we ever used to. We have salad every 
other day. And that’s not something that I used to do religiously. It was like oh 
every now and then we’ll have a salad. I go for the lean meat instead of the fattier 
meat (Whānau #29) 
 
 
This whānau continued to socialise, but reduced their alcohol intake (a 
significant change with a high return). 
 
 
The drinking, I thought, well I can’t be drinking because it will take my sugar levels 
up. How am I going to get round that, not drinking? My social life was pretty much 
… on the piss Friday, Saturday and Sunday and still drinking Sunday. I thought oh 
my God, am I able to keep doing it or do I want to get better or what do I want to 
do? So when my friends came around – Oh cup of tea? Even if I do now, if I have a  
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drink I’ll just have one glass of wine, or maybe two and that’s it. Which is good … I 
feel like I’m having a good time (laughing). But … that’s how I done it, pushed it to 
the side (Whānau #28) 
 
 
5.12.5 Tino Rangatiratanga77 
Whānau with self-awareness contributed to their own health and wellbeing by 
keeping informed and being part of the decision-making about their health care. 
As illustrated from these excerpts, some whānau clearly articulated their 
knowledge of diabetes, and were active in their own care. HPs are positioned to 
facilitate this change, by providing appropriate tools and resources to meet the 
needs of whānau, and support their decisions. 
Whānau managed their diabetes within the context of their whānau, not separate 
or in isolation from whānau. This is “self-awareness” and whānau “self- 




“If I don’t listen … my family … get on my back … I get hōhā with them. But … 
they’re doing it for me. Sometimes it pays to have people that will nag at you … 
(Whānau #39) 
“I just said no way (laughter) just show me how to use this thing (insulin) and I’ll 
just go and do it …” (Whānau #43) 
 
 
Whānau who took ownership of their health and wellbeing, were confident in 
their ability to approach their respective HP (general practitioner, practice 




                                                             
77 Tino Rangatiratanga – self-determination, power, control 
78 Kaiawhina – community health worker 
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The thing is “just look after you after yourself that’s all it is. Nothing else said, but 
just look after yourself cause no one else will”, “You’re the one carrying the mamae 
(sore, hurt), no one else – It’s your responsibility” (Whānau #27) 
I can get the blister packs, but I said to my doctor and to my chemist …I’m capable 
of doing it. When I can’t do it …I’ll let you fellas know and you fellas can (referring 
to pharmacist) (Whānau #39) 
 
 
5.12.6 Barriers to access 
Whānau deserve access to good quality health care. At times there were 
intentional or unintentional barriers that hindered access. Whānau often 
encountered road blocks and experienced financial burden when 
circumnavigating the health care sector, similar to studies by Baxter (2002) and 
Jansen, Bacal, and Buetow (2011) that identified barriers to access to care. 
 
He (GP) was fine. It was the receptionist that wasn’t too helpful (Whānau #29) 
Nah I don’t have to come back here because every time I went there I had to pay 
$10 to see a nurse (Whānau #31) 
 
 
Overall, whānau were motivated and actively engaged with their health 
professional, presenting to their doctor because they were feeling “unwell” 
and/or “not right”. 
 
 
because I wasn’t feeling well at the time … I had lost weight … and I thought … 




5.12.7 Alternative sources of advocacy and support 
All whānau had advocacy and support, either their own whānau, and/or an 
alternate source in the community, such as Hauora79, pharmacist, or general 
practice, to support them, to understand and help process information related to 
diabetes treatment and management and their related medicines. The trigger for 
change can be a different voice or person to reiterate the information; or a 
different time and place. This excerpt showed whānau were change ready; to 
listen and hear the messages and information, an example of the change process 
described by Prochaska & Di Clemente (1983) (Prochaska & Di Clemente, 1983). 
 
 
She (the Nurse) just walked me through that. Told me that this (Doctor) was a 
really good person for me to talk. I might have a better understanding. But (Nurse) 
was very good … very patient and … she could see my whole-body language was 
NAAAH (laughing) kind a thing. They just they more or less just told me, repeated 
what – (GP) – had said. I was calmer and more receptive … it started to sink in 
(Whānau #31) 
The pharmacy they ring me to tell me that my repeat is due to be picked up. And 
my GP, they also ring me to tell me that, so that comes up on the screen, to tell me if 





















                                                             





N is a Māori male living in an urban setting. N has a history he describes as a 
“been there and done that” (gang-related) time in his life. N would recall 
events that happened during this time that influenced his life. N admitted 
sometimes it takes several times or attempts for him to digest, process, 
understand and grasp some information. He has had diabetes for less than 
10 years. He thinks he has a family history of diabetes, but is not sure. N was 
raised by different whānau around the country and is one of many siblings 
spread wide and far around in the country. He has regular contact with his 
adult children and mokopuna as they live in the same city. 
N has other health problems that he receives treatment for, and he struggles to 
keep his blood sugars on track; he is not troubled about this, as he feels fine. N 
states food and lifestyle are key to managing diabetes, but is not fazed about 
this; he believes he can do it, when he sets his mind to it. He looks after himself 
by making sure he takes his pills as instructed by the nurse or doctor. He 
states, “well they the ones that are supposed to know” and this is what keeps 
him well. N does not always attend his regular appointments, but tries his best 
most times. 
Fulltime work keeps N busy and he has an interest in most sports. He is often 
out and about with his mokopuna helping with events in the community. His 
getaway is camping and going bush or beach, living and foraging off the land, 





Within some communities and whānau groupings, key individuals are 
considered “expert”. These ‘experts’ have a particular skill set, such as fishing, 
gardening, bread making, rongoa, mirimiri, health (diabetes, gout knowledge), 
and they are called upon for their expert knowledge and advice. Some whānau 




Whānau … send their friends to me. I pull out all the information. I talk to them, 
but I am honest with them … the key to it … you want to do it. Do you want to ... 
admit you got diabetes? You have to be honest with yourself (Whānau #39) 
 
 
Studies show that when whānau engage with a “lay” person/s or groups, 
effective management and positive outcomes can result (Ellison & Rayman, 
1998; Handley et al., 2010b) in role reversal (whānau become the experts and 
the HP a mentor). However, there are risks and benefits when relying on advice 
from others. This whānau risked taking advice from his (“expert”) mates, but did 
not get any better, having to visit the GP for treatment. 
 
 
Cause you listen to others … your own mates, your own friends, your own relatives 
said “oh no, that’s wrong, you shouldn’t take that”, … “that one is for this, that one” 
… they’ve turned … themselves into a doctor and they’re just as bad as … as you are 
(Whānau #44) 
You know … you take that one, well you start listen to them alright yeah but you 
were still getting crook80 (laughter) … And then the doctors gotta … pick it up. 
Balance you up again and away you go, but he don’t tell you … don’t you stop that, 
you don’t … know! you go back to … that doctor … - well he must of given me the 
wrong one, must be not enough strength in that one …” (Whānau #44) 
  
                                                             





M lives with her husband in a rural community. M works full time and is 
known for her active participation in various community groups in different 
roles and functions. Whānau live close by, and M spends what spare time she 
can with their mokopuna, who attend the local school. M has a familial history 
of diabetes and has personal experience with whānau who have died from the 
complications of diabetes. M tries to be proactive with her physical activity 
and like many others, struggles with the kai, keeping that on track – and falls 
off the wagon many times. M said she knows about diabetes and understands 
that you just need to “look after it”, but does have a challenge putting that 
knowledge into action. Life is busy and she admits to lapses of memory, often 
forgetting to take her pills. However, after experiencing unwellness for a 
period of time, which necessitated a trip for specialist care out of the district, 
M has become more deliberate in remembering to take her medication and 
making time for her check-ups with the doctor. Making the transition to 
insulin has been hard work but admits is, “what I have to do to stay well”. She 
has good supports from her whānau and friends in the community and wants 




5.12.9 Katakata (humour/laughter) 
Threaded throughout the interviews is laughter and humorous satire, used by 
some whānau as a coping mechanism to express their feelings about HP, 
medicine or diabetes. After replaying the interviews, these funny “quips” had 
hidden meanings behind the expletives and comments. More often than not, they 
represented their true emotions, feelings and thoughts. For example, this witty 
analogy whānau shared of their experience about information from the HP: 
 
 
“Wind fly past sort of thing” (Whānau #44) 
 
 
I understood this to mean that the information came in one hand and out the 
other hand (like the wind) so quickly you did not catch it and before you knew, it 
was gone. 
In this excerpt, the whānau described lots of information and advice provided by 
the HP. Although useful information to know in theory, the realities were a little 
more challenging. A humorous play on words of advice from the HP (HP, “less of 
that” whānau response, “I always do that”), and whānau doing the opposite: 
 
 
The diabetic nurse … they were really good, heaps of information. Yes – am I 
supposed to say yes? (Laughing) Yeah nah! It was helpful – it was whether I did it 
or not. She was saying … do this, try not to do this. So less of that and more of this. 
Yeah but I always do that (laughing) (Whānau #28) 
 
 
The emotion (essence) of laughter is very subjective and allows whānau to give 
meaning to situations they experience, and to describe an understanding of their 




5.12.10 Diabetes devices and medicines 
 
5.12.10.1 Devices  
Achieving and maintaining good blood glucose control is an ongoing struggle for 
many people with diabetes. The blood glucose-monitoring device is a tool that 
provides a measure of blood glucose at a particular point in time. Devices at the 
time of the study were available for purchase from recommended retailers, free 
from their HP or the Diabetes Society. There was a cost for test strips and 
lancets. Test strips were available on prescription from the HP. Instructions and 
education on use of the monitor were usually provided by the HP, and whānau’s 
use of devices was based on the individual plan of care. 
Most whānau in the study had a blood glucose-monitoring device and did not use 
them regularly (or at all). Initially whānau measured their blood sugar levels, 
early in their diagnosis; over time the practice became random and less 
important, as diabetes became part of their everyday life. Whilst others 
continued to monitor their blood sugar levels. 
 
 
Now and again, not all the time … I used to do it morning and night (Whānau #33) 





5.13.1 Whānau thoughts and feelings about medication 
All whānau in the study had a pharmacological intervention: thirteen were on 
oral diabetes medicine (OAD), seven were taking insulin and an oral diabetes 
medication. Health literacy is the ability to find, process and understand basic 
health information and services; and to make informed and appropriate 
health decisions. Retrieved December 12, 2019, from 
https://www.health.govt.nz/our-work/making-services-better-users/health-
literacy. Effective health literacy between HP and whānau is an enabler for 
whānau, to make informed decisions about their diabetes management and 
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treatment, and to meet recommended clinical biomarkers and targets (not 
necessarily whānau targets). A proactive HP’s approach with whānau is to 
have a courageous conversation (gracious and honest), to initiate medication 
interventions (if appropriate), like introducing the notion of insulin early. This 
approach is to be applauded. Clinical inertia (Strain, Cos, Hirst, Vencio, Mohan, 
Vokó, et al., 2014) is difficult to change a practice, in a system that measures 
success in targets and clinical biomarkers, rather than whānau outcomes and 
wellbeing. 
There were whānau who believed taking medication was important for their 
health and wellbeing, and that their medication kept them well. Studies 
identified in the Literature review (chapter three) found other indigenous 
populations also hold western medicine in high regard, which appears not 




Long as I take my medication. I’m cool as. I haven’t found it hard for me (Whānau 
#33) 
(Medication) It makes me live that’s what I say to people. A lot of people get a shock 
with the amount I take (the number of “pills”). I said well if I want to live. Well you 
fellas … want to see … uncle or papa die, No! Well I said that’s what keeps me alive. 
That’s the reality of it, that’s what’s keeping your uncle and papa alive. It’s those 
pills if I don’t have them … (As he slides his thumb across throat – indicating end of 
his life) (Whānau #39) 
 
 
Health beliefs and past experiences influence whānau perception, attitude and 
behaviour towards medication (Bassett-Clarke et al., 2012). This whānau had a 
phobia of needles, and recalls their father on insulin. 
Question – Are you on insulin? 
 
 
Whānau response: – “Nah … Thank goodness. My Dad was on that, I can’t stand 
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umm needles. I can’t (Laughter). They poke me and I go f**ken hell … I didn’t mean 
to swear. Oh f**k they pricked me f**k (laughter) … I’m sorry … I just can’t stand 
needles. But … it’s like I’m getting there slowly, it like f**k witch (laughter). I’m just 
… get use to this like f**ken hell, you know … to say to myself. I don’t mean to say 
aloud (Whānau #33) 
 
 
5.13.2 Medication management 
A good relationship with their doctor appears to have a positive impact for 
whānau with their outlook and attitude towards medication. 
 
 
I've had no problems with them … if there’s a new lot … M*** (doctor) will say like 
… she’s gonna have to put me on another pill. She'll explain what it’s all about and 
if an expensive one (Whānau #32) 
 
 
Those who had ten or more years with diabetes normalised the act of taking 




Doesn’t worry me. I just do it now. I haven’t found it hard for me. It doesn’t worry 
me … I don’t even think about it. Na I don’t even think about it now (Whānau #33) 
I think I just got … bored … with the whole situation. When you first starting, you’re 
very interested. Yeah sort of like same old, same old regardless you know you’re 
taking them for mate (“mate” - sickness/illness) you’ve got. Yeah … I know I’ve got 
to take them. I know … they for my betterment my health, but … but after a while it 
becomes same old same old. So you … not too worried about it. You become 
complacent I suppose is how you put it (Whānau #39) 
 
 
Whānau stopped taking their medicine for different reasons. These included: a 
different perspective and approach to western medication; started medication - 
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then forgot to take it; or they stopped taking medication because the medicine 
made them feel unwell. Others stopped their medication because they did not 
feel any different and felt they could manage the problem themselves. Whānau 
completed the prescribed medication, and did not realise they had to keep taking 




They did give me pills but it didn’t work for me. There was some ... kind of ... 
reactions that were taking place which I didn’t like. So I just stopped taking them. I 
think one was to bring my cholesterol down and I … sort of thought well, I think I’ll 
just work on it. I don’t really … like taking pills. It’s kind of like … if I’m well I try not 
to take like panadol (Whānau #43) 
 
 
Some whānau believed the medicine was not helping them, and were frustrated 
with taking the medicines, so stopped taking their medicine. 
 
 
I went through a phase last year where I was just forgetting to take them I was just 
couldn’t be bothered so aarrghh. Weren’t doing anything for me (Whānau #37) 
 
 




In 2007, when I went on the tablets. Then I just thought I’m alright now. Nothing’s 
happened so I just went off them (Whānau #28) 
 
 
Whānau openly shared their experiences and interest in either self-testing or 
changing their medication regime. Sometimes this was done on purpose in 




they were experiential with medicine doses and amounts, and were aware of the 
consequences to their actions. 
 
 
Sometimes I think oh shall I cut it down? I have tried but (laughing) afterwards I 
say oh - I don’t need the full dose I have only half of one – shit (laughing) (Whānau 
#25) 
We had a bit of a juggle around the last time I was at the diabetes clinic at the 
hospital with the nurse there. You know some of those pills that I could take at 
different times that might have suited me better. So I changed to one that she said. 
So I’m breaking my pills up twice a day. But I’ve found that, just by fluke, that even 
if I have a high in the morning I don’t know what it is but my body seems to work 
quite well in the morning after breakfast. I can have a high and not take my pills, 
you know just by mistake, by not taking my pills, and then a couple of hours’ later 
things will be fine without the pills. So I take them later in the day still when I need 
to (Whānau #43) 
 
 
Whānau taking multiple medications described their bewilderment at having to 
take so many medicines. 
 
 
They’re the same pills, so there’s 1, 2, 3, 4, I think. 5 different types, take 3 
metformin. I take an Accupril. And … I take … I forget what the yellow ones are for. 
They got 3, 4, 5 different types of pills. Add them up as individual pills there’s 14 
pills (Whānau #45) 
 
 
Managing polypharmacy is a challenge; having to remember what, where, when 
and how many medications can be confusing. There are a variety of devices, tools 




Whānau expressed their frustration with the font size on blister packaging of 




They got … more fancier now or more modern I should say, they come out … blister 
packs. Oh so you know what they’re for? Luckily I do because, before it came out in 
bottles. It’s all written on the bottles. Now it’s written on blister packs, the print is 
soo fine. A rat won’t see the printing on them (Laughter). Hard to see … even with 
glasses … (Whānau #44) 
Hard to open that thing (referring to Blister pack81) (Whānau #45) 
 
 
Medication changes triggered an increase in anxiety for some whānau. This 
whānau describes the irony of stopping one medication, and starting a new 
medication, to counteract the side effects of another medication. 
 
 
Well at first I thought oh shit I take um 5 you know it increased I never had so 
many when I started off, but when you get these other symptoms, he (doctor) adds 
on to. You better take this and then you have side effects. Then you tell him … he 















                                                             





M lives with her partner and family in an urban area, is an active member of 
her large whānau community and spends a lot of time supporting extended 
whānau and community events. Before this, M and her whānau (who were 
young at the time), spent some time living and working away out of the area in 
a metropolitan city. They returned home for a better family lifestyle. M is 
connected to a wide network of whānau living close by and overseas that she 
has regular contact with. 
M has a strong family history of diabetes, and experienced the loss of a parent 
at a young age due to the complications of diabetes. Having diabetes during 
pregnancy was not unexpected and she tried in vain to push the diabetes to 
the back of her mind (“keeping it at bay”) post pregnancy. However, that was 
not to be, as she herself explained. Side effects and unwellness caused her to 
get medical advice. M is articulate and well informed about diabetes, its 
treatment and management. She admits she struggles to keep to the healthy 
kai side of things and as for exercise, she knows she needs to do it but has not 
been able to, as she has not had time, being too busy with whānau. M has tried 
to instigate change for her whānau with healthy eating, choosing lean meats 
and more greens, and fruit, but has found it an expensive exercise for the 
whole family. 
M makes sure she attends her appointments for diabetes checks, and feels she 
has a good relationship and understanding with her GP. She has no problems 
with her medication and has been slowly getting used to the insulin, checking 
her blood sugars most of the time, but not all of the time. She wants to be 




Some whānau had developed their own individualised, highly sophisticated 
system and process for managing their medication. This whānau describes how 
he adjusted his (notebook) approach to medication changes over time. 
 
 
You can have a look … I just use to keep track of what I’m taking for what. Oh 
swapped them and new ones come and ... (went to get his pills) got quite a lot. 
That’s the whole shabang, love. I use to have a note with them but … they keep 
changing brand names … there’s some things go off the market. What you call it 
won’t buy this one and it goes off the market (Whānau #39) 
So I know … when I sort my pills out … I just finished sorting out my pills for the 
week. This morning. That’s why I band them together so I know. I use to keep a note 
with them but … (Whānau #39) 
 
 
Routine and consistency helped whānau to remember to take their medication. 
 
 
I’ve disciplined myself to get into the routine. Taking the insulin same time of the 
day. Has to be the same time because otherwise I’ll forget. So I got to take it at the 
same time, so it’s at slow release you know. Same time every day. That’s how I 
remember (Whānau #43) 
 
 
Similar to other studies (Hodgetts et al., 2011; Nikora et al., 2011; Te Karu, 
Bryant, & Raina, 2013), missing doses of medication was a common experience. 
This whānau had their own process for managing missed medication and 
realised their HP did notice when they missed medicine. 
 
 
Question: What do you do when you go home? Whānau response … I go home and 
take them. They say you can’t take them all at once - I say no I don’t, so I get home 
and if I’ve missed Sunday, and it’s Monday I move Sunday over to Tuesday 
(laughing) – cause you can’t go backwards  
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But say… there’s a gap there and … she says how come … (referring to the Dr 
asking about pills) – oh I forgot sometimes – one day it was two days but when I 
got home it was the afternoon and I took that day’s ones. 
Nurse: You don’t need pills, your pills should last you for that long? “yeah well 
whatever” Nurse: Oh you got heaps - How come your pills last you that long? 
“Well cause I missed some days – yeah they’re not silly aye – yeah no that’s right 
they know when you should run out and you’re not” (Whānau #31) 
 
 
The whānau experienced physical effects when they ran out of medication. The 
following excerpts illustrate whānau awareness of the consequences and 




For arguments sake my last … repeat. I went there (GP) and they said No you got to 
get a new … script. Time I got the script … I think it was about 3 days I hadn’t taken 
any pills. I felt it in the legs (Laughter). And … about 2 or 3 days taking your pills 
before it comes right (yeah) again. So now … I got to make sure I don’t miss … 
what’s the day I think I never took them for 3 days (Whānau #45) 
 
 




Well I take my pills … and instead of carting the whole bag, I just take enough to 
see me through. If I know I’m going there for Friday and I won’t be back until 





In a public setting whānau found taking medication challenging, and were self- 
conscious, and found that it potentially impeded on their lifestyle. 
 
 
I really don’t like carting it round with me … you got do it in public. You know and 
then everybody stares … (referring to use of insulin) (Whānau #39) 
 
 
The use of colloquial language and metaphors like “double them up” or “miss … 




I get like that … (Laughter). I miss ... the bus sometimes. Well I don’t want to 




I use to say to her (Nurse) … I haven’t taken my pills for a while. I’d just double 
them up, she come back to me and said no don’t double up like that cause they’re 
doing you harm (Whānau #26) 
 
 




I’m doing pretty good. You learn things about times with meds. Like if I don’t take 









D resides in an urban area with his young family. He works full time and is an 
avid musician. He usually keeps good health and has been a diabetic for less 
than 10 years, having recently transitioned to insulin. He has not found this 
difficult or experienced any problems with managing his diabetes, and is 
unsure if diabetes is in their (whānau) family. D recited stories of whānau that 
had experienced “not so nice” diabetes, like the loss of a limb and blindness – 
something he is very conscious of not wanting to experience – a motivator to 
ensure he keeps well. D has a good understanding of diabetes and the 
management of diabetes, and like others interviewed, struggled in reality to 
apply this practically in his life. He tries his best most of the time, and 
expressed his frustration as he struggles with keeping his weight in check and 
limited time to exercise, something he feels he needs to do as it helps with his 
wellbeing. He is mostly proactive with his appointments and visits to his 
respective health professionals and specialists. D has a supportive partner, and 




5.13.3 Transition from oral medication to insulin 
It is important to have early discussions with whānau about insulin, to assist in 
allaying any fears and related anxieties, and improve whānau engagement and 
ownership of any change (New Zealand Guidelines Group, 2012). In addition, 
studies have shown improved life expectancy and preservation of renal and 
cardiac function, decrease in the progression of microvascular disease and 
possible reduction in the risk of heart attacks (UK Prospective Diabetes Study 
(UKPDS) Group, 1998a). 
Whānau were uncertain and scared to make the transition from oral medication 
to insulin therapy. 
 
 
(GP said) I would ask … you consider … insulin. He (GP) said because … you’re not 
really managing too well. I really need for you to think about going on to insulin 
(Whānau #36) 
I’ve got used to it ... mind you. To actually start doing it … was frightening. I was 
scared of making a mistake. It’s a new territory you’re going into and you don’t 
know. Just long as you move your injections every day around. For me ... was a 
different thing. I couldn’t say na … I don’t like needle, but she said you have to. I 
can’t give you a strong enough pill to counteract, are you gonna listen? Yeah I had 
to listen (Whānau #39) 
 
 
Insulin therapy was initiated early for this whānau. Including whānau in the 
decision making means no surprises for them and less anxiety and apprehension 
for whānau making the transition to insulin. Whānau actively involved in their 
care and decision making are more likely to be adherent with medication and 




They said it that might happen anyway, the insulin on top of meds … that’s not 
scary at all. When I first tried it they said put it in, put it in I was like now? Yep now,  
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now. Doesn’t hurt at all. Real tiny needle. They gave me the extra-long because I 
was a bit thick around the ... around the puku (Whānau #27) 
 
 
The early conversation about transitioning from oral medication to insulin was 
pivotal to whānau accepting medication as part of their treatment and care. 
 
 
Hit home then, when they transferred me from that, but you know it was umm with 
the pills, just taking another pill. I was taking quite a few. It was just another pill. 
We got to actually come to that place of accepting it. Like I said my acceptance, 







C lives in her whānau home in a rural community. She shares the house with 
some of her adult children and mokopuna who work locally. C works part-time 
and is active in local community events and activities, and would often be at 
the Marae. She enjoys keeping an active social lifestyle, following local sports 
in the community. She has close and regular contact with her other whānau 
and mokopuna that live locally and overseas. 
C is aware of what she can and cannot have to eat and tries hard to stick to that 
and admits that she has good days and bad days, but finds it frustrating 
sometimes when she can’t and admits that she does fall off the waka every 
now and then, for a little while. Then gets back on the waka when she starts 
feeling a little out of sorts and realises “gee I haven’t taken my pills”. She 
knows that she has to exercise – well, that is what she has been encouraged to 
do - but struggles because of her restricted mobility. She feels the doctor 
should know this, and wonders why they keep asking her if she has been 
getting her 30 minutes a day. She gets frustrated because it can be expensive 
when they keep telling her to go back to the doctors for a check-up, and she 
has to pay for every visit. C has tried making changes at home with kai, but 
these are met with some resistance and she has not bothered anymore. 
She does not monitor her blood sugar levels and felt that was a waste of time. 
In the main, she manages her pills herself, by putting them into a daily pill 
dispenser. C could not understand why she is had diabetes, when her 





This chapter shares the lived experiences of whānau with diabetes and 
medicines. In addition, it gives an account and analysis of these reflections. Key 
findings are provided for debate and consideration when working with Māori in 
the health sector and/or resourcing diabetes related programmes and/or 
research, as an adjunct, to the earlier study in chapter four, examining the 
distribution and use of diabetes medicines of Māori in Tairāwhiti. 
Findings highlighted in this study are: the disservice Māori experience in the 
health care system; the inequitable and disparate access to care; recognising 
different health beliefs and behaviours of whānau and “mainstream health 
practitioners”; the quality of communication between the health practitioner and 
whānau; and quality of information patients received. Key to whānau improving 
adherence to diabetes treatment and management is to have courageous 
conversations about medicines; the impact of diabetes; realistic solutions; HPs 
are present and understand the “whole” whānau; improving whānau knowledge 
of diabetes. When whānau are engaged to take ownership of their health and 
wellbeing, by being present and active in the shared decision-making process 
with their HP, this will lead to positive outcomes for themselves and their 
whānau. 
The concept of “self-management” (by oneself, taking responsibility for one’s 
own behaviour and wellbeing), is not within the thinking of Kaupapa Māori and 
poses a potential barrier to why Māori have not readily engaged with 
recommended treatment and management of diabetes. Whānau will continue to 
experience poor outcomes if health services continue to practice within a 
Western medical model of care. Perhaps it is time to design a Māori model of 
care for diabetes. 
These stories demonstrate the impact diabetes has on aspects of everyday lives. 
Whānau live and experience daily the negative outcomes and consequences 
associated with poorly managed diabetes. The death of a whānau member; 
numerous specialist visits; hospital outpatients visits; appointments outside the 
region (dialysis, cardiac services in Waikato at the time of the study); daily 
dressing changes; wounds that are slow to heal; partial loss of limbs; failing eye  
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sight; kidneys and heart problems and other diabetes related illnesses. Whānau 
acknowledged diabetes, and managed their diabetes the best way they know 
how, with the resources they have at the time. Diabetes is not always a priority 
for many, but it is their constant companion, and at times is not manageable. 
 
 
5.15 Busyness of diabetes - Treatment burden 
Diabetes is complex, as whānau are expected to traverse and navigate the health 
system and processes. This can be challenging and at times confusing, with 
numerous (specialists) appointments at different times and places, barrage of 
tests, and multiple medications. At times this can lead to information being 
misconstrued; the non-attendance or missed appointments are often viewed by 
“others” as “non-adherent”, “non-compliant” with treatment and management. 
Studies have shown the greater the treatment burden, the more likely that 
whānau do not meet expectations of treatment. The treatment guidelines for 
diabetes are not necessarily shared by whānau, but guide the health professional 
(Gallacher et al., 2011). 
Health professionals are often “busy” treating the symptoms and fail to see the 
whānau as a whole. Whānau were weary, tired of repeating the same story 
several times to different people, who were often in the same facility. Diabetes is 
a very small part of whānau lives and not the sum total of their lives. 
The health system is rife with bureaucracy and is at times nonsensical, and not 
consumer driven, but fiscally driven. The hierarchical processes are difficult to 
navigate for many whānau when in need and under duress. Studies show 
supporters of “treatment burden” advocate that the management and treatment 
should be in the context of people’s lives (self-medication, individualised 
titration) and be more minimalist, but considerate and responsive to need (May 
et al., 2014). Clinical inertia is not new to clinical practice. The lack of 
appropriate treatment is accepted in every day practice, despite the availability 
of effective pharmacological therapies, and the inability to achieve established 
targets in almost half of people with diabetes (Strain, Cos, Hirst, Vencio, Mohan, 




care in the health care systems and clinical inertia among health care 
professionals, population demographics, beliefs about medicines and the 
perceived burden of procuring and taking medicine, as illustrated in quotes 
earlier (Polonsky & Henry, 2016). 
The challenge is to improve our system and processes, to be more flexible and 
responsive to the needs of people, on a minimalist pathway, with a focus on 
health and wellbeing. Ideally these guidelines and systems would consider the 
context of people and the clinicians of the services. The health environment is 
changing, and traditional Monday to Friday, 9 to 5 health services no longer best 
serve those needing health care in the community. It should be connected with 
other sectors like housing, social services, education and justice. Our health 
system has been slow to respond to meet the demand. 
This may mean extended days and times outside the normal 9 to 5, Monday to 
Friday, such as evenings or early mornings, or mobile outreach clinics. Services 
can be provided outside of the “bricks and mortar” that are mobile, remote, or 
delivered at the workplace (with the appropriate resource and infrastructure). 
Services should be whānau centered with access to wraparound services, like 




Communication between the health practitioner and patient is of poor quality 
and there is scope for improvement. Information patients receive is a critical 
factor in patient adherence to treatment. Possible explanatory models (and 
explanation) for poor adherence emerges include knowledge of illness, body 
awareness and the relationship between the health professional and whānau 
(Vermeire et al., 2003b). Clearly communicated and appropriate information that 
whānau understand about diabetes at diagnosis is associated with emotional and 
behavioural benefits for whānau over time (Polonsky et al., 2010). Improved 
outcomes were noted when health practitioners of differing health beliefs have a 
whānau understanding and perspective (Brod, Kongso, Lessard, & Christensen, 




diabetes (being done to), rather than an active participatory role in their 
treatment, as reflected in the dialogue between whānau and health practitioner. 
This led some whānau to disengage in the dialogue and treatment. 
 
 
5.17 Lived experiences 
Whānau are the experts in their own health and demonstrated confidently the 
breadth of their diabetes knowledge in the context of their lives. They have an 
insightful awareness when their situation shifted outside their prescribed 
“normal” parameters, which was rarely acknowledged by health professionals. 
Literature supports the notion of those living with long term chronic conditions 
as being “normal”. Similarly, whānau viewed themselves as being well and 
acknowledged there were particular challenges and struggles with keeping 
themselves well, but managed these as best they knew how to, and diabetes was 
just a part of life that they appeared to take in their stride. 
Initially, whānau were reluctant to express their knowledge of diabetes “things”, 
but as we moved through the interview questions, whānau became more relaxed 
and open with their responses and appeared quite knowledgeable and well 
informed in a “whānau way” not necessarily a “clinical way” about diabetes. They 
were reluctant to verbalise their knowledge, or appear whakahīhī (adjective – 
arrogant, verb - brag), about themselves. Whānau also express their reverence 
for the cleverness of the HP, “they are cleverer than me and they’re the experts”. 
 
 
5.18 Relationship with health professionals 
The balance of power between whānau and health practitioner is crucial to 
achieving positive outcomes. Using the analogy of a “waka”, consider whānau 
and health practitioner are located in a “waka” together. In order for the waka to 
paddle in the right direction, unity, communication, resilience, perseverance, 
consistency and timing are required. When one or the other is out of sync, 
difficulties are encountered; the waka slows; the waka heads off course; there is 




acknowledge the whānau and this leads from the outset to paddling on their own 
or in a different waka and where the whānau are. 
Within Kaupapa Māori, the essence of the practice kanohi ki te kanohi inherently 
portrays the notion of “mauri” or “being”– who you are. The purpose is to 
connect whānau to who they are and where they come from and how they move 
in this world – their whakapapa82. The notion of face to face (kanohi ki te kanohi) 
has literally been transformed to a preference mode of conversing information 
and knowledge between whānau and HP, possibly misconstrued when applied 
and practised from a different context and a different purpose. 
Positive relationships between those with long term chronic illnesses like 
diabetes and their HP are more likely to lead to effective change and achieve 
successful outcomes (Strain, Cos, Hirst, Vencio, Mohan, Voko, et al., 2014). This is 
consistent with the findings of (Jansen et al., 2011) that found that Māori who 
experience a negative encounter are more likely to have poorer outcomes, are 
less likely to have access to services, are more likely to not attend scheduled 
appointments, be non-adherent with medication and treatment, and experience 
morbidity and mortality earlier than non-Māori. This contributes to the widening 
health disparity between Māori and non-Māori (Baxter, 2002; Crengle, Lay-Yee, 
Davis, & Pearson, 2005; Durie, 1985; Jansen & Smith, 2006). 
Diabetes has a psychological impact on the whānau. How and what whānau are 
told about diabetes at the time of diagnosis and the recommendations from HP 
has a long-lasting impact on whānau attitudes and behaviours and how whānau 
feel about diabetes and how well they manage the disease years later (Brod et al., 
2009; Polonsky et al., 2010). Mixed messages such as “a touch of diabetes”, 
“borderline”, “good” or “bad” had a psychological impact on the whānau. 
HP should provide a clear message of hope and support to whānau, that diabetes 
is manageable. HP should provide ongoing support and assistance; and work 
with whānau to develop an appropriate action plan. Without structure and 
purpose whānau can lose confidence in treatment, feel confused and abandoned 
with managing diabetes, overwhelmed, demoralised and disengaged with their 
own care (Polonsky et al., 2010).  
                                                             




Whānau are often asked to make significant lifestyle changes. The difficulty for 
whānau was initiating that initial shift to change, then the consistency to 
maintain that habit. At the initial diagnosis, some acknowledged their motivation 
and the drivers for change – most had first-hand experience of seeing the tragic 
end points of poorly managed diabetes. Whānau struggled, in particular those 
that had diabetes for over 10 years, to keep practising changes they had made. 
More importantly, all whānau acknowledged they wanted to and were willing to 
try to make changes to make things better. It was not from the lack of wanting to 
make change – some just found it too hard to stick to the changes; others would 
try and did not bother again. 
How whānau were told they had diabetes was important, as this influenced how 
whānau managed or not their diabetes. Regardless, there were three clear 
pathways whānau took to their diagnosis; i=symptomatic diabetes 
ii=symptomatic non- diabetes iii=asymptomatic (Table 5). This conjured up all 
sorts of responses from total surprise of – “oh no, how did that happen”, to not 
surprised – “well, I kind of thought as much, it’s in my whānau”. 
Timing of the initial diagnosis and the breadth and depth of information given at 
the time also affected whānau responses. Whānau who were given lots of written 
information (pamphlets and brochures on diabetes related topics) at diagnosis 
admitted to filing them in a drawer for later, and never seeing them again. 
Timing is critical for whānau, when having to make lifestyle choices and changes. 
The barrage of information was overwhelming and many struggled to come to 
grips with the diagnosis, let alone the changes they are expected to implement. It 
was seen as all too much and too hard. 
Whānau were frustrated and confused with numerous tests and visits. Most 
whānau attended their appointments. There were those who did not bother, or 
were waiting to attend and were never contacted and so did not bother to 
contact their HP, as they thought they were well and no longer needed help. 
The relationship that whānau had with their HP affected the approach they took 
to managing their diabetes. Those that had a long-standing connection with their 
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HP were responsive and initiated changes. They did not always stick to the 
changes; and were influenced by the duration of the diagnosis. The overarching 




5.20 Whānau views/knowledge 
The whānau viewed themselves as “well”, not as a diabetic and were keen to stay 
in that space of wellness and they didn’t see diabetes as something that would 
impede that wellness. Closing the knowledge gap about diabetes is challenging 
for whānau and clinicians. Whānau are often experts in their own health, a 
resource often overlooked or undermined by clinicians. To progress change 
whānau are a resource to maintain and HP need to support their change ideas, 
such as lifestyle, medication, and appointments. 
 
 
5.21 Access to care 
Whanau priorities are not one dimensionally focused but rather a collective 
Māori world view. Baxter (2002) describes access to care and barriers to care 
for Māori. These barriers include but are not limited to; literacy, financial, 
rurality, transport, time poor. The biomedical systemic processes and 
pathways are; static, inflexible and non-compatible with the changing lifestyle 
and need of whanau – seven day working week, twenty-four shift workers and 
the rapidly changing advancement of science and technology (digital space). A 
change in how we approach and provide health care services is needed in the 
current landscape and environment or we will continue to contribute to 
widening the inequity for Māori - should we continue on the same pathway. A 
much wider transformational approach is needed across all sectors of care 
including; iwi, hapu, health, housing, social and justice. To ensure the needed 
services for whanau are appropriate, agile and nimble, will require time and a 





Whānau placed a strong belief in taking their medication to keep them well, or 
keep their “diabetes at bay”. They emphasised the role of medicines rather than 
seeing a connection between the changes they had or had not undertaken and 
their wellbeing. 
Whānau are MORE THAN - Their lives are much fuller and richer and busier 
and MORE THAN diabetes. Diabetes is really a small part of their lives (for 
some it’s an inconvenience, for some it’s a “hoha”, for some it is just “another 
thing”, for some it is your “tag” a label) you just get on with it. Diabetes has 



















“Ehara taku toa i te toa takitahi, he toa takitini” 
My efforts are not mine alone, but those of the many 
 
6.1 Introduction 
Access to health care services and quality medicines is difficult for many people 
living in rural remote areas, compared to those in urban areas. Medicines are 
important for people’s health and wellbeing and are at a significant personal cost 
and financial burden to the country’s economy. Poor access to quality medicines 
contributes to widening the inequity and disparity between Māori and non- 
Māori. Māori are also known to experience poorer health outcomes than non- 
Māori. Chapter six, seeks to understand what additional aspects of rural remote 
living (not discussed in chapter one) contribute to barriers to accessing to 
quality medicines in Tairāwhiti. The quantitative study reported in chapter four, 
identified the inequitable utilisation of diabetes medicine for Māori with type 2 
diabetes, and the high portion of young Māori with type 2 diabetes using 
multiple diabetes medicines. The qualitative study in chapter five, highlighted 
the disservice Māori experience in the health care system. The patient - health 
practitioner relationship and their respective health beliefs has is a significant 
influencing factor on their behaviour between each other. In addition, the quality 
of communication contributes to improving health outcomes between whānau 
and health practitioner. This chapter (six) focuses on aspects of rurality and 
physical access specific and unique to Tairāwhiti, not alluded to earlier in 
chapter one. How medicines are distributed in rural and remote regions and 
what are the barriers to accessing quality medicines in Tairāwhiti? The first part 
of this chapter builds on the background information discussed in chapter one, 
and highlights the challenges people experience living in the rural remote areas, 
that contribute to access quality medicines for whānau in Tairāwhiti. These 
include; the degree of rurality and remoteness of the region; transport – 
particularly roading; economy; geography; geography and environment. All 
these are areas that impact on accessing medicines, and resonate with findings 









The second part of this chapter reports on a study of the depot system and the 
process of medicines distribution in the rural areas of Tairāwhiti. The fieldwork 
for this was carried out by Andrew Davies and supervised by the author, 
between November 2011 and February 2012. The study included all the 
pharmacies in Tairāwhiti that are located in Gisborne city, and any prescription 
medicines distributed from Gisborne to designated depots located throughout 
the region (described further in the chapter). 
 
 




Findings from the literature review (chapter three) identified common themes 
for people living in rural remote areas with access to and use of medicines. These 
included: access to transport; access to medicines; access to health care and 
specialist services; the degree of rurality; cost of medicines; the patient/health 
professional relationship; the level of education; and knowledge about medicines 
use. Complementary alternative therapies and medicine were accepted practice. 
However, medicines and their use, were not always a priority for people in rural 
remote areas. Populations in these areas visited the doctors less, comparative to 
urban dwellers. People in rural areas usually travelled further on unsealed roads 
and used less medication (mental health and antibiotics medicines use), and 
were found to have an overuse of analgesia medicines. 
As described in Chapter 1, Tairāwhiti is situated on the East Coast of New 
Zealand. It is an isolated region, a third is flat land with the remaining area in hill 
country and hinterland (New Zealand Statistics, 2013). The hill country is 
covered in natural forest, commercial forestry or beef and sheep farms, or 
horticulture. Forestry is the dominant primary industry in the region. Tairāwhiti 
has a young population (<14 years), with a similar proportion of Māori and non- 
Māori. In Tairāwhiti, of the total population >15 years, 9% are unemployed, 
compared to 7% of the New Zealand population >15 years. The most common 
occupations are “labourers” and “professionals”. Sixteen percent of Māori >15 
years are unemployed. The greater portion of “labourers” in primary industries 
are Māori. The median income is less than $24,000. Of the people >15 years, 
41.9% had an annual income of $20,000 or less and a greater portion of the 
population live in decile 7 to 10 (most deprived areas). 
 
 
6.2 Definitions of remote and rural areas 
According to Statistics New Zealand, there is not one internationally recognised 
definition of a rural area. Statistics New Zealand (2004), looked at the 
classification definition of urban/rural New Zealand (Statistics New Zealand, 
2004). A highly rural/remote area is defined as rural area where there is 
minimal dependence on urban areas in terms of employment, or where there is 
a very small employed population (Statistics New Zealand, 2019).   
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Countries have their own definitions of rural and remote. Rural areas were 
traditionally residual areas not included in the urban definition, and highly 
rural/remote areas were described as “those rural areas where there is minimal 
dependence on urban areas in terms of employment, or where there is a very 
small employed population”. In Australia, the remoteness of a location is 
measured in terms of how far one has to travel to centres of various sizes 
(Australian Institute of Health and Welfare, 2004). 
The majority of Tairāwhiti is classified as highly rural/remote rural, rural area 




6.2.1 Tairāwhiti: Urban/rural profile categories – Gisborne region 
 
 
Figure 19: Tairāwhiti urban/rural profile 
Retrieved February 13, 2019, from  
 http://archive.stats.govt.nz/browse_for_stats/Maps_and_geography/Geographic -




6.3 Tairāwhiti as a rural area 
In New Zealand, highly rural/remote areas have the smallest proportion of the 
population. Two percent (76,449 people) of New Zealand’s usually resident 
population lived in highly/rural remote areas according to the 2001 NZ Census, 
compared to 6% in the 1991 Census. Highly rural/remote areas cover a huge 
proportion of New Zealand’s land mass area (Figure 20, 21), and have a very 
low population density - 18 people per square kilometre (Statistics New 
Zealand, 2004). 
In the South Island of New Zealand, 4.5% (37,413) of the population live in the 
highly rural/remote areas. In the North Island, 1.4% (39,039 people) of the 
population living in the highly rural/remote areas (Table 6 ). 
Tairāwhiti covers 8,351 square kilometres, approximately 3% of New Zealand’s 
land mass area and has a population density of 5.6 people per square kilometre. 
Over a quarter of the population live outside the main urban area Figure 19 
(Scott, 2017). Outside of Gisborne city there are only very small communities. 
(Table 6). Delivering medicines to these small communities, many of which are a 




Table 6: Usually-resident population of Gisborne City, Gisborne rural and East 





Gisborne City 32532 




Tolaga Bay 831 
Manutuke 603 
Te Karaka 543 
Patutahi 375 
Totals 8028 
East Cape  
East Cape 2703 
Ruatoria 756 
Tokomaru Bay 444 
Totals 3903 
District total 44,460 




Figure 20: Map of New Zealand population density 
6.3.1 Population density of New Zealand  
 
 
Retrieved February 2, 2019, from 
https://archive.stats.govt.nz/browse_for_stats/population/estimates_and_project 




6.3.2 People living in highly rural/remote areas by region in New Zealand, 2001 
 
 






The topography of the Tairāwhiti region is relevant to accessing medicines 
because it is a major obstacle to getting goods (including medicines) into the 
region, and moving them within the region. Tairāwhiti is the area of New Zealand 
most affected by erosion; 6% of the region is susceptible to severe erosion, 
compared to 8% of all land in New Zealand. This often blocks roads into the 
region and roads needed for movement of people and goods within the region. 
The cause of erosion is a combination of factors: the soft rock geology, climate 
and vegetation clearance and deforestation. The northern most ranges 
Raukumara and Huiarau, are composed of greywacke and argillite, and were 
formed from old strongly hardened deep-sea sediments. The highest non- 
volcanic peak in the North Island is Mount Hikurangi (1,753 m), in the 
Raukumara ranges, and it is composed of erosion greywacke. The north-eastern 
region is mainly volcanic rock and forms the steeper bluff formations. One of the 
larger land slips in the southern hemisphere, covering over 40 hectares, the 
Tarndale slip (Figure 22a, 22b) has been ongoing since 1915, the result of 
deforestation. 
Access to the farms and their families in this area, was lost with this road closure 
in 2018 (Figure 22b). The restricted access, had an immediate effect, but also a 
long-term flow on effect, such as access to schools, the inability to freight in feed 
for stock or send out stock to sell, impacting on families’ incomes (financially and 
in time) jeopardising their livelihood and way of life. The central and eastern 
areas of Tairāwhiti are composed of mainly mudstone, sandstone and argillite 
sediments. These areas have formed steep-to-hilly country, a result of tectonic 
movement, and are easily eroded as can be seen in 
The flat lands in the Tairāwhiti region are predominantly made of alluvial soils, 
approximately a third is used for pasture or unused, and a quarter for cropping 








Figure 22a: Tarndale slip in Mangatu (40 Hectares) 2000 
Retrieved February 2, 2019, from https://teara.govt.nz/en/photograph/33275/erosion-





Retrieved February 2, 2019, from https://teara.govt.nz/en/photograph/33275/erosion-















Severe erosion has caused long-term damage to the productivity of rural land. It 
threatens and isolates communities and rural businesses, including farms and 
orchards, roads and bridges. Large-scale gully erosion like that in Figure 22a, b 
(Tarndale slip), causes earthflow erosion and deep-seated slumps can result. 
Severe erosion lowers water quality by pushing large amounts of sediment and 
slash (timber off cuts left in forestry blocks) into the waterways, river systems 
and coastal areas (Figure 23, during Tolaga Bay floods, 2018). This causes harm 
to the natural environment and cultural values of the land and the coastal 
environment (Figure 24, slash washed up on the Tolaga Bay beach 2018). All of 
which has a negative cultural, environmental and economic impact to the 
region’s hill country farms, infrastructure, and high-quality land that is on 
floodplains. In 1988, a major cyclone (Bola) devastated the region, causing $120 
million in property damages (Institute for Business Research, 2013). (MAF, 
2006, cited in Institute for Business Research, 2013). The frequency and severity 
of droughts and floods is predicted to increase, causing continued disruptions to 
the region (MAF, 2006, cited in Institute for Business Research, 2013). 
 
 
6.5 Transport in Tairāwhiti 
 
6.5.1 Road 
The condition of the roads to and within Tairāwhiti also makes access to 
medicines difficult for residents. There are 1,867 kilometres of roading network 
in Tairāwhiti (2005). Seven hundred and seventy-nine kilometres (42%) are 
sealed roads and 1088 km (58%) are unsealed roads. Of the sealed roads – 237 
km (30%) are urban roads. The high proportion of unsealed roads highlights that 
the majority of the region is rural, relatively remote, with low population levels 















There are two main road links into and out of the region, State Highway 2 










State Highway 2 (SH2), is the major direct land route north and south to 
Tairāwhiti and carries the greater volume of traffic flow for passengers and 
freight, carrying approximately 1500 vehicles per day and is the main access 
route for transporting logs to the port facilities in Gisborne. The volume of 
vehicles per day peaks at up to 5000, as you get closer to Gisborne city (Gisborne 
District Council, 2006), particularly during peak harvesting periods for squash, 
corn, grapes, tomatoes and peas (late December through to late March early 
April). 
State Highway 35 (SH35), also known as the Pacific Coast Highway, winds 
around the East Coast and Gisborne, to and from Opotiki, and is the main access 














Areas of SH35 are in poor condition, very windy, narrow, with numerous one- 
way bridges, and limited areas for traffic to pass (Figure 29). There are 
numerous potholes and/or roadworks, increasing travel time. Heavy vehicles are 
not well catered for, due to seal width and the lack of passing opportunities. A 
large number of logging trucks (10-20% of all traffic) use SH35. Transit New 
Zealand predicts the volume of heavy traffic will increase over the next 25 years 




Export logs harvested in the region travel along SH2 and SH35 to the Eastland 
Port of Gisborne. In 2014, export logging increased from 1.6 million tonne to 3- 
3.5 million tonnes (NZ Transport Agency, 2015), with very little change to 
roading infrastructure. 
These networks of highways form the backbone of land transportation in 
Tairāwhiti, and local roads feed onto these. The topography is steep to hilly 
countryside and prone to erosion, climatic issues (flooding, slips), and tectonic 
movement (earthquakes). Sparsely populated communities (Table 6, Figure 2), 
dispersed in and around the network of roading also add to the utilisation of the 
roading system. Roading is expensive to maintain. Gisborne District Council 
expenditure on roading (2006), was $23,460 with an income of $17,728, 
compared to a roading expenditure budget of $30,363 and an income of $18,885 
in 2017. Retrieved March 2, 2010 from 
https://figure.nz/chart/WltFQOK08buwxX0v-ZCllmdEEsc4U7UQD 
Erosion and resilience are ongoing issues for the roading network. Road closures 
of SH2 (more than two closures per year) affect access to the north and south 
routes (Figure 25, 28). Although small in number, the closures have had 
significant economic impact for the region. The SH35 route has had an even 
greater number and severity of road closures (Figure 23, 29, 30) with similar 
flow on effects. 
In March 2012, a major slip in the Waioeka Gorge completely closed SH2 access, 
north between Gisborne and Opotiki, for a period of four weeks, before a 
temporary diversion allowed one-way traffic for limited hours (Figure 28). The 
full reinstatement of the route took over a year, and the road reopened in April 
2013. Alternative routes north included: SH2 south back to Napier, SH35 to 
Opotiki around the Pacific Highway, the Motu road (unsealed), or the unsealed 
forestry roads. All alternative routes were considerable diversions in time, 










As well as slips causing difficulties in getting medicines to people in outlying 
areas, the poor condition of the roads poses a risk to the quality of medicines 
while in transit. Medicines like insulin, if not packaged properly for transport, 
have the potential to degrade from agitation in transit, causing the insulin to be 





Location of fuel stations along SH35 
 
 
Figure 31: Location of fuel stations along SH35 
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Access to fuel is another factor impacting on people’s access to medicines. There 
are few public access points to fuel along SH35 (Figure 31), with the cost of fuel 











Figure 32b: Mode of transport (horse). Photo credit: Gisborne Herald 
 
 
Road users throughout the region also have the challenge of wandering stock on 
the rural roads. These include goats, sheep, possums, pheasants, horses, pigs, 




In 1942, the railway system opened and was available for freight and passengers 
in and out of the region. Increasing freight costs, and a decreasing number of 
passengers travelling by train led to the underutilisation of the rail services. The 
railway closed to passengers in 2002 and to freight in 2012. The railway network 
for passengers, travels through the central part of the North Island, New Zealand, 
a long way from Tairāwhiti (Figure 34). Landslips and washouts caused major 
damage to the rail line (Figure 33b). The remaining rail is the limited (public 
holidays, events) heritage steam train (Figure 33a) from Gisborne to Muriwai (a 
settlement 30 km south of Gisborne. 
 
 
Figure 33a: Steam train across the Tūranganui river (1.2km shortest river in the Southern hemisphere)  
and the only viable railway track. 
 
Figure 33 b: Paritu Loop rail slip at Paritu station in 1988 between Wairoa and Gisborne. 
 Figure 33a, b: Sourced: Retrieved March 13, 2019, from 






Figure 34: Map of North Island, New Zealand, railway lines 










Figure 35 Map of Bus route in Gisborne city.  
Retrieved March 23, 2019, from htttps://maps.gdc.govt.nz/H5V2_10/ 
 
Public transport is very limited, to a public bus service that operates within the 
city limits (Figure 35). There are no public rural bus services. Nonetheless, the 
bus service plays an important role in an area where a high proportion of the 
people live in the greatest deprivation. A courier service is available to freight 
and minimal number of passengers travelling between the communities on the 
east coast and Gisborne via S35. 
Intercity operate a public bus service north and south from Gisborne once a day, 
6 days a week. This is a 10-hour trip north to Auckland and a 4 hour trip south 
to Napier. Bookings for this service are online, as Intercity do not operate an 
office in Gisborne. 
In summary, transport options are limited in and out of the Tairāwhiti region. 




and regional road closures are frequent. Road conditions are poor and 
suboptimal, with minimal public transport (only within Gisborne city). This 
poses a risk for whānau to access medicines, and the quality of medicine 







Figure 36: Rakauroa and Smart road intersection. Road closures due to heavy snow fall.  
Photo credit: Gisborne Herald. 
 
Tairāwhiti is susceptible to regular high-intensity weather events that cause soil 
erosion and downstream flooding. Climate has an impact on access and medicine 
distribution for several reasons that include weather conditions affecting the 
roads and transport and the extreme temperatures. 
The summer month temperatures range from 20 to 28 degrees Celsius, 
occasionally rising > 30 degrees Celsius (National Institute of Water & 
Atmospheric Research [NIWA], 2001). The sunshine hours for the region average 
2,200 a year. The annual rainfall averages 1000mm to 2500mm in the higher 
inland areas. Flooding at the Puha Bridge (Figure 37a, b, c) in 2018, caused road 




Heavy snow falls have also caused road closures (Figure 36) in the region. The 
area is subject to severe weather conditions that cause major damage and 
disruptions with significant closures, causing access issues not only in and out of 
















Figure 37c: Puha bridge - road open. Photo credit: Venessa. Taylor 
 
 
Climatic conditions can have an impact on the quality of medicines. Most drug 
manufacturers specify that medicines be stored at temperatures of 25 degrees 
Celsius or less to maintain their pharmacological quality and efficacy (Crichton, 
2004). Medsafe recommend that insulin cartridges are stored in a fridge 
between 2°C - 8°C. Cartridges that are being used should be stored below 30°C 
for up to 28 days, and not near heat or in the sun. Retrieved May 5, 2018, from  
 https://www.medsafe.govt.nz/consumers/cmi/h/HumalogCartridge.pdf. 
 
A study by Hewson et.al (2013) found medicines were commonly stored outside 
the recommended storage conditions in New Zealand household locations 
(Hewson, Shen, Strachan, & Norris, 2013). Pharmacies have standard operating 
procedures for the storage of medicines, monitored by Pharmac and Medsafe but 
our study investigated whether medicines were stored appropriately during 
transport and while waiting to be picked up at medicine depots in Tairāwhiti. 
 
 
6.7 Electricity and refrigeration 
Electricity to Tairāwhiti is supplied by a single route owned by Transpower, a 
double 110kV line from the National Grid at Tuai which passes through 
geologically unstable country where problems have arisen (Paling, 2014). The 
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region is vulnerable and subject to supply interruptions and power outages. For 
several days in 2013 some households had no power. Some medicines 
(particularly insulin) require temperature control when in use, as detailed 
above. Alternative sources of power in remote areas include the use of diesel 
generation, solar power, and batteries, which are costly. There are homes 
without electricity in the rural remote areas. Not all households have access to a 




Connectivity and digital technology are important aspects of a community’s 
ability to connect. This is a challenge for businesses and households in 
Tairāwhiti, which is ranked below the national average for internet accessibility. 
However, 63.2% of the households in Gisborne have access to the internet, and 
77.5% of households have access to a cell phone (Ministry of Health, 2013). 
Internet access has improved with additional resourcing to the region, as part of 
a national strategy to have faster and better internet in the rural sectors 
(Ministry of Business Innovative Employment - MBIE). Providing UFB - ultrafast 
broadband and RBI – rural broadband, to rural communities outside the UFB 
areas in Tairāwhiti, at a cost comparable to urban dwellers, and additional 
funding to boost mobile coverage in the region. 
Connectivity, although faster, at times remains an issue; there are periods of 
slow or no connectivity and there are still rural areas with no internet or cell 
phone coverage. Access to telecommunications across the rural regions in 
Tairāwhiti is inconsistent. Not all people have access to phones and some areas 
have limited or no cell phone coverage, according to the Gisborne District 
Council digital strategy. Retrieved January 1, 2017, from 
https://www.gdc.govt.nz/digital-strategy/25/1/17. 
Mobile coverage across Tairāwhiti is marginal (Figure 38) at best, with large 
areas with no coverage at all, and three service providers (2 Degrees, Spark and 
Vodafone) in the area (Wilson, 2015). Internet access is variable, with patchy 
broadband along significant areas of SH2, SH35 and some rural settlements with 





Figure 38: Mobile coverage in Tairāwhiti 
Retrieved March 5, 2019, from 
file:///C:/Users/keosh359/Downloads/15-297-X1-Appendix%20 (1).pdf 






Figure 39: Broadband coverage in Tairāwhiti 
 
Retrieved March 5, 2019, from 
file:///C:/Users/keosh359/Downloads/15-297-X1-Appendix%20(1).pdf; 





Five percent of the total rural Māori population in New Zealand had no vehicle 
access (Ministry of Health, 2012b), according to NZ Census 2013. Of those 
households occupying private dwellings in Gisborne, 9.5% had no access to a 
vehicle (Ministry of Health, 2013). 
All vehicles used on the road in New Zealand are required (by law) to be 
registered and have a current warrant of fitness. Drivers must also hold an 
appropriate current driver’s license. The licensing process is administered by 
New Zealand Land Transport agency (NZLTA - crown agent). Additional costs 
include maintenance of vehicles, insurance, and fuel. Vehicles are exposed to 
extreme wear and tear, particularly in the rural areas, due to the poor conditions 
of the sealed and unsealed roads. Access to fuel is limited (Figure 31) and more 
costly in the rural areas than the urban areas. Other modes of transport include: 










6.10 Medicines distribution in Tairāwhiti 
Nearly all prescription medicines used in the community of Tairāwhiti are 
dispensed by community pharmacies in Gisborne. Patients registered with the 
Waikohu Health centre (Te Karaka) or community health clinics at Hauiti, and 
Ngāti Porou Hauora clinics can choose to have their prescriptions faxed or 
dropped off to a pharmacy in Gisborne. Medicines dispensed from the pharmacy 
are then distributed to a designated depot by courier or bus. Patients collect and 
pay for their medicines at the depot (there is an additional cost for delivery). 
Depots are located at: The Four-Square shop (Tokomaru Bay), Hughie Hughes 
Electrical Store (Ruatōria), Hick’s Bay General Store (Hick’s Bay), the Uawa 
Health Centre (Tolaga Bay), Tikitiki Health Centre (Tikitiki), Te Puia Hospital (Te 
Puia), Rangātira Motors at Te Karaka and Harddrive café at Matawai (see Figure 
2: Rural communities in Tairāwhiti – page 9). 
The Pharmacy Practice Handbook’s definition of a depot is “a place where 
prescriptions can be left for delivery or transmission to the pharmacy for 
dispensing and/or where dispensed medicines can be returned to for collection 
by the person for whom the medicine was prescribed” (Pharmaceutical Society 
of New Zealand, 2003). Depots must obtain an authority to possess prescribed 
medicines from the Medical Officer of Health pursuant to section 43(2) (a) of the 
Medicines Act 1981. Standard operating procedures are in place for depot sites. 
Community pharmacies are heavily regulated. However, our study found depots 
appear to be less monitored and regulated Davies (2012). The Medicines Act 
1981 requires a pharmacy to have a Licence to Operate a Pharmacy issued by the 
licensing authority at the Ministry of Health. The licensing authority maintains a 
register of Licences to Operate Pharmacy. This is held and available to view in 
the office of the licensing authority in Wellington. Retrieved December 18, 2018, 
from  https://www.health.govt.nz/our-work/regulation-health-and-disability- 
system/medicines-control/pharmacy-licensing 
Whānau registered at their respective health clinic may also access prescription 
medicines from Practitioner Supply Orders (PSO). Health clinics hold stock of 
common medicines, and PSO medicines are only used if needed urgently. 





To explore the distribution of medicines in remote rural areas of Tairāwhiti. 
Specifically; 
• What are the storage conditions for medicines in transit and while they 
are stored in depots? 
• How long do medicines stay at depots waiting to be collected? 





The School of Pharmacy granted the Ethics approval for the project, acting on 
authority delegated by the University of Otago Ethics Committee (Appendix 2 
Ethics application). 
The project was discussed with staff in several pharmacies that deliver 
medicines to the depots and with the depot owners for their permission and 
support in Tairāwhiti. Three different methods of data gathering are used to 
explore how the depot system worked. 
A questionnaire was designed to capture data about the people that collected 
medicines, their views of the depot system and any barriers they encountered in 
picking up medicines, and collection and storage of medicines including insulin. 
At each depot, people >18 years collecting medicines were invited to be 
interviewed and asked to consent to an interview. Data collected from the 
questionnaire was entered into an Excel spreadsheet and analysed using simple 
descriptive statistics (Appendix 2.1, 2.1, 2.3; participant information sheet, 
consent form and interview schedule). 
Hoboware data loggers were used to measure temperature and relative humidity 
of medicines while in transit and in storage at depots during the study period 
(November-February 2011). These small electronic devices recorded 
temperature and humidity at regular intervals and stored these measurements. 
Data was then downloaded into an Excel spreadsheet. 
Medicines are usually packaged and couriered from the pharmacy in Gisborne to 
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the respective depots for patients. Data loggers were located in with the 
medicines to measure temperature and relative humidity during transit (from 
Gisborne to Te Karaka, Matawai, and to Hicks Bay) and in storage at the 
respective depots (Te Karaka, Matawai, Tokomaru Bay and Hicks Bay). 
Interviews and observations were carried out by Andrew Davies (Pharmacy 
student). The author provided supervision and pastoral support for Andrew 
Davies while he was located in Tairāwhiti. Davies spent 93 hours (6 weeks) at 
the sites and conducted interviews; observed depot processes and systems; 
discussed how the depot system operated with key informants (depot owners 




One retail depot declined to participate and one clinic did not participate, as they 
had only a small number of medicines. 
 
6.11.1 Depot system observations and key informant interviews 
Prescriptions were faxed to the pharmacy by the prescriber or clinic and 
medicines dispensed were delivered to depots by courier or bus during the week 
(Monday to Friday), and occasionally on a Saturday. Each pharmacy had their 
own process of packaging and handling medicines for transport. 
Each depot had their own process and system for managing the medicines on 
site. All medicines dispatched from the pharmacy had an invoice attached, with 
the name of the patient and how much they had to pay. This enabled staff to 
check off who had collected their medicines and payment (when applicable). All 
depots were equipped with refrigerators for medicines, which required 
refrigeration. However, these fridges were not specifically designated to hold 
medicines. 
The standard procedure for returning medicines were that any medicines not 
collected after ten days were returned to the pharmacy. However, in one 
instance, medicine was noted to have been at a depot for longer than ten days 
(57 days).  
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6.11.2 Interviews with patients 
Ninety seven percent of the people that collected their medicine from the depots 
in the study responded to the questionnaire (2 declined). Those that responded 
were collecting their own medicines; more than a quarter were collecting 
medicines for someone else and a small portion were collecting for themselves 
and others. Respondents ranged in age from 18 to 83 years, the average age was 
54 years. Two thirds of the respondents were female and more than three 
quarters were Māori. The average length of time people had lived in their area 
was over 35 years; over a quarter were in paid employment, either fulltime 
(21%), part time (7.9%), seasonal (1.3%), and contract (1.3%). 
The average time taken to get to the depot was 8.5 minutes. A small portion (5%) 
took more than 30 minutes to and from depot. The main mode of transport was 
car. Some respondents had an additional purpose for their trip to the depot, like 
“groceries” or “mail”. However, for more than half the respondents, the sole 
purpose was to collect medicines. Most did not pay for their medicines 
(presumably because they had already received more than 20 items in the year 
and were eligible for a prescription subsidy card). Those that did pay for 
medicines, it ranged in cost between NZ$3 and NZ$93, with an average of NZ$12. 
Most of the respondents had a good understanding of how the system worked 
and knew when to collect their medicines, and were not notified that medicines 
were waiting to be collected at the depot. Half the respondents were happy with 
the current service. Comments included, “the service is wonderful”; 
“convenient”; and “efficient”. Those that did not like the service (11%) 
commented, “the wait can be an issue”; “last week’s medicines went missing 
which caused a bit of a panic”; and “I would be concerned about privacy with 
some medicines”. Respondents wanting a change to the service suggested a 
pharmacy closer to where they live, getting medicines directly from their doctor 
or having a depot closer to where they lived. 
Challenges in collecting medicines included financial problems, the cost of petrol, 
geographical access and transport issues, also having a physical disability or 
impairment. Forty-one percent of participants reported that they had already 
run out of their medicines before picking them up at the depot. 
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6.11.3 Temperature and humidity data 
The average temperature and humidity that medicines were exposed to while in 
transit to and from three sites (Te Karaka, Matawai and Hick’s Bay), ranged 
between 23.2 and 25.4 Celsius, and relative humidity ranged between 35.9% and 
44.3%. 
The average temperature and humidity of medicines during storage of medicines 
at four depot sites (Te Karaka, Matawai, Tokomaru Bay, Hicks’s Bay), ranged 
from 17.2 to 25.5 Celsius, and relative humidity ranged between 45.1% and 
50.6%. 
Medsafe data sheet recommends that Humalog (insulin) should be stored in the 
refrigerator when not in use. If this is not possible, it may be stored at room 
temperature (15-25 Celsius) for up to 28 days. Temperature recordings during 
the project were sometimes outside this range (maximum of 31.7 degrees, and a 
minimum of 13.9 degrees). Exposure to extreme temperatures can have a 
negative impact on the efficacy of insulin. Insulin was observed on the shelf for 





One depot did not participate in the study and the people collecting medicines 
from this depot were not interviewed. The length of time non-collected 
medicine remained at a depot was difficult to accurately report as new 
medicines arrived daily from different pharmacies and each depot had their 
own way of storing medicines. Measurement errors could have occurred with 
the data loggers, when recording temperature and relative humidity. People 
interviewed may not have felt comfortable discussing problems in accessing 
medicines to the interviewer, whom they had not met before. Only people 
collecting their medicines were included, not those that did not collect their 
medicines, and scope of the study did not include a complete monitoring and 






In countries with areas of low population density (for example New Zealand, 
Australia, Norway, Finland and Canada) access to pharmacies in rural and 
remote areas can be problematic. Governments sometimes control pharmacy 
numbers and locations through pharmacy licensing (Anell, 2005; Norris, 1997) 
or use criteria such as the number of pharmacies in each town (Mossialos & 
Mrazek, 2003). Other options include public ownership of pharmacies (as was 
the case in Sweden in 2009) (Landes, 2009) for extra subsidies or other 
privileges to improve the viability of pharmacies in rural areas (Mossialos & 
Mrazek, 2003; Pharmaceutical Services Negotiating Committee, 2019). 
A range of service provision models have been used in areas with poor 
geographical access to pharmacies. These include dispensing doctors, that is 
doctors who dispense their own prescriptions (Almarsdottir, Morgall, & 
Bjornsdottir, 2000; Morton-Jones & Pringle, 1993; Mossialos & Mrazek, 2003; 
Sunderland, Burrows, & Joyce, 2006). However, this does not address all the 
problems. Alternative strategies and interventions for people who live in rural 
areas to access medicine are discussed in the Literature review (chapter two). 
These include web-based platforms (such as DRgoogle, iMOKO); applications 
on mobile devices; telepharmacy; telemedicine; virtual consultations; 
diagnostics on line; point of care diagnosis; complementary therapies (natural 
and alternative); wider use of nurse practitioners; clinical nurse prescribing; 
internet webdoctor; and patient portal platforms – such as manage my health 
(patient access to health records). These tools are common practice in many 
countries (Kimber & Peterson, 2006). Other options include automated 
dispensing machines, and mobile pharmacists (Sunderland et al., 2006). The 
major issue to use these tools and resources for many in the rural remote 
areas, is the cost, and the very poor internet access and connectivity. Figure 40 
illustrates the poor access issues in the Tairāwhiti region. 
In New Zealand, as in some other countries, the primary solution to medicines 
access in rural and remote areas has been to allow pharmacy depots, such as 
shops or health centres, where pharmacists deliver medicines regularly for 




 depots regularly (Almarsdottir et al., 2000), although this is not usually the 
case in New Zealand. 
Key challenges in access and the distribution of medicines in the Tairāwhiti 
region include the poor state of some roading in the area, the vulnerability of the 
roading network to erosion, flooding and other climate-related problems, the 
financial cost of medicines; lack of access to vehicles, the cost of petrol and 
physical disabilities or impairments that make it difficult for patients to get to 
the depots. The depot system partially addresses some of the problems in 
distributing medicines to patients and their whānau in rural remote areas. 
However, transport and the storage conditions of medicines and quality of 
medicines were a challenge and also the minimal monitoring and scrutiny of the 
depot system. 
The barriers identified to medicines not being collected from the depot were 
similar to other studies and findings of indigenous populations and access to 
medicines in chapter three. These included financial constraints - people may 
owe monies at the depot; medicines dispensed on an off-pay week; and many 
people had run out of medicine (41%) before they collect their medicines; and 
people struggling to get to the depot (fuel/petrol cost, disability or impairment). 
Staff at one depot notified the general practice staff of uncollected medicines, and 
the practice staff made contact with those people and discussed any concerns 
regarding collection of medicines. In other cases, medicines were returned to the 
pharmacy if they were not collected. 
Temperature and humidity data suggest there is reasonable concern for the 
medicines exposed to variable conditions during transit to the depot and whilst 
in storage at depots (temperatures exceeded 25 degrees Celsius at three of the 
four depots). Studies indicate agitation or vibration of insulin during storage and 
transport can denature the protein, resulting in its inactivation and loss of 
potency (American Diabetes Association, 2003; Malik & Roy, 2011), 
compromising the quality and efficacy of insulin. These issues are worthy of 
further investigation and research. 
This study has shown key barriers people experience in the rural areas of 
Tairāwhiti to access quality prescribed medicines; issues with temperature 
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control of medicines have also been identified; and observations highlight how 
the depot system operates. The intent is to use the findings from the experiences 
of others to better improve access to quality medicines, and the care and services 




Recommendations include: Depots and pharmacies with a depot system should 
be regularly reviewed and monitored, and pharmacy roles and responsibilities 
should be clearly specified and monitored. 
Improving storage and distribution conditions for medicines. Ideally, all 
pharmacies should pack items appropriately for transit and refrigeration (for 
example; the use of slicker gel pads). 
Items needing refrigeration could be labelled (by colour) to assist depot staff to 
identify them easily. Depot staff are busy with their regular tasks, and do not 
always have time to check each package in detail. 
At the time of the study, any pharmacy could dispense and deliver medicines to 
depots in the Tairāwhiti region. There would be advantages to allowing only one 
pharmacy to distribute to depots. This would be easier and less confusing for 
patients, depot staff and others. It would also reduce the potential for mistakes to 
occur, and allow the pharmacists to work with the funder to improve services 
(although this decision might be commercially sensitive and restrict patient 
choice). 
Further research is needed into why medicines are not collected at the depots, 
and the barriers people experience to access these. It is likely those who do not 
pick their medicines up have greater barriers to access than those who pick up 
their medicines on a regular basis. Whānau experiences (of the depot system) 
are important to inform and aid with the quality improvement of the depot 
system to ensure the needs and expectations of whānau are meet. 
Further research could look into the cost of medicines and payment of medicines. 
Particularly for those on multiple medication, collecting a three-month supply of 
medicines is a financial burden for many people. 
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The possible instability of insulin during storage and transport in rural 




7 Chapter 7: Discussion 
 
 
Equity is defined by the World Health Organization as: 
 
"The absence of avoidable or remediable differences among groups of 
people. The concept acknowledges that not only are differences in health 
status unfair and unjust, but they are also the result of differential access to 
the resources necessary for people to lead healthy lives."  
 





The thesis is grounded in te ao Māori and uses a range of methods, bringing 
quantitative data and lived experiences together into one cohesive story. The 
concepts of Kaupapa Māori are weaved through the thesis, as explained in 
chapter two. That chapter (two) is an endeavour to contextualise and expand the 
notion of Kaupapa Māori concepts, drawn from tikanga mo Te Hauora o 
Tūranganui a kiwa, and their relevance in terms of the study. Findings from an 
international literature review on indigenous populations and diabetes and 
access to medicines are summarised in chapter three. This thesis originated out 
of a wider project funded by the Health Research Council, based in Tairāwhiti. 
The project included the position for a Māori PhD student, hence my 
involvement. The quantitative study in chapter four used the dataset of diabetes 
medicines dispensed in Tairāwhiti, derived from the wider project. These 
analyses formed the basis for which the thesis chapters are framed around. 
The detailed distribution pattern of diabetes medicines dispensed in Tairāwhiti 
are explored in chapter four. Primarily we wanted to know whether the 
medicines dispensed for diabetes matched the pattern of the population with 
diabetes. Results from chapter four demonstrate the differential treatment of 
Māori and non-Māori with diabetes in terms of diabetes medication. These 
results raise a range of questions about why? This led on to the collection of 
stories in chapter five exploring the views and experiences of Māori with type 2 
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diabetes and a Māori perspective on managing medicines. Chapter five provided 
the opportunity to bring a human perspective to the study. Analysis was based 
on the principles described in chapter two, stressing the importance of whānau 
and whānaungatanga (matauranga). The results suggest that initial encounters 
are critical to influencing outcomes; communication and relationships are key 
for change; health professionals should improve the quality of their 
communication; whānau have differing health beliefs and priorities related to 
diabetes and medicines. The challenges of accessing diabetes medicines are 
amplified if living in the rural remote reaches of Tairāwhiti and detailed in 
chapter six. This study examined the medicine depot system, which is an 
attempt to address some of these challenges. The results identified the 
opportunities for quality improvement in the transport and storage of medicines 
in rural remote areas, and further investigation is needed into the effects of on 
insulin in storage and transit. Barriers to accessing medicines include physical 
disability; the direct financial cost of medicines; and the cost of transport. As a 
consequence, medicines were uncollected and many people had run out of 
medicines before they came to collect them. The challenge is to find solutions, by 
working with the local stakeholders and pharmacies and patients. 
This discussion chapter summarises the findings from the study, provides 
limitations and strengths of the study, and opportunities and challenges for 




In New Zealand, the life expectancy of Māori is considerably lower than that for 
non-Māori. Overall, mortality rates are also higher for Māori than for non-Māori 
at nearly all ages. Māori health status remains unequal with non-Māori, across 
almost all chronic and infectious disease/conditions as well as injuries 
(accidental and non-accidental). Māori live in the most deprived areas of 
Tairāwhiti and experience the poorest outcomes compared with non-Māori. 
This study asked the question of whether medicines dispensed for the 
management and treatment of diabetes meet the recommended guidelines for 
treatment of Māori with diabetes in Tairāwhiti. At a glance, people diagnosed 
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with type 2 diabetes received diabetes medication for the treatment of type 2 
diabetes, but further analysis provided a different perspective of need vs 
medicines dispensed, and is discussed further in chapter three. Firstly, here is a 
summary of the discussion points highlighted in the preceding chapters to 
articulate and support my argument. Literature review findings found Māori and 
indigenous population’s shared similar experiences of inequity and disparity for 
type 2 diabetes, medicines use and access to medicines. 
 
 
7.2 Kaupapa Māori 
This chapter provided an understanding of Kaupapa Māori and why the study is 
framed within this context. The notion of Kaupapa Māori is woven throughout 
the thesis. Chapter two describes the key principles of tikanga o Te Hauora o 
Tūranganui a kiwa, which formulate the basis for the thesis and findings for the 
reader. Experts in Kaupapa Māori are not the focus of the thesis, but have guided 
the project and are referred to in the writing. Indigenous populations and their 
respective cultural way of being are acknowledged, as explained in the literature 
review. Understanding and acknowledging te ao Māori and Māori health beliefs 
are important to achieve positive outcomes and support the notion of by Māori, 
for Māori, and the explicit advancement of Māori. 
 
 
7.3 Literature review 
A pragmatic “as needed” approach to literary sources was applied during the 
writing of earlier chapters. A further comprehensive literature review was 
conducted during the latter part of the thesis to capture emergent research 
evidence that may further enlighten or illuminate thesis findings. Findings from 
these studies reviewed were pertinent to those noted in the early chapters. 
Literature searches were contained to creditable databases and reviewed 
research journal articles. Subject topics included indigenous people with a 
history of British colonial settlement – similar to New Zealand, Māori, type 2 




There were commonalities across the subject topics. Poorly managed diabetes 
had a significant impact for indigenous populations and risk factors were similar 
to Māori. Latent presentation at diagnosis, is an indicator the condition of 
diabetes, is advanced along the diabetes disease continuum and a greater 
severity of diabetes related conditions and a likely need for treatment with 
multiple medications. Indigenous people are diagnosed at a much younger age. It 
is estimated that for every one person diagnosed, there are two people 
undiagnosed (International Diabetes Federation 2017). Poor outcomes had a 
greater effect on indigenous populations and was associated with poor 
treatment and management of diabetes. Culturally appropriate group 
programmes are more acceptable and effective in behaviour change than the 
recommended self-management approach. 
The challenges and barriers for indigenous people is the unequal use of 
medicines for the treatment of some conditions. Barriers include cost, access and 
knowledge, poor medication adherence and health literacy. 
People in rural remote areas had poorer access and medicine use, visited the GP 
less, used less medication and lesser amounts of medication, and were less likely 
to engage in regular screening and monitoring. The prevalence of some 
conditions was high, but there were low prescribing rates for the recommended 
medicine. Contrastingly, some conditions had high medicine use – potentially 
over treatment. There had been an increase in the use of complementary and 
alternative medicines therapies, as rural populations had poor access to 
conventional medical care. 
Early access to services had been critical. “Tele” programmes and interventions 
had been effective with positive outcomes, providing better access to service 
options for rural populations and practitioners. Point of care diagnostics as a tool 
had also been effective for drug monitoring and adherence for some conditions. 
Sustainability of a competent rural workforce required key strategies that also 






7.4 Quantitative study 
In 2005, the prevalence of type 2 diabetes was greater for Māori than non-Māori 
(11% vs 4%). The Health Quality Services Commission’s (2010) work on the 
Atlas of Healthcare Variation and Virtual Diabetes Register supersedes these 
analyses. However, these quantitative analyses remain relevant and important, 
and provided the impetus for the remaining study. 
The study described differential treatment for diabetes medicines between 
Māori and non-Māori. Non-Māori received the greater portion of medicine for all 
ages. The study (adjusted for age) did not account for data specific to medication 
adherence, difficulties or assumptions people had in their treatment pathway, 
dosing titration up or down, newly diagnosed – starting medication, established 
therapeutic levels, other comorbidities, and the study excluded clinical and 
laboratory dataset. The low levels of medicines use by Māori potential result in 
premature mortality and low life expectancy; and are a result of poor access to 
healthcare and healthcare related services; low income (average income 
$24,000); the high proportion of Māori in decile 9 and 10 (most deprived) areas; 
low levels of education. 
Metformin had been dispensed more than sulphonamides, not an unexpected 
outcome. Metformin is the recommended first line of pharmacotherapy for 
treatment and management of type 2 diabetes. 
Tairāwhiti is geographically a physically isolated region with a high proportion 
of Māori, who live mostly in rural areas of deprivation 9 and 10. Māori are 
overrepresented in low socioeconomic status (unequal distribution of wealth), 
high mortality rates compared to other New Zealanders and experience greater 
prevalence of diabetes, cardiovascular disease and cancers. Differential 
treatment was evident, as the greater prevalence of oral diabetes medicines 
were to non-Māori. 
This quantitative study provided insight into the overall use of medicines by 
Māori with diabetes, but does not tell us about the lived experience of diabetes 
and the use of diabetes medicines, or barriers to access. These are explored 
further in chapters five and six.  
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7.5 Qualitative study 
This study is a collection of stories collected and collated of the lived experiences 
of Māori in Tairāwhiti with type 2 diabetes within a Māori framework. Data 
analysis identified key themes to further inform and contextualise the study. The 
recruitment of whānau into the study was completed with relative ease as an 
insider researcher perspective (within Kaupapa Māori framework). Challenges 
encountered during analysis were to clearly transcribe and articulate those 
conversations into written prose that best reflected the interaction, but were 
also a true and accurate account of the conversation (interview). Those 
conversations were a blend of spoken and unspoken words and meanings, 
within an intuitive space that was shared between myself and those interviewed 
(whānau). 
Findings are explained in the study and highlight the importance of respecting 
and understanding people and their context and view of the world (although as 
the author you may have been of that context and similar world view). 
Communication was a key element at all levels of the study; being brave and to 
engage in healthy conversations are encouraged to improve outcomes. 
The role and responsibilities of health professionals, and the relationships 
experienced between whānau and health professionals determined and shaped 
positive and/or negative outcomes of whānau attitudes and behaviours in the 
context of health and diabetes treatment and management. 
 
 
7.6 Access to medicines in rural remote Tairāwhiti 
This chapter explained the medicine depot system in the study area and 
examined barriers to access medicines, the storage of medicines in transit and 
depots, the length of time medicines are held at depots, and the barriers patients 
encounter collecting medication. The study merged the mixed methods used; 
data from the data loggers and interviews of participants collecting their 
medicines from the depots. The results are explained in chapter six. Findings 
showed suboptimal temperature and humidity data (in transit and at the depot). 
Temperatures ranged from 18 to >30 degrees (insulin is recommended to be  
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stored at 25 degrees), a potential risk to the quality and efficacy of medicine 
particularly insulin, and an area for further investigation and research. Most 
drug manufacturers specify that medicines be stored at temperatures of 25 
degrees Celsius or less (Crichton, 2004) to maintain their pharmacological 
efficacy. The region is known to have extreme temperatures during summer; 
along with the poor roading conditions, this is a concern for the storage and 
transit of medicines and the quality and efficacy of medicines. The roading 
network (sealed and unsealed roads) in the rural remote areas is marginal at 
best. Access to treatment and services is a challenge for those living in these 
areas and the service providers. 
Medication adherence was not part of the study; however, it is of concern that 
almost half of the participants had run out of medicine before picking up their 
new medicines. Reasons for this are worthy of further research. This also 
prompted further questions as to what other contributing factors there were to 
poor access to medicines in rural remote areas of New Zealand, why this might 
be occurring and was this common practice for people living in these areas. This 
is supported by findings in the literature review. Similar barriers for indigenous 
people to access medicines were encountered. This included rurality, cost – 




Caveats applied to the interpretation of the data; the study is based in Tairāwhiti, 
and medicines studied relate to the management and treatment of diabetes, 
specifically Māori with diagnosed diabetes and their use of medicines. Data is 
“dated” in terms of collection and analysis of the study results contribute and are 
relative to the wider study discussed. The study predated the centralised 
database now available (Virtual Diabetes Register), and used aggregate diabetes 
data from the Tairāwhiti District Health Board. The study excluded clinical data 
as a measure. 
The Māori participants in the study are representative of a small number of 




Chapter six only included people that were collecting their medicines – not those 
that didn’t collect their medicines. This was also not a monitoring and auditing of 
the systems and processes in practice or depot. The study did not include 
monitoring the adherence of medicine, nor the cost of medicines (cost was 




The study is Māori for Māori, using Māori data and Māori interviews, the 
researcher is Māori and whakapapa to the study area. The researcher also has 
twenty years’ experience working as a registered nurse in community settings 
with primarily Māori whānau with chronic conditions (diabetes, heart, 
respiratory), working for a Māori Hauora, focused within a Kaupapa Māori 
framework that links to her tūpuna. Data collected and collated is local and 
relevant to Tairāwhiti, a unique area of New Zealand. Data analysis used from the 
EIPMU study was built specifically for the local data set, as the Pharms data set 
was not adequate for the study. 
A range of methods were used to address the study questions: qualitative semi- 
structured interviews; quantitative analysis of datasets; quantitative data to 
capture temperature and humidity conditions of medicines. 
This study fills an important gap in the literature and adds to understanding 
Māori with diabetes and their management and treatment within Te ao Māori. 
A strength of indigenous populations is their shared holistic view of wellbeing; 
this includes but is not limited to health. Similar in health beliefs and behaviours, 
indigenous populations have a much wider perspective on health and illness, but 
also experience diagnosis at a younger age; a progressive advanced disease; poor 
outcomes for diabetes related co morbidities; premature mortality; socio- 





More research and evaluation into new and innovative models of diabetes care is 
needed, by working with Māori and indigenous populations to find solutions that 
will best meet their needs. 
It is also important to investigate the efficacy and quality of medicines (insulin) 
used (transit, storage, depot, and personal use, in houses) (Hewson et al., 2013). 
Equitable access to medicines – prioritises resources to the right place to create 
equal access to medicines for Māori and people who can not afford medicines, 
providing medicines at no cost, reducing a significant barrier. 
It is useful to investigate further the reasons why people run out of their 
medication or do not collect their medication from depots or pharmacies. 
Research is needed into the disparity of medication for at risk groups and 
populations and what are the drivers for these disparities and how can we 
improve these disparities. 
Further research should explore funding decisions regarding whether resource 
should follow the person or should we incentivise positive behaviour, and 
contestable publicly funded health activities. This may enable better support to 
people in need and other high-risk groups so they receive the appropriate 
medicines that assist them with their health and wellbeing. It will also provide a 
better understanding of access and treatment issues surrounding prescription 
medication as described in the literature review in chapter three. 
 
 
7.10 Key learnings where to from here: 
To have courageous healthy conversations between health professionals, 
researchers, stakeholders and whānau to find solutions that best support 
whānau towards positive outcomes – and not set whānau up to fail. 
The status quo is not good enough; whānau need to be encouraged to be 




Allocate appropriate resources to reducing inequity for Māori and make this a 
political priority. 
Improving access to medicines for Māori, and marginalised and at-risk 
populations. 
Inform interested parties-stakeholders to assist with planning and co designing 
diabetes services for Māori. 
Health literacy is key to closing the knowledge void – look to the “experts” within 
whānau to lead those conversations. 
The relationship between whānau and health professional is important, and 
contributes to positive outcomes. 
Health professionals need to be cognisant of other world views of health and 
wellbeing, and what this looks like in reality and how this view can transform 
their practice. 
Research – Investigate the cost of medicines – can people afford to pay for their 
medication. Understanding the rules, custom and practice of medication 
adherence for whānau, for example taking medication; returning to get a 
prescription; stopping medication, forgetting medication. 
Is the depot system the most efficient and effective system to distribute 
medication? 
What implications are there for medicines that are not used? 
 
Investigate the use of recyclable products that are environmentally friendly – 
especially the blister packaging, which is challenging to open, and whānau use 
their own containers. 
Relationships - Data analyses demonstrate that health beliefs, the quality of 
doctor/patient communication, and the quality of the information patients 
receive are important factors for patient adherence to treatment. Possible 
explanatory models for adherence emerged, relating to knowledge of the illness, 
body awareness and the doctor/patient relationship (Vermeire, Van Royen, 




The model of diabetes care should be tipped upside down and inverted to reflect 
“whānau ownership”, paying attention to the patient expertise and experiences, 
and their voice, to find strategies that work best for them. People have complex 
lives, whānau responsibilities, and the priorities of daily living can outweigh 
personal care such as diabetes. The notion of self-management as best practice 
for managing diabetes is a contradiction to Māori health beliefs and wellbeing, 
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1. University of Otago staff member responsible for project: Pauline Norris 
 
2. Department:  School of Pharmacy 
 
3. Contact details of staff member responsible:  pauline.norris@otago.ac.nz 
 
4. Title of project: 
 
Exploring the views and experiences of Māori with type 2 diabetes in Tairāwhiti 
 







Level of Study (e.g. PhD, Masters, Hons) 
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When will data collection be completed? 
 
End of December 2011 
 
6. Brief description i n lay terms of the aim of the project, and outline of research 
questions (approx. 200 words): 
 
 
This study is part of a wider project that has been looking at the patterns and 
utilisation of dispensed medicines in the Tairāwhiti region during 2005 - 2006. 
To date Shirley has been looking at the medicines that are used in the treatment 
and management of type 2 diabetes. She has found that Māori with type 2 
diabetes were less likely to receive anti diabetic drugs than non-Māori. This has 
led her to ask; “Why is there a difference between these two groups?” and “How 
are Māori with type 2 diabetes managing their illness?” To partly understand 
this, she would like to korero with Māori who have type 2 diabetes, so they can 
share their views and experiences of how they are managing their diabetes, so 
we can then get a better understanding of why those patterns may occur and the 
possible ways to improve outcomes for Māori. 
 
7. Brief description of the method.  
Please include a description of who the participants are, how the participants 
will be recruited, and what they will be asked to do:- 
Shirley will invite interested Māori with type 2 diabetes to take part in the study 
and are willing to korero and share their experiences and stories of having 
diabetes, by using open semi structured questions. A panui inviting participants 
to take part in the study will be sent out via the local iwi trusts and also through 
other local networks e.g. marae, kohanga, Kura, kaumatua, pakeke, Turanganui a 
Kiwa Runanga, Ngati Porou Runanga. Shirley will attempt to include males and 
females, rural and urban dwellers, young and older people, people newly 
diagnosed and those who were diagnosed years ago. Participants may choose to 
have someone else present during the interview. Shirley will be audio recording 
the interviews at an agreed venue, day and time.  
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A draft of the interview schedule is attached. During the course of an interview, 
and the research as a whole, new questions and areas of interest may emerge 
from the responses of participants. These questions and areas of interest will 
still be confined to achieving the overall purpose of the research but may 
necessitate changes being made to the interview guide. 
 
8. Please disclose and discuss any potential problems:  
(For example: medical/legal problems, issues with disclosure, conflict of 
interest, etc) 
It is not anticipated that there will be any discomfort or harm for those sharing 
their stories in the interviews. Any concerns or doubts people might have about 
being interviewed on a personal topic will be minimised by explaining and giving 
them the information sheet and consent form. These are to inform participants 
about the interview topic and purpose. The information discussed and disclosed 
during the interviews will be done so at the discretion of the participants. There 
will be no pressure placed on people to participate and they may withdraw at 
any time. 
The interviews will be audio recorded and then transcribed by Shirley and an 
employee of the Pharmacy School (Vicky McLeod). Only Shirley, Vicky and her 
supervisors (Dr. Pauline Norris and Dr Simon Horsburgh) will have access to the 
digital audio recordings and transcripts of the interviews. ID numbers will be 
utilised to identify transcripts during analysis and transcripts will have any 
details that would identify a participant removed. 
The digital audio recordings, typed transcriptions and data will be stored on a 
password protected computer. No information will be stored that would identify 
a person and link them to their results; however, a list of contact details of 
participants will be retained for a limited time for practical purposes. 
Shirley does whakapapa to an iwi of Turanganui a Kiwa and is working as a 
registered nurse in the community, where she has whānau connections and 
networks.  At all times Shirley will reassure participants that her role in the study 
is one of researcher not whānau or health professional. If participants seek her 
advice during the interview, she will give this advice only after the interview is 
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completed. Shirley will recommend seeking professional advice if necessary 
(post interview). She will also reassure participants that all information shared is 
strictly confidential and used only for the purposes of this study, and that 
participating in the study will in no way affect their future healthcare. 
 
 
DATE OF CONSIDERATION: .................................. 
 
Signed (Head of Department): ............................................................... 
 
Name of Signatory (please print): ………………………………………… 
 
IMPORTANT: The completed form, together with copies of any Information 
Sheet, Consent Form and any recruitment advertisement for participants, should 
be forwarded to the Manager Academic Committees or the Academic 
Committees Assistant, Registry, as soon as the proposal has been considered 




Appendix: 1.1 Participant Information sheet 




Exploring the views and experiences of Māori with type 2 diabetes 
INFORMATION SHEET FOR 
PARTICIPANTS 
 
Thank you for showing an interest in this project. Please read this information 
sheet carefully before deciding whether or not to participate. If you decide to 
participate we thank you. If you decide not to take part there will be no 
disadvantage to you and we thank you for considering our request. 
What is the Aim of the Project? 
 
Māori with type 2 diabetes experience poorer health outcomes than non-Māori 
with type2 diabetes. We want to explore the views and experiences of Māori 
with type 2 diabetes. This project is being undertaken as part of the requirement 
for a PhD at the School of Pharmacy, University of Otago. 
What Type of Participants are being sought? 
 
We are inviting approximately 20 Māori with type 2 diabetes that live in the Te 
Tairāwhiti region to be part of the study. 
What will Participants be asked to do? 
 
Should you agree to take part in this project, you will be asked to talk about 
your experiences of having diabetes with Shirley, at a time and place that is 
convenient for you. The interview should take about one hour and will be audio 
recorded with your permission 
Please be aware that you may decide not to take part in the project without any 




What Data or Information will be collected and What Use will be made of it? 
Shirley is going to ask you to korero to her about “what you do about your 
diabetes and how your diabetes affects your life” 
This project involves open-ended questions. If any of the questions make you feel 
uncomfortable, you can refuse to answer these question(s) and you may 
withdraw from the project at any stage without any disadvantage of any kind to 
yourself or your whānau. 
The results of the project may be published but every attempt will be made to 
preserve your anonymity. 
The data collected will be securely stored in such a way that only those 
mentioned below will be able to gain access to it. 
You are most welcome to request a copy of the results of the project should you 
wish. We will keep a list of contact details of people who wish to get a copy of the 
results, but this will not be linked in any way with the recording of your 
interview, or any information from the interview. 
 
Can Participants Change their Mind and Withdraw from the Project? 
 
You may withdraw from taking part in the project at any time and without any 
disadvantage to yourself of any kind. 
 
 
What if Participants have any Questions? 
If you have any questions about our project, either now or in the future, please feel free to 
contact either:- 
Shirley Keown Dr Pauline Norris 
School of Pharmacy School of Pharmacy 
University Telephone Number: University Telephone Number: 
(03) 479 7321 /0272831677  (03) 479 7359 
Email Address shirley.keown@otago.ac.nz Email Address 
 Pauline.norris@otago.ac.nz 
This study has been approved by the Department stated above. If you have any concerns 
about the ethical conduct of the research you may contact the Committee through the Human 
Ethics Committee Administrator (ph 03 479-8256). Any issues you raise will be treated in 
confidence and investigated and you will be informed of the outcome. 
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Appendix: 1.2 Consent form 
 
 
Exploring the views and experiences of Māori with type 2 diabetes 
CONSENT FORM FOR PARTICIPANTS 
 
I have read the Information Sheet concerning this project and understand what it 
is about. All my questions have been answered to my satisfaction. I understand 
that I am free to request further information at any stage. 
I know that: - 
 
1. My participation in the project is entirely voluntary; 
 
2. I am free to withdraw from the project at any time without any 
disadvantage; 
3. Audio-tapes will be destroyed at the conclusion of the project but any raw 
data on which the results of the project depend will be retained in secure storage 
for at least five years; 
4. This project involves an open-questioning technique. I know that if the 
questions make me hesitant or uncomfortable, I may refuse to answer them 
and/or may withdraw from the project without any disadvantage of any kind. 
The results of the project may be published but every attempt will be made to 
preserve my anonymity. 




(Signature of participant) (Date) 
 







Exploring the views and experiences of Māori with type 2 diabetes in Tairāwhiti 
 
Māori with type 2 diabetes are less likely to be on an anti-diabetic drug than non-Māori 
with type 2 diabetes. Māori with type 2 diabetes also experience poorer health outcomes 
than non-Māori with type 2 diabetes. This research study explores the views and 
experiences of Māori with type 2 diabetes, so we can have improved outcomes for Māori. 
 
Māori living in Tairāwhiti with type 2 Diabetes are invited to participate in the research 
study. It is anticipated the interviews will take at least an hour to conduct. 
 
Shirley Keown, Pharmacy School, Shirley.keown@otago.ac.nz 





Qualitative study exploring the views and experiences in Tairāwhiti of Māori with 
type 2 Diabetes 




How did you find out you were a diabetic, and did you have any idea that you might have 
been diabetic? (screened in community setting, in hospital, went to GP for something 
else like checking BP, CVD risk assessment, FHX) 
How long ago was it that you were told you had diabetes? 
 




At the time can you recall what if any information, advice and resources you might have 
been given? (Education, pamphlets, meter to monitor blood glucose – prick your finger, 
offered follow up) 
Have you any other health ailments/problems that are troubling you? 
 
(Apart from diabetes) 
 
What’s your understanding of diabetes and what does it mean for you having diabetes? 
Since having your diabetes have you made any changes for you and your whānau? 
(Drinking less, healthy kai, activity, garden, walking) 
Is there anything you do that helps you with your diabetes? 
 
(Alternative practices – karakia, rongoa, Mirimiri) 
 
Korero mai about diabetes - Can you tell me what’s it like having diabetes? 
 
Are there things you did or use to do or enjoyed doing that you don’t do so much of now 
since having diabetes? 
(hui hui, kai, hīkoi, tangi, ringawera, karanga) 
 
With having diabetes, have there been any changes for you and or your whānau? 
 
(attending hui, marae, travelling away, participation in activities, feeling better, different, 
healthier, to the doctor more often, eyesight, podiatry, relationships (tinana, 
Whānaungatanga – mokopuna/tamariki, hinegaro - social, wairua/spiritual- hahi) 
Pills and Dr visits 
 
What pills or medicine do you have – are any of them for diabetes - was this your own 
doctor that prescribed them? 
(GP, Diabetic specialist, physician) 
 
Do you know what your pills are and what they do? 
 
Can you recall any changes to your pills since you have had diabetes? 
 
(Taking more pills, different pills, less pills, started insulin) 
 
When was the last time you went to the doctor and was it for your diabetes? How often 
do you see a doctor about your diabetes? 
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1. University of Otago staff member responsible for project: 
Norris, Pauline, Professor 
 
2. Department: School of Pharmacy 
 
3. Contact details of staff member responsible: 479 7359, 
pauline.norris@otago.ac.nz 
 
4. Title of project: Geographical access to medicines in Te Tairāwhiti 
 











Student Research  XX mes 
 




External Research               Names 
Collaboration 
Institution/Company 
6. When will the recruitment and data collection commence?  November 2011 
When will the data collection be completed?  Feb 2012 
 




7. Brief description i n lay terms of the aim of the project, and outline of research 
questions (approx. 200 words): 
The only pharmacies in the Te Tairāwhiti region are in Gisborne. Two of these 
pharmacies deliver medicines to depots outside Gisborne, where they are picked up 
by patients. The depots are shops or service stations rather than pharmacies and 
have no particular expertise or facilities for handling, storing or dispensing 
medicines. We have previously found that temperatures during transport to the 
depots can be quite high, and all kinds of medicines (including those which should be 
stored at low temperatures) are sent in the same manner. To our knowledge none of 
the depots store any of the medicines in a fridge. In addition, staff at depots have 
told us that some medicines are not picked up, some sit in the depot for several days 
before they are picked up, and in some cases people come to pick up their medicines 
but do not do so because of the cost. The geography of the region also makes it 
difficult for some people to access the depot. 
 
8. Brief description of the method. Please include a description of who the 
participants are, how the participants will be recruited, and what they will be asked 
to do: 
 
The project will be discussed with local pharmacy managers who deliver medicines to depots, 
and depot owners. Their consent and goodwill is essential to the success of the project. 
Temperature and humidity will be recorded during transport and storage of 
medicines at the depots. For each depot studied, the researcher will record how 
many packages of prescription medicines are delivered (but not the nature of the 
medicines delivered). He will then stay at the depot during opening hours and record 
the time and date at which each package is collected, and ask people who collect 
their medicines if they consent to be interviewed. Interview questions will focus on 
people’s access to medicines: questions will include how participants got to the 
depot, how long it took them to get there, have they already run out of the 
medicines and if so when, and what prevented them picking up their medicines 
sooner, and whether they can afford to pick up their medicines? A draft interview 




9. Please disclose and discuss any potential problems: (For example: medical/legal 
problems, issues with disclosure, conflict of interest, etc) 
 
Participation will be voluntary, and this will be stressed to participants. Any publications will 
not identify individuals. No health information, such as what the medicines are, or what they 
are for, will be collected, except for whether the person is diabetic, and whether the medicine 
is for their diabetes. These questions will be asked because we have particular concerns about 
access to diabetes medication and storage conditions for insulin. 
 
DATE OF CONSIDERATION: .................................. 
 
Signed (Head of Department): ............................................................... 
 
Name of Signatory (please print): ………………………………………… 
 
IMPORTANT:  
The completed form, together with copies of any Information Sheet, Consent Form and 
any recruitment advertisement for participants, should be forwarded to the Manager 
Academic Committees or the Academic Committees Assistant, Registry, as soon as the 








Geographical access to medicines in Te Tairāwhiti 
INFORMATION SHEET FOR PARTICIPANTS 
Thank you for showing an interest in this project. Please read this information sheet carefully 
before deciding whether or not to participate. If you decide to participate we thank you. If 
you decide not to take part there will be no disadvantage to you and we thank you for 
considering our request. 
What is the Aim of the Project? 
 
To find out what problems people in Te Tairāwhiti have in getting their medicines. The 
project is Andrew Davis’ summer research project during his pharmacy degree. It is also part 
of Shirley Keown’s PhD project. 
What Type of Participants are being sought? 
 
Anyone over 18 collecting medicines from a depot in Te Tairāwhiti 
 
What will Participants be Asked to Do? 
 
Should you agree to take part in this project, Andrew will ask you some questions about your 
trip to pick up your medicines today. This should take about 5 minutes. 
Please be aware that you may decide not to take part in the project without any disadvantage 
to yourself of any kind. 
What Data or Information will be Collected and What Use will be Made of it? 
 
Andrew will write down the answers you give to his questions. You will be asked whether 
you have diabetes and whether your medicines are for diabetes, but otherwise you will not be 
asked about your health problems or what your medicines are for. Only basic information like 
your age and ethnicity will be collected, not your name. Andrew will write a report about the 
problems people in Te Tairāwhiti face in getting their medicines. Your name or any 




The data collected will be securely stored in such a way that only those mentioned below will 
be able to gain access to it. No personal information will be collected. As required by the 
University's research policy, any raw data on which the results of the project depend will be 
retained in secure storage for five years, after which it will be destroyed. 
The results of the project may be published and will be available in the University of Otago 
Library (Dunedin, New Zealand) but every attempt will be made to preserve your anonymity. 
 
This proposal has been reviewed and approved by the School of Pharmacy, University of Otago. 
 
Can Participants Change their Mind and Withdraw from the Project? 
 
You may withdraw from participation in the project at any time and without any 
disadvantage to yourself of any kind. 
What if Participants have any Questions? 
 
If you have any questions about our project, either now or in the future, please feel free to 
contact either:- 
Andrew Davis and/or Professor Pauline Norris 
School of Pharmacy  School of Pharmacy 
Phone: 03 479 7359 or 0274 80 95 
95 
 
Email: davan927@student.otago.ac.nz Email: pauline.norris@otago.ac.nz 
 
This proposal has been reviewed and approved by the School of Pharmacy, University of 
Otago. If you have any concerns about the ethical conduct of the research you may contact 
the Committee through the Human Ethics Committee Administrator (ph 03 479-8256). Any 









Geographical access to medicines in Te Tairāwhiti 
 
CONSENT FORM FOR PARTICIPANTS 
 
I have read the Information Sheet concerning this project and understand what it is about. All 
my questions have been answered to my satisfaction. I understand that I am free to request 
further information at any stage. 
I know that:- 
 
1. My participation in the project is entirely voluntary; 
 
2. I am free to withdraw from the project at any time without any disadvantage; 
 
3. No personal identifying information will be collected about me. Any raw data on which 
the results of the project depend will be retained in secure storage for at least five years; 
 
4. The results of the project may be published and available in the University of Otago 












This proposal has been reviewed and approved by the School of Pharmacy, 




Appendix: 2.3 Interview schedule 
 
 
ACCESS TO MEDICINES IN TE TAIRAWHITI QUESTIONNAIRE QUESTIONNAIRE NO.: 
 




Did anyone tell you that the medicines were at the depot? Y or N 
 
How did you get to the depot today?      
 
How long did it take you to get to the depot?    
 
How long will it take you to get home?    
 
Did you come to the shops/village/town for anything else, or just for your medicines? 
 
 
Have you already run out of your medicines? Y or N. If so, when did you run out? (answer may differ 
for each medicine) 
  _ 
  _ 




Did anything make it hard for you to come and pick your medicines up sooner? (eg lack of transport, 
family responsibilities, special events?) 
  _ 
  _ 




Do you have to pay for your medicines?  Y or N.  If so, how much do you have to pay? $ 
How difficult is it for you to pay this? 











How would you ideally like to get your medicines? 
 
 
Could you please tell us a bit about yourself 
Age:    
Gender:  M or F 
Which ethnic group do you belong to? Please say any which apply to you 
New Zealand European 
Māori 
Samoan 





Do you work in paid work? Y or N. Part-time or full-time? Seasonal? 
How long have you lived in this area?            
 
If this medicine is for you: 
Do you have diabetes? Y or N. 
Is this medicine for diabetes? Y or N. Does this include insulin? Y or N. 
 
 
If the medicine is not for you 
Could you please tell us a bit about the person the medicines are for 
Age:    
Gender:  M or F 
Ethnicity:    
Is he/she in paid work? Y or N. Part-time or full-time? Seasonal? 
How long has he/she lived in this area?    
Does he/she have diabetes? Y or N 
Is this medicine for diabetes? Y or N. Does this include insulin? Y or N 
